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Abstracts 
Abstract 
The room temperature polymerising heterocyclic polymer system, poly(efhyl 
methacrylate)/tetrahydrofurfuryl methacrylate (PEM/THFM) has been shown 
previously to be biocompatible and supported tissue repair, specifically for bone 
and cartilage, and biologically inert when in contact with the dental pulp. It 
proved more effective, than other glassy methacrylates, in the release of active 
species. 
The PEM/THFM system is a rigid material. The aim of this study was to develop 
and characterise the use of this system as a flexible patch, for application and 
retention to the buccal mucosa, thus facilitating sustained regulated release. 
Model species, dextrans, were used to represent macromolecular drugs whereby 
the effect of molecular weight could be studied. N-methyl pyrrolidone was added 
to the polymer system as a biocompatible plasticiser to enhance molecular 
mobility, and hence the transport of species. The effect of the addition of chitosan 
was also studied, due to its bioadhesiveness and permeation enhancing ability. 
A range of systems was investigated both in terms of water and species release. 
The release of the agent was measured by a fluorometer, the leachable 
components by HPLC and Confocal microscopy demonstrated the transport of 
water and active species through the system. Immunological and viability studies 
established whether the leachants or released components of the polymeric 
systems had an inflammatory or irritant action on `in vitro' stratified epithelium. 
The addition of N-methyl pyrrolidone, dextran and chitosan substantially 
increased water uptake, thus affecting the release kinetics. Analysis of the 
kinetics of water uptake showed Case I, combination of Case I and Case II, and 
Case II kinetics, depending on the systems studied. Dextran release was largely 
diffusion controlled, from which diffusion coefficients were calculated; the 
amount released varied between the systems studied. 
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CHAPTER 1 INTRODUCTION 
The relatively recent evolution, of recombinant DNA research and modern 
synthetic and biotechnological methodologies, allow the biochemist and chemist 
to produce vast quantities of a variety of peptides and proteins possessing better 
pharmacological efficacy. However, the therapeutic potential of these compounds 
lies in our ability to design and achieve effective and stable delivery systems. 
This can be particularly challenging due to the extensive pre-systemic metabolism 
and instability in acidic environment resulting in inadequate and erratic oral 
absorption of these compounds. The parenteral route of administration is the only 
established route that overcomes all the drawbacks associated with such orally 
inefficient drugs. But, these formulations are costly, have least patient compliance 
and require repeated administration, in addition to the other hazardous effects 
associated with this route. 
The difficulties associated with parenteral delivery and poor oral availability 
provided the drive to explore alternative routes for the delivery of such drugs. 
Alternative routes, such as transdermal and transmucosal routes, have been 
explored over the, last few decades. Among the various transmucosal sites 
available the buccal cavity was found to be the most convenient and easily 
accessible site for the delivery of therapeutic agents for both local and systemic 
delivery. It has an expanse of smooth muscle, which is relatively immobile, has 
abundant vascularisation and exhibits a rapid recovery time after exposure to 
stress. It also has direct access to the systemic circulation through the internal 
jugular vein and the drugs bypass the hepatic first pass metabolism, leading to 
their high bioavailability (Alur et al., 2001). This is most attractive as a systemic 
delivery route for proteins and peptide compounds. However the barrier function 
of the buccal mucosa stands as the major limitation in the development of buccal 
adhesive delivery systems. 
Developing a dosage form for the buccal cavity with the optimum 
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pharmAcokinetics is a promising area for continued research, and this can be 
achieved with the use of polymers as delivery vehicles. With the right dosage 
form design, the local environment of the mucosa can be controlled and 
manipulated in order to optimize the rate of drug release and its' permeation. 
This thesis describes an exploratory study of the development of a potential 
buccal delivery system, based on the room temperature polymerizing methacrylate 
system, poly(ethyl methacrylate)/tetrahydrofurfuryl methacrylate (PEM/THFM). 
This system has been extensively studied for dental and orthopaedic applications, 
and has been shown to be biocompatible in bone (Downes et al, 1994) and dental 
pulp (Pearson et al, 1986). It is a rigid polymeric material that has been shown to 
delivery drugs in a controlled manner, and is studied as a control in this work. 
Because the delivery system is being investigated for potential use on the buccal 
mucosa, it needs to be flexible for comfort and for maintaining on this site. 
Therefore, also in the current work, a biocompatible plasticiser, n-methyl 
pyrrolidone (nMP), has been added to PEM/THFM to: 
i) to increase compliance (ie reduce the systems's modulus), and 
ii) to enhance the release of the active species. 
However, this thesis has concentrated solely on enhancement of release. 
PEM/THFM was compared with a polymer system that is naturally elastomeric, 
poly(ethyl methacrylate/tetrahydrofurfuryl acrylate (PEM/THFA). It must be 
emphasized that this system is not suitable for clinical applications, due to the 
well known toxicity of acrylate monomers in general (Nethercott, 1978). 
The potential delivery system is also required to be retained on the buccal mucosa 
for a suitable period of time, to allow a sufficient amount of drug to diffuse out of 
the material and across the mucosa. Therefore chitosan was added to some of the 
systems, due to time constraints, as a potential adhesive/permeation enhancer. 
Dextrans are sugars that are available over a wide molecular weight range, 
without altering their chemical structure, so these have been used as models for 
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high molecular weight active species. Three different molecular weight dextrans 
(10,35 and 71 KD) were incorporated respectively in all of the above systems. 
Water uptake is a prerequisite for the release of the active species. Therefore the 
effect of the plastisicer, the active species and chitosan, on the water uptake of the 
potential delivery systems was studied in detail. 
Release profiles of the dextrans from the various systems were studied using 
fluorometry. In particular the effects of molecular weight on the release of 
dextran were examined because earlier studies have shown that the amount of an 
active species released varies inversely with its molecular weight (Parker et at 
1997). The results of both water uptake and release, as well as the release profiles 
were analysed using appropriate diffusion theories. 
High performance liquid chromatography (HPLC), under a range of experimental 
conditions, was used to analyse and quantify the leachants from these systems. 
Novel methods had to be developed during this work, for the detection of the 
various leachants, since there were no prior methodologies. 
Scanning Electron Microscopy (SEM) was used on selected samples, before and 
after hydration, and following desorption (dehydration), in order to gain an insight 
into the micro-structure of the systems. Confocal Laser Scanning Microscopy 
(CLSM), on selected samples, was used to monitor hydration during the water 
absorption process. This technique was also used to study the distribution and 
movement of water and FITC dextran within the systems. 
Finally, because the potential delivery system is for use in the oral cavity, on the 
buccal mucosa, the biocompatibility of some potential systems was examined. 
This section involved epithelial viability and immunological responses and 
quantification using a Skin Ethic reconstituted epidermis model. 
This outline of the project may be summarised in terms of the aims and objectives 
of the study, which are to: 
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" Study the effect of three molecular weight dextrans on the water uptake 
process of the parent PEM/THFM system, and the release kinetics of these 
dextrans. 
" Study the effect of three molecular weight dextrans on the water uptake 
process of the PEMJ1'HFA system, and the release kinetics of these dextrans. 
" Study the effect of two levels of addition of the plasticiser n-methyl 
pyrrolidone(nMP) on the water uptake properties of the PEM/THFM system. 
" Investigate the water absorption characteristics of a range of PEM/THFM 
systems containing both plasticiser and dextran at various levels, and the 
dextran release profiles. 
" Study the effect of the further addition of Chitosan on selected systems on 
water uptake and dextran release. 
" Analyse theoretically the data obtained in the previous four areas 
" Determine the character and quantity of various leachants 
" Characterise the microstructure of some of the systems studied before, during 
and after immersion in water, using scanning electron and confocal laser 
scanning microscopy. 
9 Carry out a brief study of the biological effects of the systems studied on a 
reconstituted skin model. 
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CIMPTER 2 , 
INTRODUCTION TO DRUG 
DELIPERYAND POLYMERIC SYSTEMS 
This chapter initially reviews current drug delivery methods and the various routes 
of delivery that are available, with particular emphasis on the oral mucosa and its' 
potential as a delivery route (e. g. buccal drug delivery). This is followed by a 
section on controlled drug delivery and related systems. Water absorption 
processes (precursors for drug delivery) are subsequently described, as well as 
polymethacrylates used in the medical/dental field. The latter part then focuses on 
one potential delivery system, named PEM/THFM. nMP's suitability as a 
plasticiser is then discussed together with Chitosan as a mucoadhesive material. 
Finally, because dextrans are used as drug models, the chapter discusses some of 
their properties and closes on an overall conclusion on the Literature Survey itself. 
2.1 INTRODUCTION 
Traditionally, the focus of pharmaceutical research has been on the design and 
synthesis of new drugs. However, more recently the routes and the forms by 
which these are administered, has become an area of interest. Drug delivery is 
becoming a whole interdisciplinary and independent field of research. It has been 
developing rapidly, gaining the interest of both scientists and the pharmaceutical 
industries. Particularly, since some drugs have an optimum concentration range 
within which benefit is derived, concentrations above or below this range can be 
toxic or produce no therapeutic benefit at all. The slow progress in the efficacy of 
the treatment of severe diseases has suggested a growing need for a multi- 
disciplinary approach to delivery of therapeutic drugs. These approaches enable 
possibilities of developing an effective drug delivery system that can transport and 
deliver a drug precisely and safely to the site of action, at the required level. This 
targeted delivery could not only improve the performances of some of the 
classical medicines already on the market, but it will also have implications 
towards the development and success of the more novel therapeutic strategies, 
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such as peptide and protein delivery, glycoprotein administration, gene therapy 
and RNA interference (RNAi) (Check, 2003). 
New or improved drug candidates developed by rational design, combinatorial 
chemistry or the screening of natural products must be delivered effectively to be 
of clinical use. It is critically important to capitalise on these interesting new 
opportunities through the parallel development of effective drug delivery systems 
(Charman et al., 1999). 
2.2 DESIGN AND DEVELOPMENT OF DELIVERY SYSTEMS 
In the design and development of drug delivery systems (DDS) there are four key 
areas of research and these are mapped in Figure 2.1. Research into the design of 
the drug molecule has been carried out for several years, specifically to improve 
the chemical stability and pharmacokinetic properties. This enables the drug to be 
tailored to give the required properties in terms of absorption, distribution, 
metabolism, excretion, and transfer across biological barriers and targeting to the 
site of action. Understanding the processes by which drugs pass through 
membranes and are transported around the body is essential for reliable drug 
delivery (discussed in section 2.3). 
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2.3 ROUTES OF ADMINISTRATION 
Currently there are numerous routes via which local and systemic drug delivery 
can be achieved (Figure 2.1). The type of delivery route used is driven by patient 
acceptability, the type and site of the disease, as well as the properties of the 
active drug. Some novel systems are only suitable for local delivery whereas 
others can successfully achieve systemic distribution of the drug. For example an 
intravenous route is suitable for a rapid response or for a drug which may degrade 
via the oral route. This is due to its immediate presence in the blood circulation 
system which transports the drug to the site of action directly. However, in this 
instance if the oral route was used (i. e. tablet) the effect would be achieved at a 
slower rate, since the drug would have to be metabolised into the circulatory 
system. 
For each of these routes there are several modes of delivery which can be 
applicable. Alternative formulations can improve the desired action of the drug, 
within the various routes of administration. Examples of these are listed in Figure 
2.1 DDS, technologies. A new formulation also offers several other benefits; 
these include providing drugs with a competitive edge following expiry of patent, 
market extension, and reduction of the drug development budget. The choice of 
formulation is often dependant on several factors such as the active drug in 
question and the effect that is to be achieved. For example, placement of the drug 
within a tablet or a capsule, both are delivered via the oral route, however 
different release profiles can be achieved. As a result of these advances the 
market for drug delivery is changing drastically. 
2.3.1 PERORAL 
The oral route is one of the most preferred routes of drug delivery, owing to its 
non-invasive nature; it is also often referred to as the Peroral (p. o) route. It is 
easily accessible and the effects are also easily evaluated, making it convenient for 
both patients to use and research scientists to develop. It takes many years to 
research and develop alternate delivery routes, which can be highly expensive, 
Hence an established route has cost advantages. 
10 
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The administration of active specimens via this route is in various forms such as 
tablets, solutions and suspensions. However, despite its popularity, the traditional 
peroral route has its limitations. Not all drugs can be administered via the mouth 
due to the poor bioavailability of the drug at its site of action. A drug with poor 
bioavailability would require a higher frequency of administration or an increase 
in the dose administered to initiate a pharmacological response (therapeutic 
effect). In turn this could lead to greater incidences of side effects; in particular, 
toxic effects to healthy cells are possible. 
Often the success of a drug will depend on its ability to be delivered to the site of 
action hence it is of great significance. The distribution of the drug around the 
body is via the blood circulation system. The drug must enter the circulatory 
system by overcoming barriers following ingestion, prior to reaching the blood 
circulation. Two major barriers identified are, the gastrointestinal tract (GI Tract) 
(Alberts, 2002) and the first pass hepatic clearance, passage via the liver (Brayden 
and O'Mahony, 1998). 
The main function of the GI tract is to aid the digestion and absorption of food. 
Hormones' present within the GI tract control and regulate the release of enzymes, 
which promote digestion. This specifically occurs during ingestion, mainly in the 
acidic medium of the stomach and the small intestines; the process breaks down 
all substances ingested including drugs. Subsequent to surviving the passage 
through the GI Tract, the components diffuse through the endothelial lining of the 
gut and travel via the blood system to the hepatic portal vein, where the drug 
encounters the first pass hepatic metabolism, within the liver. 
First pass hepatic clearance is the primary route for eliminating all types of 
compounds absorbed from the GI tract, Kupffer cells present within the hepatic 
portal vein engulf and digest old red and white blood cells, micro organisms and 
other foreign particles (Hadley, 1990). The level of breakdown of the delivery 
vehicle and the active component, by either of the barriers, depends on the drug 
and its formulation. Some macromolecules, proteins and peptides are more prone 
to breakdown under these conditions since both the GI tract and the liver are 
11 
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specifically designed to breakdown proteins, lipids and carbohydrates, which enter 
into the body. Consequently adequate peptide or protein drug delivery has not yet 
been attained via this route. As a result of this millions of' diabetics worldwide 
have to give themselves insulin injections daily (up to 4 times a day depending on 
treatment schedule). Non adherence to their strict protocols can occur due to 
lifestyle implications, but this can have grave implications on their health. 
2.3.2 INJECTIONS 
Following the use of the oral route, injections and nasal drug delivery are used 
most frequently. Injections are delivered via two routes, Intravenous (IV) and 
Intramuscular (IM). They are relatively simple methods of ensuring direct 
delivery into the systemic circulation without any degradation. As mentioned 
earlier, injecting is a useful method when immediate action is required and in 
cases where the patient is unable to comply. However it is a highly invasive and 
difficult method for the patient to administer themselves, particularly when 
regular dosing is required. Also there are possibilities of local toxicity effects 
since the site is exposed to a high concentration of the drug on injecting. 
Although sustained delivery can be achieved with long acting drugs, (i. e. long 
acting insulin) controlled release of the drug is not possible via this route, 
therefore it is difficult to introduce a therapeutic level of the drug in the body, 
consistently, without repeat injections. 
2.3.3 NASAL DELIVERY 
In recent years, the nasal route has received a great deal of attention as a 
convenient and reliable method for the systemic administration of drugs. This 
route has been a therapeutically viable alternative for two decades. However it 
has been more seriously considered for systemic drug delivery with the early work 
of Hussain et al (1979), where the nasal absorption of propranol was found to be 
comparable to the intravenous route in a Rat Perfusion Model. Subsequently 
Chien's group have completed comprehensive reviews on the use of this route 
(Chien, 1989; Chien, 1990; Chien and Chang, 1987; Sayani and Chien, 1996). 
12 
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The nasal route can offer numerous advantages (O'Hagan and Ilium, 1990) due to 
the large surface area of the nasal cavity, which has a highly vascularised mucosa. 
The latter enables the hepatic 1ST pass clearance to be avoided for systemic 
delivery. It can also offer other advantages such as rapid onset of action, reduced 
dosage and subsequently lower side effects (Behl et at., 1998). These advantages 
are particularly important for certain symptoms such as pain relief, nausea, 
erectile dysfunction, sleep induction, seizures, Parkinson's and other diseases of 
the central nervous system, which are currently being investigated. 
The nasal route has already reached commercial status with several drugs 
including Calcitonin (MiacalcinTM) for Osteoporosis and Paget's disease 
(Norvartis Pharmaceuticals; Overgaard et al., 1989), Buserelin (Suprefact(b), 
hormone analogues for prostate cancer (Shimamoto, 1987; Schally, 1999) (Table 
2.1). ExuberaTM (Aventis, Pfizer) is a nasal delivery system for insulin which has 
been filed for regulatory approval with European Medicines Agency (EMEA) in 
Europe. Table 2.2 lists a few examples of the many drugs currently being 
evaluated for nasal delivery. Despite initial success not all of the drugs in Table 
2.2 have achieved commercial status. Most of the drugs delivered via this route 
have relatively low bioavailability (particularly polar agents) (Ilium, 2002). 
An improved understanding of the structure and function of tight junctions in the 
nasal epithelial barrier is needed before significant improvements in the delivery 
of large molecules, such as heparin, can be made. The large variability in mucus 
secretion from the nasal mucosa may also significantly affect drug absorption 
alongside the enzymic activity within the cavity (Lee and Yamamoto, 1990). 
The barrier properties of the mucosal membranes contribute to the low 
bioavailability of the drug via this route (Corbo et al, 1990). This may be 
improved by the incorporation of permeability enhancers (Section 2.3.6. aii). 
However the addition of these may potentially irritate and cause irreversible 
damage to the cilliary action of the nasal cavity, following long term application. 
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Different absorption enhancers are being studied to improve the absorption of 
polar drugs. For example, formulations based on Chitosan powder have been 
tested for the nasal administration of insulin and vaccines (Dyer et at., 2002; Blum 
et al, 2001). The use of cyclodextrins, poly-L-arginine and lipids as absorption 
enhancers is also under investigation (Merkus et al, 1999). 
Table 2.2 Example of investigational nasal products 
Drug Status Indication Reference 
Norethisterone Human studies Contraceptive agent Kumar, et al., 1991 
Diphenhydramine Human studies Antihistaminic and Gaffey et al., 1987 
hydrochloride antitussive agent 
Leuprolide acetate Human studies Prostatic cancer, Adjei et al., 1992 
endometriosis 
Octreotide acetate Human studies To reduce blood levels Kissel et al., 1992 
of growth hormone 
and IGF-I in 
acrome al Patients 
Scopolamine Human studies Prevention of nausea Tonndorf et al., 1953 
hydrobromide and vomiting induced 
by motion sickness 
Sufentanil citrate Human studies Analgesic agent Hanes et al., 1993 
Tixocortol pivalate Human studies Anti-inflammatory Larochelle et al., 
agent 1983 
Insulin Human studies Diabetes Mellitus Frauman et al., 1987 
2.3.4 PULMONARY DELIVERY 
For many years, drugs such as ß-agonists and corticosteroids have been 
administered via this route for the treatment of asthma, providing a rapid onset of 
bronchodilation, Pulmonary delivery offers a number of advantages such as 
providing a large absorptive area, extensive vasculature, easily permeable 
membrane, and low extracellular and intracellular enzyme activity (Patton, 1996; 
Liu et al., 1993). Another benefit is the direct targeting of drugs to the lungs for 
treatment of pulmonary diseases (Gavalda et al, 2005; Beyer et al, 1993). 
15 
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More recently the pulmonary route of drug administration has been investigated 
by many research groups as a site for systemic delivery (Sayani and Chien, 1996; 
Agu et al, 2001; Yu and Chien, 1997; Shoyele and Slowey, 2006). Table 2.3 lists 
drugs that are currently in clinical trials, to assess the possibility of using this 
systemic pulmonary delivery route (Vanbever, 2005), alongside their current 
methods of delivery. Some of these delivery systems have been successfully 
developed for systemic therapeutic applications (Nerbrink, 2003), and it is 
apparent that many of these drugs do not have a non-invasive alternative delivery 
option. Hence this method is an attractive alternative (Epinephrine and Insulin; 
Simons, 2004 & Patton et al, 2004). 
Most of these drugs delivered via this route have relatively low bioavailability 
(particularly polar agents) (Ilium, 2002), and some specifically need to be 
delivered deep into the alveolar region of the lung for efficacy. However this is 
not consistently achieved either due to incorrect use by patient or due to the 
inadequate performance of the inhaler system. Even with highly efficient inhaler 
systems the pulmonary bioavailability usually does not exceed 10%, indicating 
that the clearance mechanism within the respiratory tissue operates efficiently. 
The delivery of insulin via this route has produced good clinical results, acting as 
fast as or in some cases faster than the subcutaneous injections administered. 
However the 10% biopotency means that the dose must be 10 fold higher than the 
subcutaneous application (Heinemann et al, 2001). 
Although the inhalation route is more rapid than the subcutaneous, there are 
concerns relating to compromising lung capacity or damage in lung tissue. This 
can be caused by infra-alveolar deposition of insulin within the lung due to long 
term usage, since insulin is known to have growth-promoting properties. The 
long-term safety of these products has yet to be fully established and this has 
slowed progress towards a commercial product. 
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Chapter 2: Literature Review 
Alternative methods such as implantation, transdermal and transmucosal passages 
can optimise effects and reduce side effects. The type of delivery used is 
predetermined by the type and site of the particular condition, as well as the active 
drug to be delivered. Some novel systems are only suitable for local delivery 
whereas others can successfully achieve systemic distribution of the drug. 
2.3.5 DRUG IMPLANTATION 
Implants are one of the dosage forms used to achieve effective sustained 
concentrations for long term release. These devices are useful for patients having 
difficulty in taking drugs orally, and therefore avoid frequent dosage by sustained 
supply (Wakiyama et al., 1982; Juni et al., 1985a; Juni et al., 1985b; Okada et al., 
1991; Sasabe, 1994; Kunou et al., 2000 and Birnbaum et al., 2000). These 
devices are particularly useful, in the case of time-dependent drugs, as it is 
therapeutically essential to maintain the drug concentration above the effective 
lower limit for a long time, avoiding excessive drug concentration (Shimoyama 
and Kimura, 1972; Aoshima et al., 1976; Hirano et al., 1984 and Okada et al., 
1994). The carrier vehicles for implants must be biocompatible. Both 
biodegradable and non-biodegradable polymers are often used as carrier vehicles 
(Okada et al., 1991; Kunou et al., 2000 and Birnbaum et al., 2000). 
The most successful implants to date have been the family of implantable 
contraceptive devices (Olsson et al, 1987). Norplant® was the first in the series 
for delivering levonorgestrel, at efficacious levels, from the time of implantation 
up to periods of 5 years (Qureshi and Attaran, 1999; Sivin, 2003). Orthopaedic 
implants have also seen the introduction of delivery of species such as antibiotics 
(Sanchez et al, 2001; Soriano and Evora, 2000) and bone inducing agents. 
However the problem with these implants is that they may cause an inflammatory 
response around them and implant infections can be extremely resistant to 
antibiotics and host defences (Schierholz and Beuth, 2001). These infections 
frequently persist until the implant is removed, which involves revision surgery in 
some cases. 
More recently, biodegradable polymers have been used to avoid the problems 
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associated with removal of the non-biodegradable polymer implants. These 
degradable implants are used for a more targeted or localized delivery of drugs. 
Examples include the delivery of Oculex pellets, an anti inflammatory 
biodegradable system, which has been clinically proven to reduce post cataract 
surgery inflammation (DDS; Oculex pharmaceuticals, Inc, Sunnyvale, CA) (Tan 
et al, 2001). ' They have also been used for specialised and specific delivery, for 
example the delivery of anticancer agents in the brain, by passing the blood brain 
barrier (Brem et al, 1995). Highly toxic and insoluble chemotherapy drugs for 
cancer treatment, such as Camptothecin, can be delivered locally to the brain 
tissue in high doses without causing systemic side effects (Berrada et al., 2005). 
Also with the introduction of in situ delivery, the implant can be injected, in the 
liquid form, to the required site where the material sets, removing the need for 
surgery. These studies have demonstrated positive indication in delaying the 
growth of the tumour, hence this method may be used for the delivery of other 
insoluble drugs such as Taxol, another anticancer agent (Berrada et al., 2005). 
2.3.6 TRANSDERMAL DELIVERY ROUTE 
The skin offer's potential as both a local and systemic drug delivery site via 
topical applications using gels, ointments and patches. This is a convenient route 
for patients due to the ease of administration. Patches can provide a sustained 
release of drugs from the device, although permeation across the skin is not 
controlled. Several drugs have been delivered in this manner, For example via 
Nicotine patches (NicoretteTM) (Karnath, 2002), contraceptive patches (Othro 
EvraTM) (Zieman, 2002) and scopolamine patches (ScopodermTM), (used to 
prevent motion sickness) (Clissold and Heel, 1985), which are already 
commercially available. 
The skins primary function is protection and as such it is designed to act as a 
barrier to prevent the transfer of species into the body. Hence there are limitations 
in the transport of active agents across the skin. A schematic cross-section of the 
skin is presented in Figure 2.2, with different layers identified according to their 
role in influencing skin permeability through various pathways. The stratum 
corneum is a unique biomembrane and forms the least permeable part of the skin. 
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This is mainly due to the highly organized structure of the stratum corneum. In 
order to achieve systemic delivery, suitable quantities of the drug need to be 
transported through the skin, for which certain structural changes must be made to 
the skin by the drug/delivery system (Barry, 2001). 
There are two major pathways by which transport of the drugs can occur across 
the barrier membranes (e. g. epithelial membrane); transcellular (intracellular) and 
paracellular (intercellular) pathways (Rathbone and Tucker, 1993; Narawane and 
Lee, 1994) as shown in Figure 2.2 and highlighted in Figure 2.3. Although much 
of the research has been carried out using skin, the two processes also apply to 
most mucosal barrier membranes (e. g. oral mucosa) (Senel and Hincal, 2001). 
The transcellular route involves the drug molecules crossing the cellular 
membranes alongside polar and lipid regions (Figure 2.3). This encourages the 
transport of moderately and highly lipophilic molecules to passively diffuse 
through using this pathway. The paracellular route is the result of passive 
diffusion through the extracellular lipid area. It is generally recognized that the 
lipid matrix of the extracellular space plays an important role in the barrier 
function of the paracellular pathway, especially when the compounds are 
hydrophilic and have a high molecular weight, such as peptides (Rathbone and 
Tucker, 1993). 
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(b) 
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comeum 
Epidermis 
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Figure 2.2 Pathways for skin absorption of drugs (a) and potential pathways 
achieved by various topical drug delivery systems (b). Key: 1, intercellular 
pathway; 2, intracellular pathway; 3, appendageal pathway; 4, drug release from 
immobilized multilamellar liposomes with drug diffusion through skin, or, 
alternatively, penetration of intact liposome through skin; 5, drug delivery via 
biphasic lipid vesicle penetration and mixing with skin lipids; and 6, drug delivery 
via transfersomes (small deformable lipid vesicles) 
Drugs may use both routes simultaneously but one is usually preferred over the 
other, depending on the physicochemical properties of the diffusant. Hence, the 
route which provides least hindrance will be the one that dominates' (Senal and 
Hincal, 2001). The transcellular route is generally the most important route for 
drug delivery, except in transdermal drug delivery, where the paracellular 
transport is most important since the drug travels through the pores and hair 
follicles. 
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Figure 2.3: Transcellular and paracellular transport across epithelial cells 
2.3.6. a METHODS OF ENHANCING DRUG PERMEATION 
In general, various enhancement strategies have been explored to deliver 
therapeutically relevant quantities of drug systemically for all routes. They 
include physical methods such as iontophoresis (Singh and Bhatia, 1986), 
enhancing the metabolic stability of the drug (Walker et al., 2002), and addition of 
permeation enhancers (Chataraj and Walker, 1995). 
2.3.6. a. i PHYSICAL ENHANCEMENT 
Physical enhancement can be achieved by stripping, scraping or application of an 
electrical field across the epithelium (Hoogstraate and Wertz, 1998). Stripping, 
involves removal of the epithelium by using an adhesive, thereby reducing the 
thickness of the barrier. Scraping again results in removal of the outer cells from 
the epithelium using a spatula or an instrument of a similar type (Hoogstraate and 
Wertz, 1998). 
A recent review by Langer (2004) has reported that there are two novel physical 
mechanisms (iontophoresis and ultrasound) which are currently being applied to 
circumvent the physical barrier of the skin. Iontophoresis is referred to as the 
application of small amounts of physiologically acceptable electrical current to 
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accelerate the permeation process of ionic drugs (Singh and Roberts, 1989; Green 
et al, 1991; Singh and Bhatia, 1996). This method has been mainly researched for 
transdermal systemic delivery. of ionic drugs including proteins and 
oligonucleotides (Barry, 2001; Banga and Prausnitz, 1998). Iomed Inc. 
(http: //www. iomed. com) has developed Phoresor®, for the administration of 
iontocaine (using iontophoresis), for local dermal anaesthesias. 
Ultrasound is the application of high frequency sound waves which perturb the 
polymer chains within the delivery device, increasing the release. This method 
can be used to control release of drugs (Kost et al., 1989; Lavon and Kost., 2004). 
Another approach to transdermal drug delivery is the development of 
microneedles, which create microscale pathways across the skin improving its 
permeability (Henry et al, 1998; McAllister et al., 2000). 
Although these advances are promising they still require substantial development 
for regular use by patients. There are also other factors which affect the delivery 
rate, such as the skin thickness and blood flow, which varies with age. These can 
have significant effects on the pharmacokinetics of transdermal delivery systems 
(Moore and Chien, 1988). Hence the dosage required may vary from one patient 
to another; a therapeutic dose for one patient can cause systemic toxicity in others, 
particularly when applied to damaged skin, such as burns or cuts (Marquardt, & 
Grubor, 1986). There still remains a need for an alternative delivery system, for 
the systemic delivery of drugs, avoiding the degradation of the active agents and 
patient compliance. 
2.3.6. a. ii PERMEATION ENHANCERS 
Permeation enhancers are chemical substances that are added to pharmaceutical 
formulations, in order to increase the mucosal membrane permeation rate or 
absorption route of a co-administered drug. They are usually added to drugs 
which normally have poor membrane permeation properties, in order to increase 
their bioavailability (Chataraj and Walker, 1995). The theoretical and practical 
effects of permeation enhancers, on the kinetics of absorption, have been 
investigated for a number of years, mainly for delivery across the skin (Guy et al., 
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1987). 
Ideally, the chemicals which are used as permeation enhancers should be safe, 
non-toxic, pharmacologically and chemically inert, non irritant and non allergic 
(Aungst, 1993). In addition, the tissue should revert back to its' normal integrity 
and barrier properties, upon removal of the chemical. 
The cellular morphology, membrane thickness, enzyme activity, lipid composition 
and potential interactions, all contribute to the effectiveness of the enhancers 
which vary from site to site (Lee et al, 1991). Permeation enhancers may act in 
various manners, for example by reducing the enzyme activity so that drugs do 
not degrade (Walker et al, 2002), perturbing the membrane lipids (Figure 2.5 pg 
32) and upsetting the cell-cell adhesive (Hoogstraate, 1996a; Hoogstraate et al., 
1996b). 
2.3.7 TRANSMUCOSAL DELIVERY ROUTE 
The transmucosal route is another option for drug delivery and structurally it is 
very similar to the skin. However it lacks the highly organized stratum corneum 
layer, which causes the greatest hindrance in the transport of drugs across the skin 
(Figure 2.4, pg 28). As discussed earlier in Section 2.3.3 the nasal mucosa is the 
most frequently used transmucosal site, followed by the oral mucosa. There are 
various other mucosal sites for delivery, which have been reported, such as rectal 
(Murakami et al, 1984), vaginal (O'Hagan and Blum, 1990), and ocular mucosae 
(Saettone and Salminen, 1995). These offer certain advantages; however the poor 
patient acceptability associated with these sites renders them reserved for local 
applications rather than systemic drug administration. 
2.3.8 MUCOSAL SITES IN THE ORAL CAVITY 
The mucosal sites within the oral cavity also provide alternatives to delivery via 
the peroral route. There are three different sites which have been identified as 
suitable for drug delivery: (i) sublingual: delivery of drugs through the mucosal 
membranes lining the floor of the mouth, (ii) buccal delivery: administration 
through the mucosal membranes lining the cheeks (buccal mucosa) and the lower 
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and upper lips, and (iii) local delivery, to the tissues in the oral cavity (Swai, 1997 
and Sample, 2001). The latter has already been investigated and current 
applications include treatment for toothache (Ishida et al, 1982) and bacterial and 
fungal infections (Samaranayake and Ferguson, 1994) amongst others. However 
the sublingual route is by far the most widely studied of the three routes and has 
achieved commercial success with rapidly dissolving tablets, such as glycerol 
nitrate used for angina (Silber, 1990). Such systems create a very high drug 
concentration in the sublingual region before the drug is systemically absorbed 
across the mucosa. The sublingual route is suited for rapid drug absorption due to 
its higher permeability and hence it is used in the treatment of acute disorders, as 
the speed of onset is rapid. It is a convenient, accessible, and generally well- 
accepted route (Harris and Robinson, 1992). 
2.4 Tim BUCCAL MUCOSA 
The interest in buccal drug delivery is comparatively more recent. The 
developments in biotechnology, which have made peptides readily available for 
therapeutic use, have made routes such as this an attractive alternative. The 
buccal mucosa is highly vascularised and has direct drainage of blood from the 
buccal epithelium into the internal jugular vein (Lamey and Lewis, 1990). This 
enables peptide drugs to bypass the liver circulation initially and avoid pre- 
systemic degradation in the GI tract; these drugs can be delivered directly to the 
systemic circulation due to them having a problem with post ingestion breakdown. 
This gives a more rapid onset of action with a reduced but effective dosage in 
comparison to the peroral route (Shojaei, 1998). 
The buccal mucosa is four times more permeable than skin (Hoogstraate and 
Wertz, 1998), however it is less permeable when compared to the sublingual 
route. This results in a slower absorption of the drug, into the bloodstream 
compared to the latter (Harris and Robinson, 1992; Gandhi and Robinson, 1994), 
which is more suitable for treatment of chronic disorders where prolonged release 
of the active substance is required. Also the buccal mucosa route presents a 
reduced enzymatic activity with respect to intestinal, rectal and nasal mucosa and 
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is less sensitive to damage and irritation than the nasal epithelium. The buccal 
mucosa also has an expanse of smooth muscle and is relatively immobile 
compared to sublingual mucosa, which makes it a more desirable region for 
retaining systems (such as patches) used for oral transmucosal drug delivery. In 
contrast, the sublingual mucosa lacks smooth muscle and has constant 
accumulation of saliva making it improbable for attachment of any systems. 
2.4.1 THE LIMITATIONS OF THE BUCCAL MUCOSA 
There are two main limitations holding back the progress of the use of the buccal 
mucosa delivery route. Firstly, it is the inability of a delivery vehicle to adhere to 
the buccal mucosa, for a sufficient length of time. This affects the ability to 
achieve and maintain a therapeutic drug concentration, which will be discussed 
later. Secondly, the low membrane permeability for various species is an 
important limitation, since this prevents it from being among one of the most 
effective routes and hinders its use for systemic drug delivery (Hoogstraate and 
Wertz, 1998). Knowledge of the permeability barrier, transport pathways and 
transport mechanisms of the human buccal mucosa is important for the 
development and optimisation of drug and drug delivery systems intended for 
buccal administration. 
The oral cavity is lined by several types of epithelia, all with different 
permeability characteristics, determined by whether they are keratinized or non 
keratinised (Figure 2.4). In vivo studies of drug transport across the human buccal 
epithelium was studied, using animal tissue (Hoogstraate et al., 1994; Hoogstraate 
et al., 1996a; Garren and Repta, 1988) and cell culture models based on human 
buccal epithelial cell line (Jacobsen et al, 1995), revealed a more non-keratinised 
stratified epithelium (Figure 2.4b). The keratinised epithelium is present in skin 
and other regions of the oral cavity such as the gingivia and palate. 
27 
Chapter 2: Literature Review 
KERATINISED 
Keralini 
Laycr 
Superficial 
Layer 
Intermediate 
Layer 
Layer 
MCG tusin; 
Membrane 
j with cell coating 
y plasma 
Granules ýJy 
4 
01 
membrane 
Prickle-cell 
A 1' 
a) 
Membrane- 14 
coating 
Granules 
Prickle-cell 
Layer 
Basal Layer 
b) 
MCG fusing 
with cell 
plasma 
membrane 
Figure 2.4: The major structural changes during maturation in a) keratinised 
epithelium b) non-keratinised epithelium in the oral cavity (based on Squier, 
1984) 
The primary function of the buccal mucosa is to protect the underlying structure 
from foreign agents, similar to skin. Although the buccal mucosa lacks a 
cornified surface present in the keratinized epithelium, the primary barrier 
function of the buccal epithelium depends upon the stacks of lipid lamellae. 
These are present in the intercellular spaces between the epithelium surface and 
the connective tissue, alongside water and proteins (Squier et al, 1991). The lipid 
lamellae are derived from small organelles called membrane coating granules 
(MCG) or lamellar granules, when cells undergo differentiation. Such granules 
migrate to the apical surface of the cell where their membrane fuses with the cell 
membrane (Squier, 1977), and the lipid content is extruded in the intracellular 
space (Gandhi and Robinson, 1991) (Figure 2.4). 
In 1969, Schreiner and Wolfe used a tracer to demonstrate the location of the 
NON KERATINISED 
Intercellular 
space 
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permeability barrier in the epidermis of skin. Following this, similar studies were 
carried out on oral mucosa, using large molecular weight tracers, such as 
horseradish peroxidase (Squier, 1984) and lanthanum nitrate (Squier and Rooney, 
1976), applied topically. When applied to the outer surface of the epithelium the 
tracer only penetrated the outermost layer of the epithelium. However, when 
applied to the sub mucosal surface, it permeated up to the region where the 
MCG's first appeared, but not into the outermost cell layers. This indicates that 
the flattened surface cell layer at the top is permeable. It is specifically the 
presence of MCGs below these, which act as the barrier. 
The buccal mucosal barrier must be overcome for the systemic delivery of the 
drugs. In general the trans-epithelial permeation of drugs through the buccal 
epithelium is considered to be passive and via the paracellular pathway (Gandhi 
and Robinson, 1994; Ho et al., 1992). It is thought that the epithelial cell 
membranes are rather lipophilic and hence may pose a barrier to polar hydrophilic 
permeants. Therefore hydrophilic molecules probably permeate the buccal 
mucosa via the paracellular route (Shojaei, 1998). This has been confirmed by the 
observation of tracer compounds staining only the intercellular spaces, using 
electron microscopy (Squier and Rooney, 1976). More recently, confocal laser 
scanning microscopy (CLSM) has been used to determine the route of transport of 
fluorescently labelled dextrans, and it was shown that these hydrophilic 
macromolecules also penetrated the oral mucosa via the paracellular route 
(Hoogstraate et al, 1994; Hoogstraate et al, 1996a). This information may 
indicate only the paracellular route is active in the buccal mucosa but highly 
lipophilic compounds may become associated with the cellular membrane lipids 
and pass via the transcellular route (Nicolazzo et al., 2005). In addition to the 
above there has been a suggestion of a specialised active transport system for 
cephadroxylan, an aminocephalosporin antibiotic uptake in the human buccal 
membrane by Kurosaki et al (1992). 
Several in vivo investigations of drug delivery in a definite oral region or in a 
specific oral area have employed a filter paper disk (Pimlott and Addy, 1985), a 
perfusion chamber mechanically attached to the buccal mucosa (Ho et al, 1992; 
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Rathbone 1991), and different buccal adhesive formulations (reviewed by Smart 
1993). However these have a disadvantage in that they only provide information 
regarding the release of the drug from the devices and not the actual amount 
reaching the systemic circulation. 
Knowledge of the route taken by the permeant is important since it allows the 
investigator to use the appropriate enhancer to limit the efficacy of the barrier 
present in the buccal mucosa for the systemic delivery of drugs. 
2.4.2 METHODS OF ENHANCING BUCCAL DRUG PERMEATION 
2.4.2.1 METABOLIC STABILITY OF THE DRUG 
A number of peptide drugs have been shown to degrade in the buccal tissue, 
including insulin (Yamamoto et al, 1990), enkephalin analogues (Kashi and Lee, 
1986), thyrotropin releasing hormone (Dowty et at., 1992), and calcitonin 
(Nakada et al., 1987). If the metabolic degradation of peptides can be reduced, 
then it may increase the possibility of them being transported through this tissue. 
This may be achieved by the use of pro-drugs or co-administration of enzyme 
inhibitors. 
A study by Walker et al., (2002) investigated the metabolic barrier of the mucosal 
surface, which revealed aminopeptidase as the primary enzyme to be active. 
Hence, the incorporation of different aminopeptidase inhibitors, amastatin, 
ethylenediaminetetraacetic acid disodium salt (EDTA) and sodium deoxycholate 
in a bioadhesive delivery system, dramatically inhibited the hydrolysis of Leu- 
enkephalin (an enzyme which contributes to the breakdown of peptide drugs). 
The stabilisation of Leu- enkephalin by these aminopeptidase inhibitors suggests 
that the co-administration of inhibitors in buccal delivery systems could improve 
the bioavailability of the peptide. This would depend on using the appropriate 
inhibitor with respect to the peptide drug involved. 
2.4.2.11 BUCCAL MUCOSA PERMEATION ENHANCERS 
As discussed in section 2.3.6. aii, a permeation enhancer may be incorporated into 
delivery devices to increase the permeation rate of the drugs. However, little 
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research appears to have been done to demonstrate the effects of such chemicals 
with respect to the buccal mucosa. Research on enhancement through other sites, 
such as intestinal epithelia (Junginger and Verhoef, 1998; Aungst, 1999 Ward et 
a!, 2000) and skin (Lee and Yamamoto, 1990; Aungst, 1993), have been carried 
out. 
Permeation enhancers can be divided into many categories according to their 
structure, mechanism of action, and the type of drugs whose permeation they 
enhance. Many of the compounds used for the buccal mucosa, are primarily 
general enhancers which work by compromising the barrier functions. There are 
three main mechanisms via which the disruption occurs. The most common 
mechanism is extracting the membrane proteins or lipids and disarranging the 
lipid bilayer structure (Ganem-Quintanar et al, 1997) (Figure 2.5). The alteration 
of the lipid structure causes fluidisation, creating aqueous channels through which 
the drugs pass through (Lee and Yamamoto, 1990) (Figure 2.6). Figure 2.6 
demonstrates the fuidisation effects of both lipid and polar species, on the lipid 
bilayer. Other mechanisms entail the inclusion of membrane compounds, which 
conduct ionic interactions with charges on the bilayer (Table 2.4). 
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Figure 2.5: The phospholipid bilayer (Natural Toxins Research Center at Texas 
A&M University - Kingsville). 
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Various classes of these transmusocal permeation enhancers such as bile salts, 
surfactants, fatty acids and derivatives, chelators, cyclodextrins and chitosan 
(Aungst and Rogers, 1989; Ishida et al, 1982) have been investigated in vivo and 
in vitro (Senel et al, 2000). A review of all the various permeation enhancers with 
potential for use on the buccal mucosa has been conducted by Serval and Hincal 
(2001). Table 2.4 lists the various classes of chemicals used, and the proposed 
mechanisms of action. 
The most common classes of buccal penetration enhancers used include fatty 
acids that act by disrupting the intercellular lipid packing (Figure 2.6) (Ganem- 
Quintanar et al, 1997) and surfactants. 
A variety of compounds within the surfactants group have been investigated, 
particularly for the enhancement of protein and peptide drugs across the buccal 
mucosa (Hoogstraate et al 1996b; Shin and Kim, 2000). Subsequent to these 
investigations, bile salts have been reported to successfully enhance the 
transmucosal delivery of insulin (Zhang et al, 1994), Calcitonin (Nakada et al, 
1989), Interferon (Steward et al, 1994) and low molecular weight heparin (Ebert 
et al, 1994). Bile salts, a type of surfactants, are present in the intestine, assisting 
in the absorption of lipids and lipid soluble vitamins (Lee and Rorstad, 1990). It 
is thought they act in a similar manner to the fatty acids, for enhancing permeation 
of the drugs (Lee and Kellaway, 2000). 
Among all the different types of bile salts, sodium deoxylate (GDC) showed the 
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best enhancing effect (Shin and Kim, 2000). These effects appeared to depend on 
the concentration of GDC present, with the optimum in vitro level being at 10mM 
(Hoogstraate et al, 1997; Senal et al, 1998). However it also caused irreversible 
tissue damage at similar concentrations (Senal at al, 1994). 
Sodium glycocholate has also been shown to have inhibitory effects on the 
mucosal membrane peptides, in addition to acting as a permeation enhancer. It 
has been shown to inhibit insulin metabolism in homogenates of rabbit nasal, 
buccal, rectal and intestinal mucosal membranes (Yamamoto et al, 1990) and 
inhibit calcitonin degradation on the mucosa (Nakada et al, 1987). This 
contributed to the permeation enhancing effect of the compound. 
A significant problem with the enhancers is that they have a narrow concentration 
range between their ability to increase the permeability and their cytotoxic effects 
(Ward et al, 2000). In general a positive correlation between the toxic and the 
enhancement effects has been established (Quan et al, 1998). Since most 
permeation enhancers act by disrupting the membrane integrity, as described 
earlier, it is highly likely that damage will be caused to the epithelial tissue. At 
times this damage to the lipid membrane can be irreversible, thus leaving it open 
for penetration of toxic agents and other organisms (Hoogstraate et al, 1996b). 
When using a chemical permeation enhancer it is important to consider 
i) the irritation level of the mucosal tissue 
ii) the extent of damage to the tissue and 
iii) the rate at which the damage can recover 
The rate of buccal tissue repair is quicker than other epithelial surfaces, such as 
skin (Harris and Robinson, 1992), since the keratinocytes in the buccal tissue 
maintain a constant turnover of cells in the process of desquamation. However, 
the high cell turnover in this membrane may still not be able to repair the 
irreversible damage resulting from enhancers. Therefore, the search for a 
permeation enhancer, which does not alter tissue integrity, still remains. 
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2.4.3 CURRENT STATUS OF BUCCAL DELIVERY DEVICES 
Various buccal mucosal devices have been investigated over the last decade, 
many of which have been developed for the local delivery of drugs, such as the 
conventional non-steroidal anti inflammatory drugs (NSAID) (Senal et al, 1998). 
The drug has been reported to demonstrate gastric mucosal ulceration when 
delivered through the peroral route hence alternative routes have been 
investigated. A buccal bioadhesive tablet formulation was developed due to 
excellent accessibility, and high patient compliance (Senel et al., 1998). 
Naproxen Sodium (drug) was incorporated in a mixture of hydroxy propyl methyl 
cellulose (HPMC) and Carbomer. The topical form appears to affect localised 
pain positively in comparison to the conventional form (for example tablets); 
however, mucosal irritation occurred from the tablet. Other such drugs which 
have achieved local deliver via this route are Triamcinolone acetonide and 
metronidazole (Miconazole Lauriad®, BioAlliance Pharma) for treatment of 
Oropharyngeal Candidiasis) (Cardot et al., 2004) (Figure 2.7) and local 
anaesthetics such as bupivacaine (Bernardo et al, 2003). 
Systemic delivery of drugs via this route has also been investigated (Tables 2.5 
and 2.6), in the form of adhesive tablets (Davis et al., 1982), patches (Heiber et 
al., 1995; Wong et al., 1999), ointments (Milan et al., 1998), 'gels (Ishida et al., 
1982), polymeric films (Eouani et al., 2001), hydrogels (McNeil and Graham, 
1984) and chewing gum (Woodford and Lesco, 1981). The former two are the 
most popular dosage forms for this site. Alongside these more innovative drug 
delivery systems, such as lipophilic gel, buccal spray (Modi et al., 2002) and 
phospholipid vesicles (Yang et al., 2002) have been recently cited to deliver 
peptides systemically via the buccal route. In particular, some authors proposed 
the use of cubic and lamellar liquid crystalline phases of glyceryl monooleate as' a 
buccal drug carrier for peptide drugs (Lee and Kellaway, 2000). Table 2.5 and 2.6 
summarise some of these drugs which are currently being investigated, on clinical 
trials or already marketed. 
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Table 2.4 Various classes of permeation enhancers with their proposed 
mechanisms (Shojaei, 1998) 
Classification Examples Mechanism Reference(s) 
Surfactants 23-lauryl ether, Polyoxyethylene, Perturbulation Aungst and Rogers, 
Dextran sulfate, Sodium lauryl of intercellular 1988,1989; Steward et 
sulfate, Sulfoxides, Polysorbate lipids protein al, 1994; Oh and 
80, Benzalkonium chloride, domain Ritschel, 1988, Siegel 
Cetylpyridinium chloride, integrity and Gordon, 1985, 
Cetyltrimethylammonium 1986; Kurosaki et al, 
bromide " 1994) 
Other Bile salts Aungst, et at, 1988; 
Surfactants Shojaei and Li, 1997; 
Sodium glycocholate, Sodium Hoogstraate eta!, 
glycodeoxycholate, Sodium 1996; Nakane et al, 
taurocholate, Sodium 1996; Senel et al, 
taurodeoxycholate, Sodium 1994; Hoogstraate et 
deoxylate (GDC) al, 1996; 54, Ishida et 
al, 1981, Shin and 
Kim, 2000 
Chelators Aprotinin, Sodium EDTA, Interfere with Aungst and Rogers, 
Sodium salicylate, Ca 2+ 1988 
Methox salic late 
Fatty acids Methyloleate, Oleic acid, Laurie Increase Manganaro and Wertz, 
acid fluidity of 1996 
phospholipids 
domains 
Cyclodextrin Inclusion of Steward et al, 1994 
membranes 
Others Propylene glycol, Menthol, Coutel-Egros et al, 
Lysophosphatidylcholine, 1992; Aungst and 
Phosphatidyicholine Various Rogers, 1989; Zhang 
alkyl glycosides et al, 1994, Aungst, 
1994 
Azone Kurosaki et al, 1989 
35 
Chapter 2: Literature Review 
Fý k 
w 
Figure 2.7 Miconazole Lauriad® tablet on the buccal mucosa 
(www. BioAlliancePharma. com) 
A novel liquid aerosol formulation of insulin (Oralin, Generex Biotechnology) has 
been recently developed, and it is in clinical phase II trials (Modi et al, 2002). 
This system allows precise insulin dose delivery via a metered dose inhaler in the 
form of fine aerosolized droplets directed into the mouth. Levels of drug in the 
mouth are dramatically increased compared with conventional technology. This 
oral aerosol formulation is rapidly absorbed through the buccal mucosal 
epithelium, and it provides the plasma insulin levels necessary to control 
postprandial glucose rise in diabetic patients. This novel, pain-free, oral insulin 
formulation has a number of advantages including rapid absorption, a simple 
(user-friendly) administration technique, precise dosing control (comparable to 
injection within one unit) and bolus delivery of drug. Another citation of insulin 
delivery concerns the use of Phospholipid deformable vesicles, also referred to as 
transfersomes (Yang et al., 2002). They are morphologically similar to liposomes 
but have the peculiarity of responding to external stresses by rapid shape 
transformations requiring low energy. This high deformability allows them to 
deliver drugs across epithelial barriers. To prepare these vesicles, surfactants, such 
as sodium cholate or sodium deoxycholate are incorporated into the vesicular 
membrane. The insulin administration in rabbits surpasses that seen with 
traditional liposomes; compared with subcutaneous administration of insulin 
solution, the bioavailability of deformable vesicles was significantly greater than 
that of the conventional vesicles. 
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Table 2.6 Buccal formulations marketed on clinical trials intended for both 
mncosal (local) and transmucosal (svstemic) administration 
Brand Active 
Effect Functional agent Company 
name ingredient 
Aphtach Triamcinolone Local Hydroxypropylcellulose 
Teijin Ltd 
(tablet) acetonide (mouth) Polyacrylic acid 
Buccastem 
Xanthan gum Reckitt 
buccal Prochlorperazine Systemic 
Povidone Benkiser Plc 
(tablet) 
Oralin- Generex 
Generex Insulin Systemic Unknown Biotechnology 
(solution) (Phase II trials) 
Local (mouth BioAlliance 
Lauriad 
Miconazole and Unknown Pharma (Phase (tablet) 
oropharynx) III trials) 
Carbomer 934P Ardana 
Striant SR 
Bioscience Ltd 
buccal Testosterone Systemic 
Hypromellose 
(tablet) 
i Polycarboph l 
Suscard 
Glyceryl Forest 
buccal Systemic Hypromellose 
trinitrate Laboratories 
(tablet) 
As noted in Tables 2.5 and 2.6 a range of drugs are being investigated for use via 
the buccal mucosal route. Most of these novel formulations use permeation 
enhancers to achieve delivery and all require adhesion to the mucosa. One such 
formulation was investigated to deliver Antisense Oligonucleotides genes, due to 
the current restrictions of delivering these via traditional routes, which cause 
degradation of these molecules (Jasti et at., 2000). The addition of a permeation 
enhancer, sodium glycocholate to the formulation, appeared to enhance the 
delivery further, by effectively decreasing the resistance of the paracellular 
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pathway. However, even with the addition of the enhancers only some drugs 
achieve satisfactory passage across the buccal mucosa. 
2.4.4 DEVELOPMENT OF A BUCCAL MUCOSAL DELIVERY SYSTEM 
The study of the mechanisms of interaction between the formulations of the 
delivery device and the mucosa is fundamental to the design and development of 
these new materials with improved performances. The main considerations which 
need to be taken into account for the development of a delivery device are: 
1. The active species should be able to maintain its therapeutic effect within 
the carrier system 
2. The controlled release of the active species from the delivery vehicle to the 
mucosal surface needs to match the rate of transport across the mucosal 
surface. The concentration at the interface should be optimum for both 
processes to work. 
3. The system needs to be able to be retained on the mucosa for a sufficient 
period of time for the drug to transfer across. 
4. A steady rate of systemic drug delivery across the mucosal surface is 
required so that the therapeutic concentration can be maintained at the 
plasma level. 
Figure 2.8 illustrates a model where various stages of delivery of the active 
species are highlighted. Here the carrier system (delivery vehicle) containing the 
active species absorbs fluid and the active species dissolves slowly in the fluid. 
This solution (fluid containing drug) diffuses out into the interface where it 
accumulates and crosses the mucosa/skin epithelia. This process is complex as 
demonstrated by the limited number of systems available on the market, or under 
clinical evaluation. 
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Patch containing drug 
Flow of 
Drug ---. 
º 
Mucosal surface 
Blood circulation 
Figure 2.8 A model demonstrating the drug delivery stages across the mucosal 
surface 
2.5 CONTROLLED DRUG DELIVERY 
As shown in Figure 2.9 one of the disadvantages with the traditional methods of 
delivery (i. e. tablets) is the irregular plasma-time profile. The irregular dosing can 
reduce the efficacy of the drug and often lead to resistance of the body to a 
particular drug. More significantly there are side effects associated with the rise 
of the drug concentration beyond the maximum effective concentration (MEC), 
however when the concentration falls below the minimum therapeutic 
concentrations (MTC), therapeutics effects are unlikely. Regular dosing can 
control the peaks and troughs to a certain degree however this requires strict 
patient compliance, particularly for certain drugs such as anti-asthmatic (Lemmer, 
1994), anaesthetic (Shin and Yoon, 2002), cardiovascular (Wei et al., 2007) and 
anti cancer (Hrushesky, 2001). 
The prolonged drug delivery at a steady state is termed controlled release; it also 
implies predictability of the release kinetics (Robinson and Lee, 1987). 
Controlled release involves devices where the formulation controls the release of 
the drug hence, absorption of drug occurs in a predictable manner (Peppas, 1997). 
From the early 1930's, attempts to develop sustained release drug delivery 
systems were made, by reducing the solubility of the drug and combining the drug 
with suitable substances, to slow down the rate of drug release, as described by 
Tenenbaum (2002). Other attempts involved coating the drug with materials 
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resistant to stomach acid, compressing into dense tablets or placing into 
suspensions and emulsion (Langer, 1990). These methods sustained the drug 
release process by slowing down the dissolution of drug and hence its transport in 
the blood stream. 
(a) 
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(c) Drug Release Profile 
Plasma Maximum Effective 
Concent- Concentration (MEC) 
ration 
-Meal Drug Release 
\Minimum 
Therapeutic 
Concentration (MTC) 
Repeat dosage 
Time 
Figure 2.9 Drug levels in the blood with (a) traditional drug dosing and (b) 
controlled-delivery dosing (c) Conventional and ideal drug release profiles 
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Development of these systems led to research into controlled release devices using 
polymers. In the 1950's, a device was created, which produced longer term and 
controlled release of drug, at safe and efficacious levels, by Langer and Folkman 
(1976). However the amount and rate of release was affected by patient variations 
and factors such as pH of GI tract, hence repeated dosing was still required in 
some cases (Langer and Peppas, 1981). 
Controlled release systems are designed to deliver a single constant therapeutic 
dose of drug directly to, or in the vicinity of, the area requiring treatment. If a 
delivery device, which is capable of controlled delivery, can be developed, the 
frequency of the dosing may be reduced. Extreme boundaries of drug levels in the 
blood system, ranging from toxic to ineffective levels are eliminated, due to a 
constant, predictable and reproducible release of the drug by sustained release 
systems (Langer 1990). The maintenance of optimum therapeutic drug 
concentration in blood or in a cell is important, particularly in cases such as heroin 
addicts, where narcotic antagonists are administered to block the euphoric effect 
of heroin and prevent re-addiction (Milne et al., 1979). 
The side effects relating to a drug are mainly caused by accumulation at non- 
target sites, in addition to the intended sites, leading to wastage, reducing the 
efficacy of the drug and causing secondary effects which may not be desirable 
(Rawls, 1991). 
The shortcomings of traditional drug administration can be improved by well- 
designed drug delivery devices. These systems also have other advantages, such 
as shielding biologically sensitive drugs or proteins until the time of their release, 
and permitting a broader range of molecules to be used (Langer 1990). They can 
enhance the activity duration for short half-life drugs, such as benzodiazepines 
and diazepam, due to improved delivery to the required site (Canon, 1979), as 
well as improved patient compliance and, in certain cases, increased patient 
comfort, due to all the aforementioned advantages (Rawls, 1991). In turn this 
would reduce the costs related to the health care, since the need for follow up by 
the healthcare professionals is reduced (Rawls, 1991). 
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2.5.1 DISADVANTAGES OF CONTROLLED DRUG DELIVERY 
There are some disadvantages associated with controlled release systems 
discussed by Langer and Peppas (1981). Some controlled delivery devices, such 
as implants, may require a surgical procedure to place them in the appropriate site. 
This can cause patient inconvenience and the removal of the implant would be 
difficult, if treatment was required to be halted. At times, the presence of the 
implant can be painful for the patient and leakages may occur, causing localised 
toxicity. The biodegradable polymers can cause side effects on degradation, 
resulting in products which maybe harmful. Also the polymeric carrier may not 
be biocompatible. 
Overall, the cost of developing these complex, controlled delivery systems and 
administering them would increase the cost of the drug (Shastri, 2002; Kefalides, 
1988). 
2.5.2 POLYMERS FOR CONTROLLED DELIVERY DEVISES 
Focusing on novel means of delivering pharmaceutical agents increases the 
potential of overcoming many of the problems associated with drug 
administration. The development of these novel controlled delivery devices has 
been possible due to the amalgamation of polymer science with pharmaceutical 
science. This is due to the versatility and adaptability, in terms of physical state, 
shape, size, and surface of the polymers, offering scope for an almost infinite 
variety of structures for drug delivery (Pillai and Panchgnula, 2001). 
Langer introduced the use of polymers in drug delivery. A biodegradable 
synthetic polymer based drug delivery system was developed using polyglycolic 
acid (PGA) (Langer, 1990), which lead to heightened interest in the design and 
synthesis of novel polymers. Polymer pellets of PGA were prepared, which had 
an intricate porous structure that allowed the diffusion of the large drug molecules 
(Chien, 1982). This polymer system had been the basis for most of the recent 
developments of polymeric drug delivery technology. 
Both natural and synthetic polymers are available for development however 
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synthetic polymers are generally favoured, with their wide variety of compositions 
and readily adjustable properties (Dunn and Ottenbrite, 1991) (Table 2.7). These 
polymers feature in the delivery systems either as molecular carriers for drugs, 
where they modify the disposition and improve absorption of the drug, or as 
matrices for implants and tablets for modified and controlled release. Table 2.7 
lists the various types of polymers currently used or studied for controlled drug 
delivery. The synthetic polymers can be broadly classified as biodegradable and 
non-biodegradable. 
Table 2.7 A representative list of the various classes of polymers used in 
drug delivery 
CLASSIFICATION POLYMER 
Polyesters Poly(lactic acid), poly(glycolic 
acid) 
Polyanhydrides Poly(sebacic acid) anhydride 
Polyamides Polyamino acids 
Biodegradable Phosphorus-based Polyphosphates, 
polymers polyphosphazenes 
Others Poly(cyano acrylates), 
polyurethanes, polyortho 
esters, chitosan 
Cellulose derivatives Hydroxypropyl methyl 
cellulose, carboxymethyl 
cellulose, Collagen, 
polysaccarides, alginates Non-biodegradable 
Silicones Polydimethylsiloxane, 
Acrylic polymers Polymethacrylates, 
Others Polvinyl pyrrolidone, ethyl 
vinyl acetate, cyclodextrans, 
Cyclodextran is a natural polymer; it has been studied closely, due to its ability to 
act as a drug carrier. It forms a complex, in a solution and a solid, enveloping the 
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drug, and thus protecting it from physical and chemical damage. Natural 
cyclodextrans have had widespread usage; many derivatives have been developed 
to expand their physiochemical properties and inclusion capabilities (Szente and 
Szejtli, 1999). Polysiloxanes have been used for sub-dermal implants, to deliver 
water-soluble drugs and steroids, due to their physical properties such as 
flexibility, hydrophobicity and biocompatibility (Siepmann et al., 1999). 
2.6 CONTROLLED RELEASE DEVICES 
There are two main factors to consider when developing a controlled drug release 
system, the kinetics and the mechanism of drug release. 
2.6.1 KINETICS OF DRUG RELEASE 
The kinetics profiles can be summarised into three categories: 
i. Diffusion controlled, whereby the amount released (Mt) is a t/ 
ii. Zero or 
iii. First order 
ii) and iii) are terms which have been taken from Physical Chemistry, i. e the 
various types of chemical reaction kinetics 
dc/dt = kc" Equation 2.1 
Equation 2.1 relates to the rate of decomposition of a single compound, and k is 
termed the rate constant. 
By analaogy with chemical terminology, Mt now defines the quantity of drug 
remaining in a drug delivery device at time t: 
dMt/dt = kM, ", Equation 2.2 
where n=0 or 1 respectively for zero or first order. 
When n=0: 
dM, /dt =- k Equation 2.3 
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i. e. the rate is constant with time and Mt is proportional to time. 
Integrating Equation 2.3 gives: 
Mt =-kt+A Equation 2.4 
where A is a constant of integration. 
If Mo is the amount of drug at t=O, then A=Mo, and : 
Mt = Mo - kt Equation 2.5 
Noting 0< t5 1/k( Mo-Me) 
or the amount released (A) Mo-Mt. =kt Equation 2.6 
Now if n=1, 
dMt/dt = -kMt Equation 2.7 
To solve this first separate the variables and integrate: 
f dMt/Mt =-k 
f dt 
hence loge Mt = -kt +B Equation 2.8 
When t=0, Mt =Mo and :B =loge Mo, and Equation 2.7 becomes: 
loge M, = -kt +logeMo 
or logM, /Mo =-kt 
whence Mt = Moe k` 
or the amount released A= Mo-Mc = Mo(1-e A) Equation 2.9 
The classification of a delivery device into one of these kinetics types only implies 
that it is the predominant route, since one kinetic process does not occur 
exclusively (Bibby et al, 2000). 
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2.6.2 MECHANISMS OF DRUG RELEASE 
2.6.2. a DIFFUSION CONTROLLED SYSTEMS 
In diffusion controlled drug delivery systems, an active agent is released from a 
polymeric device by permeation from its interior to its surrounding environment. 
The diffusion can occur on a macroscopic scale, through pores in the polymer 
'matrix or on a molecular level, by passing between polymer chains. The rate of 
release is governed by the diffusion rate of the active agent. There are two main 
types of diffusion controlled systems, matrix and reservoir systems. Examples of 
diffusion-release systems are shown in Figure 2.10 (Peppas, 1985). 
2.6.2. a. i MATRIX SYSTEMS 
Generally, in matrix systems, the drug is uniformly distributed throughout the 
polymer to form a homogeneous system (Figure 2.10i). Diffusion occurs when 
the drug passes from the polymer matrix into the external environment. As the 
release continues, its rate normally decreases with this type of system, since the 
active agent has a progressively longer distance to travel and therefore requires a 
longer diffusion time to release. Langer (1990) has suggested that the release 
process obeys Fick's laws of diffusion, following t' kinetics (see section 2.7.4. a). 
2.6.2. a. ii RESERVOIR SYSTEMS 
The reservoir system (Figure 2.10ii, Langer, 1990) consists of a core of drug 
surrounded by a swollen or non-swollen polymer film membrane. The drug 
delivery rate can remain fairly constant since a reservoir, whether solid drug, 
dilute solution, or highly concentrated drug solution within a polymer matrix, is 
surrounded by a film or membrane of a rate-controlling material, The only 
structure effectively limiting the release of the drug is the polymer layer 
surrounding the reservoir. Since this polymer coating is essentially uniform and of 
a non-changing thickness, the diffusion rate of the active agent can be kept fairly 
stable throughout the lifetime of the delivery system. The system shown in Figure 
2.10ii is representative of an implantable or oral reservoir delivery system, 
whereas the system shown in Figure 2.11 illustrates a transdermal drug delivery 
system, in which only one side of the device will actually be delivering the drug. 
The rate of drug release from the membranes after an induction period is at a 
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constant rate. However, with time, as the drug in the core becomes depleted and 
the latter is saturated with the external solution, the rate of release falls. 
Drug in Polymer 
(::: 
r 
E 
i) 
Free drug 
i; i; } ICI 
MATRIX SYSTEM 
ii) 
Polymer layer 
r 
Drug in core 
RESERVOIR SYSTEM 
Figure 2.10 Cross section of a spherical diffusion controlled release systems i) 
Matrix system ii) Reservoir system (Langer, 1990) 
There are problems associated with reservoir systems; the rupture of the polymer 
membrane will release a large amount of drug in the body with potentially highly 
detrimental effects. Also high molecular weight (>1000) species are unable to 
readily diffuse across these membranes. 
:.: ý ._. 
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Transdermal Drug Delivery 
Rate 
controlling 
polymer with 
drug 
Backing 
Figure 2.11 Schematic representation of drug delivery from a typical 
trandermal reservoir system 
2.6.2. b SOLVENT ACTIVATED SYSTEMS 
It is also possible for a drug delivery system to be designed so that it is incapable 
of releasing its agent or agents until it is placed in an appropriate biological 
environment. The solvent activated release systems are initially dry. When placed 
in the body they will absorb water or other body fluids and swell. The swelling 
increases with the aqueous solvent content within the formulation as well as 
opening the polymer network, enabling the drug to diffuse through the swollen 
network into the external environment. There are two types of solvent activated 
release mechanisms, osmotically controlled and swelling controlled reservoir 
systems (Langer, 1990) shown in Figure 2.12. In an osmotically controlled 
system water permeates into the drug-polymer matrix, due to the presence of an 
osmotic potential, which facilitates drug release (Figure 2.12i). The drug is 
subsequently delivered via pores or other channels in the polymer. 
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i) Osmotically Controlled Matrix 
Polymer form 
Polymer reservoir 
Time 
Drug (dispersed/ 
dissolved) 
ii) Swelling Controlled Reservoir 
(dissolved in polymer) 
Time 
d 
)lved in polymer) 
Figure 2.12 Cross section of spherical solvent controlled release systems: i) 
Osmotically controlled matrix ii) Swelling controlled matrix (Langer, 1990) 
The swelling controlled reservoir system acts in the same manner as the reservoir 
systems. However the influx of fluid causes the transition temperature (Tg) of the 
polymer to be lowered and drug molecules diffuse into the surrounding medium. 
Release follows Case II diffusion theory, as discussed in section 2.7.4. c. The 
Thomas and Windle model (1982) predicts swelling to be a function of the 
exposure time and assumes release to be driven by osmotic pressure. The rate is 
also controlled by the viscosity of the polymer which will be affected as the Tg is 
lowered. 
One of the most remarkable and useful features of a polymer's swelling ability 
manifests itself, when swelling can be triggered by a change in the environment 
surrounding the delivery system, for example water in hydrogels. Depending on 
Drugs released through pores/crack 
Polymer beads swell and 
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the polymer, the environmental change can involve pH, temperature, or ionic 
strength, and the system can either shrink or swell upon a change in any of these 
environmental factors. Most of the materials used in solvent activated release 
systems are based on hydrogels. 
2.6.2. b. i HYDROGELS 
Hydrogels are cross-linked hydrophilic polymers that will swell without 
dissolving when placed in aqueous media. These hydrogels can absorb a great 
deal of fluid and, at equilibrium, typically comprise 60-90% fluid and only 10- 
30% polymer. Despite imbibing large amounts of water they are insoluble 
because of crosslinking and crystalline regions. The hydrophilicity is due to the 
presence of the functional groups such as: -OH, -000H, -CONH2, and SO3H in 
the polymer chain (Peppas and Sahlin. 1996). A number of these environmentally 
sensitive or "intelligent" hydrogel materials are listed in Table 2.8. For most of 
these polymers, the structural changes are reversible and repeatable upon 
additional changes in the external environment. Such swollen hydrophilic 
networks have had a considerable amount of interest for drug delivery, due to 
their high water content and tolerance by the body (Peppas and Barr-Howell, 
1986; Lowman and Peppas, 2000). Hydroxyethyl methacrylate (HEMA) is the 
most common monomer used to produce hydrogels. 
Hydrogels have been shown to have the potential to be used as carriers for the 
peptide drugs, especially insulin (Morishita et al, 2001). Also, hydrophilic matrix 
tablets (Siepmann et al, 1999), prepared by direct compression, using hydroxyl 
propyl methylcellulose (HPMC), have been loaded with drugs such as propranolol 
HCL, acetaminophen and theophylline. More recently, the possibilities of using 
molecular imprinted mechanisms within controlled release gels have been 
explored (Byrne et al, 2002). 
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Table 2.8 Environmentally sensitive Hydrogels for drug delivery 
Stimulus Hydrogel Mechanism 
pH Acidic or basic Change in pH - swelling - release 
hydrogel of drug 
Ionic Ionic hydrogel Change in ionic strength - change in 
strength concentration of ions inside gel - 
change in swelling - release of drug 
Chemical Hydrogel containing Electron-donating compounds - 
species electron-accepting formation of charge/transfer complex 
groups - change in swelling - release of 
drug 
Enzyme- Hydrogel containing Substrate present - enzymatic 
substrate immobilized enzymes conversion - product changes 
swelling of gel - release of drug 
Magnetic Magnetic particles Applied magnetic field - change in 
dispersed in alginate pores in gel - change in swelling - 
microshperes release of drug 
Thermal Thermoresponsive Change in temperature - change in 
hydrogel poly(N- polymer-polymer and water-polymer 
isoproplacrylamide) interactions - change in swelling - 
release of drug 
Electrical Polyelectrolyte Applied electric field - membrane 
hydrogel charging - electrophoresis of charged 
drug - change in swelling -- release 
of drug 
Ultrasound Ethylene-vinyl Ultrasound irradiation - temperature 
irradiation alcohol hydrogel increase - release of drug 
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2.6.2. c CHEMICALLY CONTROLLED SYSTEMS 
All of the previously described systems are based on polymers that do not change 
their chemical structure beyond what occurs during swelling. However 
chemically controlled release occurs either via biodegradable polymers or pendant 
chain systems (Brannon-Peppas, 1995), which does cause change to their 
chemical structure, as described below. 
2.6.2. c. i BIODEGRADABLE POLYMERS 
All of the previously described systems are based on polymers that do not change 
their chemical structure. The interest in biodegradable polymers stems from a 
desire to have biocompatible systems which erode naturally over an appropriate 
time period. These materials degrade within the body as a result of natural 
biological processes, eliminating the need to remove a drug delivery system after 
release of the active agent has been completed. 
Most biodegradable polymers are designed to degrade as a result of hydrolysis of 
the polymer chains into biologically acceptable, and progressively smaller, 
compounds. In some cases as, for example, polylactides, polyglycolides, and their 
copolymers, the polymers will eventually break down to lactic acid and glycolic 
acid, enter the Kreb's cycle, and will be further broken down into carbon dioxide 
and water and will be finally excreted through normal processes. 
Biodegradability in itself does not eliminate toxicity. They may cause an adverse 
effect due to local tissue toxicity, caused by degradation by-products (Heller, 
1985). Hence the search for polymers which, will degrade to small innocuous 
molecules, and avoid high dosage release caused by irregular breakdown of the 
polymer. 
Some early examples of biodegradable polymers include poly(lactic acid) (PLA), 
poly(glycolic acid) (PGA), and poly(lactic acid -co- glycolic acid) (PLGA). 
The polyamino acids (Table 2.7 pg 44) have satisfactory biocompatibility for 
delivery of low molecular weight compounds (Wu, 2004); however they have 
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limited use, due to poor control of release and antigenic potentials. 
Figure 2.14i illustrates the release of drug through a biodegradable polymer 
system. The drug is uniformly distributed throughout the polymer and release 
occurs, in to the surrounding fluid, as the polymer erodes with time. Assuming 
that the amount released by diffusion is negligible, the rate is controlled by the 
speed of the eroding polymer. Advantages of these systems are as follows, the 
delivery device does not need to be removed once maximum release is obtained, 
and if the surface area remains the same then zero order release can be achieved. 
Also they are not required to be water soluble in nature. However, bulk erosion 
may occur, as well as surface erosion, thus making it difficult to achieve a 
predictable release of drug (Acemoglu, 2004). As shown in Figure 2.13 
polyorthoesters, which are surface eroding polymers, have significant surface 
degradation after 9 and 16 weeks of implantation in rabbits, but the core of the 
drug delivery system remains intact (Heller, 1985). 
The mechanical and biological properties of these biodegradable polymers can be 
adjusted by various methods such as altering the stereochemistry, adjusting the 
ratio of copolymer (Heller and Gurney, 1999), alternating the side chains and 
functional groups (Andrianov and Payne, 1998). 
Figure 2.13 Biodegradable polyorthoester rods after (left) 9 and (right) 16 weeks 
of implantation in rabbits. (Heller, 1985) 
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2.6.2. c. ii PENDANT CHAIN SYSTEMS 
Of the drug delivery systems enabling specific drug release, the water -soluble 
polymer-drug conjugates are promising due to their versatility and efficiency 
(Ulbrich et al, 2004). The concept of such macromolecular systems was proposed 
by Ringsdorf, nearly 30 years ago as reported by Neumann (et al, 1987), and 
many research groups are working on the realisation of this original idea. Figure 
2.14ii demonstrates that release occurs via chemical cleavage of the drug 
molecule that is chemically attached to the polymer backbone. Chemical 
cleavage occurs when the polymer is in contact with body fluids, due to the 
presence of enzymes (Kost and Langer, 1992). 
More recently, cationic polymers such as poly(ethylene imine) (PEI) (Bubenik, 
2001) and poly(lysine) have been used to mediate transfection to a variety of 
different cell lines. The problem with using PEI and poly(lysine) is that both 
polymers are extremely cytotoxic, meaning they are not suitable as delivery 
vehicles. Another drawback to using these polymers is their long synthesis 
process. 
Researchers have been working on this approach, particularly for the treatment of 
diabetes for over a decade, however there are few systems which show significant 
progress. An optimum delivery system for diabetes would be one that could 
deliver insulin on detection of glucose in the bloodstream. Currently the systems 
which have been researched are based on the reaction of glucose in the blood with 
glucose oxidase. This causes a lowering of the pH in the delivery systems micro 
environment, leading to swelling of the polymer system and an increased insulin 
release for delivery systems' that are based on copolymers containing N, N 
diethylaminoethyl methacrylate (Leong et al., 1986) or polyacrylamide. It is 
important to note that related alkyl amino methacrylates have been shown to have 
high levels of toxicity (DeVries and Roylance, 1973). Such polymers have been 
studied as the central core of the drug delivery system in which the polymer- 
insulin matrix is surrounded by a membrane containing glucose oxidase, which 
provides the reaction substrate. The rate of insulin release can be adjusted by 
using polymers which are more pH sensitive, such as Polyorthoesters (Heller et 
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al., 1987). There have been other applications for this polymer, such as delivery 
of 5-Fluroracil via the ocular route (Heller, 2005), periodontal delivery systems 
for tetracycline (Heller et al., 2002) and polymeric disks for chemotherapy of 
brain cancer (Piliai and Panchangnula, 2001). The latter was the first Food and 
Drug Administration (FDA) approved polymer-based chemotherapy drug delivery 
system (Kost and Langer, 2001). 
Poly(ß-amino esters) and Poly(ß -amino amides) are ideal polymers for the 
encapsulation delivery, and for the release of various therapeutic agents to cancer 
cells, which have an acidic extra cellular pH level, near 6.8 (Lim et al., 2000). 
These polymers are specifically designed to degrade by hydrolysis of the ester and 
amide bonds respectively, found in the polymer backbone. However a major 
factor affecting the development of these delivery systems is the maintenance of 
the hydrolysable backbone. 
Polyphosphoesters have also been investigated for use as chemically controlled 
pendant chain systems, since they have a unique backbone containing reactive 
phosphorus atoms. A wide-range of compounds can be attached to the backbone, 
as side chains. In turn this increases the ability to modify the rate of degradation 
of the polymer, alongside other properties (Andrianov and Payne, 1998). 
2.6.3 ALTERNATIVE RESPONSIVE SYSTEMS 
The systems discussed in the earlier sections, can be further controlled by external 
stimuli such as ultrasound and the addition of magnetic particles within the drug- 
loaded polymer (Kost et al, 1989). An increased dose of drug can be released by 
applying an oscillating magnetic field to the delivery device, causing the magnetic 
particles to alternate compression and expansion of the matrix channels (Edelman 
and Langer, 1993). The particles strain the matrix, altering the integrity of the 
channels, which may facilitate diffusion and produce sudden bursts of drug 
release from a drug delivery device (Kost et al, 1989). With biodegradable 
polymer systems, when gelatine microspheres were exposed to ultrasound, they 
significantly increased the release of growth hormone (Di Silvio et al, 1994). 
Other stimuli, which polymeric delivery devices may respond to, are electrical 
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potential (i. e. iontophoresis) (Jadoul and Preat, 1997; Banga and Prausnitz, 1998), 
heat (Minko, 2005) and pH (Kalia et al, 2004). 
2.7 TRANSPORT PROCESSES 
This thesis is concerned with polymeric delivery systems based essentially on 
hydrophobic polymers. In such systems it is well known that water uptake is a 
necessary precursor for release. Therefore a review follows on the various factors 
controlling water uptake. These polymeric delivery systems are methacrylate- 
based so relevant methacrylates, used for clinical applications, are reviewed next. 
Because this thesis concerns the transport processes of one system in particular, 
the PEMITHFM system, it is reviewed in more detail. 
2.7.1 WATER SORPTION IN POLYMERS 
Many drug delivery mechanisms for polymers are related to their water sorption 
behaviour (Peppas, 1997). Hydration represents the initial step in the drug release 
process because the presence of water is necessary for diffusion through the drug 
delivery system and drug dissolution. Additionally, particularly for biodegradable 
polymers, it is essential for initiating and sustaining the hydrolytic 
degradation/erosion process of the polymeric matrix (Blasi et al., 2005). 
The water sorption properties of the polymers are not only responsive to the 
chemical composition of the macromolecular matrices, but also to the surrounding 
conditions such as pH, temperature, ionic strength, magnetic field, ultraviolet light 
(Barrie and Machin, 1969; Bajpai and Shrivastava., 2002). 
In terms of composition of a polymer, the presence of amide groups (Auerbach 
and Carnicom, 1991), carboxyl groups (Kalachandra and Kay, 1991) and hydroxyl 
groups have been shown to increase the ingress of water. Also the structural 
arrangement of the polymer molecules has an effect on the water uptake 
(Kalachandra and Kay, 1991). It has been reported that in a low molecular weight 
polymer the molecules are packed closer, resulting in fewer voids within the bulk 
of the material and causing more water resistance (Turner, 1987). 
58 
Chapter 2: Literature Review 
The water absorption characteristics may influence the mechanical and physico- 
chemical properties of the polymer, such as strength and dimensional stability. 
Further, the absorbed water can act as a plasticiser, reducing the glass transition 
temperature (Tg) of the hydrophilic polymer materials, which increases the 
mobility of polymer chains (Hancock and Zografi, 1994). The influx of water 
modifies the solvent permeation properties through some polymers , which can 
result in the ingress of micro-organisms (Wilson and Khomami, 1993). This can 
also reduce the strength of the material and distort the shape of the polymer due to 
swelling (Wilson and Khomami, 1993). The leaching of soluble constituents, 
resulting from the influx of water, also has detrimental effects to the dimensional 
stability and it can compromise the biocompatibility of the materials if the 
leachants are cytotoxic. Hence the water absorption properties of polymers is a 
particularly important property to evaluate. Especially for polymers which 
function in an aqueous environment, such as in the oral cavity or the stomach, 
since it gives an indication of their behaviour in vivo. 
2.7.2 GRAVIMETRIC ANALYSIS 
There have been many methods used to study the movement of the solvent fronts 
through various materials, such as mechanical instrumentation (Caramella et al., 
1989), optical methods, back scattering spectroscopy (Yoshioka et al., 1995), FT- 
IR, NMR imaging and He 3+ ion beam techniques (Chan and Kazarian, 2007; 
Riggs et al., 1999). Image analysis has also been used as a quantitative technique 
to simultaneously measure axial and radial swelling, alongside solvent 
concentration gradients in hydrophilic matrices (Moussa et al, 1998). He 3+ ion 
beam analysis has also been used to simultaneously study water and drug 
transport through a polymer matrix in real time (Riggs et al, 1999). However, 
gravimetric analysis is a useful way of quantifying water absorption 
characteristics for polymers due to its convenience and reproducibility (Barrie and 
Machin, 1969; Kovac, 1948). This technique is particularly useful in qualitatively 
comparing the long term effects of uptake, by comparing the uptake profiles of the 
materials, diffusion coefficients and solubility. Hence, alternative techniques, like 
NMR imaging, are useful in complimenting gravimetric analysis, to provide 
imaging of the water within the material (Artemov et at, 1988; Fyfe et al., 1993; 
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Riggs et al., 2001). 
2.7.3 MECHANISMS OF WATER SORPTION 
There are two aspects of water uptake to be considered: 
i) the kinetics of uptake - this is discussed in detail in 2.7.4. 
ii) the equilibrium amount absorbed - this is discussed in this section. 
There are various mechanisms by which water sorption occurs within a polymer. 
These may act independently but commonly they occur in combination to give the 
final uptake characteristics (Kalachandra and Kay, 1991). Water is present in the 
polymer due to trapping in pre-existing voids within the polymer or by dissolution 
of the matrix following flux of external solution. 
The dissolution of matrix is affected by the hydrophilicity of the polymer 
accompanied by the presence of hydrophilic components within the polymer. 
Electrostatic attraction between the water molecules and the hydrophilic groups in 
the polymer will encourage an influx of water leading to the formation of either 
clusters or droplets (Barrie and Machin, 1969). 
2.7.3. a CLUSTERING 
Starkweather (1975) pointed out that the tendency for absorbed water to form 
clusters in polymers seem to be related to a tension between hydrophilic and 
hydrophobic characteristics. Polyvinylpyrollidone, which dissolves in water, 
exhibits very little clustering. The polymers which demonstrate a high number of 
clusters are those where hydrophobic - hydrophilic tension is most marked 
(Rodriguez et al., 2003). It is in these cases that the water - polymer interaction is 
forced to assume its most highly structured character. Clustering should not be 
confused with droplet formation (see 2.7,3. b); the former occurs at the molecular 
level and involves specific sites in the polymer structure. It doesn't necessarily 
cause opacity since opacity is caused by light scattering, which only occurs if the 
site is greater than the wavelength of visible light. 
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2.7.3. b DROPLET FORMATION 
If a polymer contains water soluble particles such as impurities or additives (e. g. 
fluoride) then the water uptake process is modified. When the water reaches such 
a particle, the latter dissolves and a droplet is formed. Since the concentration of 
impurity in the droplet is greater than the concentration of impurity in the external 
solution, an osmotic potential arises, encouraging further water absorption (Figure 
2.15). This will persist causing the droplet to grow until osmotic and elastic 
restraining pressures equilibrate. 
Drug released into 
at drug particles 
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Figure 2.15 Droplet formation in polymers subsequent to water absorption 
The processes identified in the above diagram indicate there are four basic 
processes involved in the water uptake process: 
i) diffusion of water through the polymer matrix 
61 
i 
Chapter 2: Literature Review 
ii) the dissolution of water soluble moieties to form droplets 
iii) growth of the droplets due to the osmotic pressure developed 
iv) development of an elastic pressure resisting growth. 
These factors have been embraced in the theory due to Muniandy and Thomas 
(1987) (see Section 2.7.4b). From iii) and iv) above, it is evident that equilibrium 
uptake occurs when the osmotic and elastic stresses balance, unless the elastic 
strains set-up cause failure. This latter eventuality has been used to facilitate drug 
delivery (Amsden et al 1994,2003). 
2.7.4 DIFFUSION PROCESSES 
Water absorption in polymers is characterised by a diffusion process (Kovacks et 
al., 1948). In order to quantify water sorption characteristics, following 
gravimetric analysis, diffusion theories are used. These are based on classical 
diffusion theory (Fick, 1855), which has been based on Fourier's equation on heat 
flow (1822). This has been developed further by Barrer (1951), Barrie and 
Machin (1969) and Crank (1975). These authors did not take into account the 
presence of water-soluble impurities (see 2.6.2) or hydrophilic groups within a 
polymer neither that any stress relaxation occurs. See section 2.7.4. b. 
Diffusion can be divided into three distinct classes: Fickian, Case II and 
anomalous/non-Fickian. These are idealised processes and different mechanisms 
may occur and dominate at different times throughout the absorption cycle. 
2.7.4. a FICKIAN DIFFUSION 
The mathematical theory of Fick's law is based on the hypothesis that the rate of 
transfer of the diffusing substance, through a unit area of an isotropic medium, is 
proportional to the concentration (c) and the gradient of the section (Fick, 1855 
and Crank, 1975), (Equation 2.10). 
F= -D 
äC 
Equation 2.10 
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Where: 
F=rate of transfer per unit of section 
c=concentration of diffusing substance 
x=the space measured normal to section 
D=diffusion coefficient. This is temperature dependant and may be expressed as 
Arrehnius type of equation: 
D =-Doe -EIRT Equation 2.11 
Where D° is a pre-exponential term, which involves the entropy of activation, E is 
the activation energy, R is the Universal Gas constant and T is temperature (°C). 
It is generally assumed theoretically that the diffusion coefficient is constant at a 
given concentration of the diffusing species. Experimentally, this may not be the 
case; however it is assumed in order to simplify mathematical solutions. If the 
diffusion coefficient is independent of concentration then Fick's second law 
applies, which has been derived from the first law (Equation 2.10) and Equation 
2.12 is obtained: 
ac a'c 
at -D axe Equation 2.12 
Equation 2.12 can be solved to give c as a function of x and t. Subsequent 
integration of the equation of concentration, in terms of distance and time, gives 
equations for mass uptake (Mt), which can be measured easily using (equation 
2.13). 
Mt/M. = 2[Dt/nl2]'n Equation 2.13 
Where: M = mass uptake at equilibrium 
21 = sample thickness 
Cp = equilibrium concentration = M. /2Al 
A= main surface area of the specimen, ignoring edges 
Mt = mass uptake at time t, 
t= time 
This applies only in the early stages of diffusion, corresponding to the stage 
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before the diffusion fronts, from the two faces, meet and overlap. Equation 2.13 
predicts that the uptake is linear to ty. The plot of Mt/M. versus 0 can be used to 
derive the diffusion coefficient since the slope (s) from the initial linear stage is 
given by 
Dt 
s= Equation 2.14 
For the latter stages of diffusion, equation 2.15 applies, which involves an infinite 
series; this can be used to compare experimental and theoretical data. 
m 
Mc/1V1 =1-8ht2 E 1/(2n+1)2exp[-n2 (2n+1)2Dt/412] 
°=O Equation 2.15 
2.7.4. b MUNIANDY AND THOMAS THEORY 
As stated previously, this theory took into account droplet formation. The latter is 
a consequence of the presence of water-soluble moieties within the polymer 
matrix, which grow due to osmotic pressure but restrained by the resulting elastic 
stresses. 
An important prediction arriving from this theory is that uptake is dependent on 
the osmolarity of the external solution (Thomas and Muniandy, 1987). This 
emphasises the necessity of using the appropriate external solution for uptake 
measurements. (e, g. artificial saliva or PBS for biomaterials, or in the case of 
marine applications, the osmolarity of brine). (Further details in Appendix 1). 
2.7.4. c CASE 11 DIFFUSION 
The diffusion behaviour of many polymers cannot be adequately described by 
Fick's law, especially if the penetrating medium causes extensive swelling. 
Generally glassy polymers exhibit this "anomalous" behaviour in the presence of 
a solvent, whereas rubbery polymers are typically Fickian. Case II diffusion is 
associated with molecular relaxation of glassy polymers caused by swelling at the 
diffusion front (Thomas and Windle, 1982; Alfrey et al., 1966). Here, the rate of 
diffusion is very rapid compared to the relaxation processes. Case II diffusion is 
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characterised by a sharp advancing boundary as the liquid penetrant diffuses into 
the polymer. The kinetics of this mechanism is characterised by a linear 
relationship with time, as opposed to the square root of time, as with classical 
Fickian diffusion. Thomas and Windle could explain this on the basis of Fick's 
law in terms of chemical potential (1982). 
2.7.4. d ANOMALOUS DIFFUSION 
Anomalous diffusion is also referred to as non-Fickian diffusion. A particular 
case of non-Fickian diffusion falls between Fickian and Case II diffusion, such 
that the process is expressed as a power law relationship M, = At°; A being a 
constant, t is the temperature and n takes an intermediate value between 1/2 
(Fickian) and 1 (case II). It occurs when the diffusion and polymer relaxation 
rates are comparable (Crank, 1975). Unlike the previous two diffusion processes, 
it requires two or more parameters to describe the interacting diffusion and 
relaxation effects inherent in it. 
2.7.4. d. i INTERMEDIATE DIFFUSION 
A further anomalous diffusion process, apart from the three discussed above, has 
also been investigated. It is referred to as an intermediate diffusion process as it is 
a combination of Case I and II, obeying an equation of the type: 
Mt = at'/ + bt Equation 2.16 
This may be re-written as 
M1/t'2 =a+ bt/ Equation 2.17 
This reveals a linear relationship between M, /tV2 and t/, where a= intercept and b= 
slope. This was first reported by Hartley (1946) and subsequently by Wong et al., 
(1970) for cases where the boundary moved with a constant velocity through the 
polymer. It was thought to be due to the existence of large internal stresses due to 
the interaction of the swelling polymer and the central un-attacked core of the 
polymer sheet. It has also been reported by Peppas and co-workers; with 
reference to diffusion of water into hydrogels (Peppas, 1984). 
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2.8 POLY METIIACRYLATES 
Although there are many polymeric systems being investigated for use as drug 
delivery vehicles, the following section concentrates on methacrylate-based 
polymers. They are the basis of this thesis due to their well known uses in the 
medical and dental field and their potential to deliver therapeutic agents in a 
controlled manner. Rigid (glassy) polymers have had a number of uses in 
dentistry hence their use in the mouth is well established (for example Brook and 
Van Noort, 1985). They also demonstrated potential as drug delivery agents 
(Downes et al., 1994). 
2.8.1 METHYL METHACRYLATE (MMA) 
The first reports of the polymerisation of acrylates and methacrylates date back to 
the nineteenth century (Linneman, 1872; Caspary and Tollens, 1873; Fittig and 
Endelhorn, 1880), and the father figure of methacrylate and acrylate chemistry 
was Röhm (von Pechman and Röhm, 1901). However the main industrial 
development was poly(methyl methacrylate) (PMMA) (Figure 2.16), in the form 
of transparent sheets, appearing under a number of trade names (e. g. Perspex, 
Plexiglas; Rowland Hill, 1943). 
CH3 CH3 
CH2 =C -4 -- [- CH2- C -------]n I I. 
COOR COOR 
Methyl methacrylate Poly(methyl methacrylate) 
(MMA), R= CH3 (PMMA), R= CH3 
Figure 2.16 Structure of polymethacrylates, where R= substituent group 
The key development for biomaterials was with the Kulzer patent (Kulzer, 1938) 
for the manufacture of articles by the dough technique in the early 1950's. This 
involves the mixing of a PMMA bead polymer powder, with methyl methacrylate 
(MMA) monomer, to form an easily mouldable dough. 
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The dough technique was used to manufacture PMMA denture bases, as an 
alternative to Vulcanite (Manley and Stonebanks, 1980). This technique is also 
used to produce ear moulds (Okpojo and Braden, 1993) and artificial eyes 
(McDermott and Chandler, 1989). With the advent of room temperature 
polymerisation (self curing) systems (For example, Patel and Braden I, 1991; 
Patel and Braden II, 1991), the use was extended to in situ manufacture of dental 
impression trays, denture relines and temporary crown and bridge materials. 
However, such uses have disadvantages, in that the MMA monomer produces 
hypersensitivity to the oral tissue (Giunta and Zablotsky, 1976), and causes pulp 
irritation (Hochman and Zalkind, 1997) and hypersensitivity in skin (Maxey, 
1980). 
The next major advance was the development of an orthopaedic bone cement 
based on PMMA, by Charnley and Smith (Charnley, 1970; Freeman et al., 1982), 
for use in hip and later in knee arthroplasty. However, in the early years 
considerable concern was generated because of the hypotensive effects of MMA 
during surgery and the incidence of fatty embolisms (Wheelwright et al., 1993). 
Subsequent research has reported that the presence of the monomer, MMA, did 
not contribute to these clinical outcomes (Elmaraghy et al., 1998) and by 
improving the operating procedures, they have been greatly reduced over time. 
Hip and knee replacement surgeries are now well established worldwide, and 
bone cements based on poly(methyl methacrylate) (PMMA) remain an important 
material for anchorage of artificial joints (Breusch and Kühn, 2003). 
Another one of the more serious complications of orthopaedic surgery was 
bacterial infections of the bone (osteomyelitis). Previous studies have made it 
clear that systemic administration of broad-spectrum antibiotics is insufficient to 
diminish the rate of infection. Techniques for treatment of this include systemic 
antibiotics, wound drainage and implant removal in order to avoid further damage 
(Bucholz et al., 1989). Sustained high local concentrations of antibacterial agents 
are required to minimise and cure osteomyelitis. 
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The possibility of localised release of antibiotics from the implanted site has been 
widely studied and used. Gentamicin was included in the bone cement 
formulations, to reduce the risk of post operative infections (Wahlig et al, 1978; 
Vecsei and Barquet, 1981; Acros et al, 2001). The concept of treating local anti- 
bacterial infections using bone cements was introduced in the 1970s (Buchholz 
and Engelbrecht, 1970) and PMMA beads containing the antibiotic, Gentamicin, 
was one of the first systems used for the treatment of bone infections post-surgery 
(Baker and Greenham, 1988). 
Since then many alternative systems, such as biodegradable materials (Yagmurlu 
et al., 1999), bioceramics (Itokazu et al., 1998) or ceramic/polymer composites 
(Vallet-Regi et al., 1998), have been developed. Hence in addition to acting as 
bone cement, PMMA also acted as a drug delivery system where drug delivery 
was not its primary function. Studies undertaken to understand the mechanism. by 
which drug delivery occurs from the PMMA have shown that the poly(methyl 
methacrylate) bone cement matrix is impermeable to Gentamicin, and release 
primarily occurs from the surface (Downes and Maughan, 1989). Contrary to this 
it has been reported that the antibiotic is released through an interconnecting 
series of voids and cracks in the cement, rather than through diffusion (Brook and 
Van Noort, 1985; Baker and Greenham, 1988). 
2.8.2 POLY(ETIIYL METIIACRYLATE) (PEM) BASED SYSTEMS 
Polyethyl methacrylate) (PEM, Figure 2.17) has been used in conjunction with 
other monomers for room temperature polymerising systems, to avoid the 
problems that occur PMMA/MMA based systems in clinical applications. PEM 
itself is used industrially in printing ink and surface coating applications (De Gans 
and Schubert, 2004). 
68 
Chapter 2: Literature Review 
CH3 
CH2 =C 
COOC2H5 
Ethyl methacrylate (EM) 
CH3 
-, -- [- CH2- C -------]ý--- 
COOC2H5 
Poly(ethyl methacrylate)(PEM) 
Figure 2.17 Structure of ethyl methacrylate and poly(ethyl methacrylate) (PEM) 
2.8.2. a PEM/n-BUTYL METHACRYLATE (nBM) SYSTEMS 
The first applications used PEM with n-butyl methacrylate monomer (Fig 2.16), 
for outlining the denture bearing area of a special tray, (Schwarz and Braden 
1973). Subsequently Basker and Spence (1976) were able to demonstrate the 
successful application of this system in other aspects of Prosthetic Dentistry. The 
PEM/nBM system was later developed as a temporary crown and bridge material 
(Braden et al 1976b). These systems have a much lower polymerisation exotherm 
than the corresponding PMMA systems, and are generally more biocompatible 
(Braden et al., 1976a; Pearson et al., 1986). 
Davy and Braden (1991) established that residual monomer extracted from 
PEM/nBM was very low, mainly due to the low solubility in aqueous solutions 
(compared to the PMMA/MMA system). Hence this system was investigated for 
use as an alternative orthopaedic bone cement (Weightman et al., 1987; Behiri et 
al., 1991). Biological studies, in vitro and in vivo, reported less tissue damage and 
a significantly smaller macrophage and cell reaction, after placement of the new 
bone cement (Revell et al., 1992; Revell et al., 1998), which is indicative of 
reduced infection. These differences may be related to the lower heat of 
polymerisation of PEM/nBM and its smoother surface contour, as demonstrated 
by scanning electron microscopy (Revell et al., 1992). 
The smooth surface contour referred to above is consequent on PEM and poly (n- 
butyl methacrylate) forming an Interpenetrating Polymer Network, as 
demonstrated by there being only one broad Tg peak, instead of two separate 
peaks, corresponding to PEM and poly (n-butyl methacrylate) ( Braden 1978). 
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CH3 
CH2=C 
COOC4H9 
CH3 
-º -- 
coo C4H9 
Butyl methacrylate (nBM) monomer Poly (butyl methacrylate) 
Figure 2.18 Structure of butyl methacrylate (nBM) and poly(butyl methacrylate) 
With respect to drug delivery, this system has been shown to release more 
gentamicin than a PMMA/MMA based bone cement (Downes, 1991; Patel et al, 
1994). 
2.9 POLY(ETIIYL METHACRYLATE) (PEM) - TETRARYDROFURFURYL 
METIIACRYLATE (TIHFM) SYSTEMS 
2.9.1 INTRODUCTION 
Because the PEM/THFM system is the basis of this PhD, its' properties are 
reviewed in detail. The structure of tetrahydrofurfuryl (THFM), a heterocyclic 
monomer is shown in Figure 2.19; it is a comparatively reactive monomer, and is 
virtually insoluble in water (Patel, 1987). 
CH3 
1 
CH2=C 
1 
COOCH2- 
0 
O 
CH3 
1 
--º -- [- CH2- C -------]ý--- 
1 
COOCH2 - 
0- 
C) 
Tetrahydrofurfuryl methacrylate (THFM) Poly(tetrahydrofurfuryl 
methacrylate)Poly(THFM) 
Figure 2.19 Structure of Tetrahydrofurfuryl methacrylate and 
Poly(tetrahydrofurfuryl methacrylate) 
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Poly(THFM) is a cross-linked (Patel and Braden, 1989), glassy polymer with a Tg 
of -. 70°C (Clarke, 1989). The polymerisation shrinkage of THFM is much lower 
than MMA and nBM, due to its much higher molar volume (Patel et al, 1987). 
THFM will dough satisfactorily with PEM, thus making it suitable for room 
temperature polymerising systems. 
2.9.2 HEARING AID APPLICATIONS 
PEM/THFM's first application (medical) was as low shrinkage systems for 
hearing aids, where, in contrast, the high polymerisation shrinkage of MMA 
results in ill-fitting hearing aids (Bhusate and Braden, 1985). 
2.9.3 PHYSICAL PROPERTIES 
The mechanical, room temperature polymerising and water absorption properties 
of the PEM/THFM system were evaluated (Patel and Braden, 1991i, ii and iii 
respectively). The paper on room temperature polymerisation (Patel and Braden 
1991, ii) showed the system to have a low polymerisation exotherm. However, 
the water absorption behaviour was anomalous, a feature that transpired to be of 
relevance to drug delivery systems, and indeed is of major importance in this 
thesis. 
PEM/THFM absorbed up to 34% water over 2 years, without reaching 
equilibrium (Patel, 1987; Patel and Braden 1991). Initially this was thought to be 
a disadvantage, particularly for use in dentistry, since excess water uptake may 
influence the dimensional stability of the polymer and allow the ingress of micro- 
organisms (Wilson and Khomami, 1993). However, this transpired to be an 
extremely beneficial property for its use as a drug delivery system (Riggs et al., 
2000). As previously discussed most delivery mechanisms are dependant on the 
water sorption properties of the polymer since hydration is the initial step to the 
drug release process. 
The water uptake of PEM/THFM is essentially divided into two components. The 
first involves absorption of water into the matrix, by Fickian diffusion, 
dominating the initial linear stage. When the matrix is close to saturation the next 
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stage of cluster/droplet formation begins, dominating the subsequent uptake. This 
indicates the presence of water solute sites in the polymer. The fact that this 
behaviour is not shown by the PEM/nBM system suggests that the poly(THFM) 
phase is responsible. This was confirmed by Riggs et al (1999) work on the 
homopolymer, poly(THFM), which was shown to have a water uptake of >70%; 
The THFM monomer itself is hydrophobic, so the high water uptake is not that of 
a hydrogel, but a highly clustered system. It is not clear what the hydrophilic sites 
are at present. However it is interesting to note that heat polymerised 
PEM/THFM does not exhibit anomalous water uptake behaviour (Patel et al., 
1999). 
Furthermore, when placed in various biological solutions, such as artificial saliva 
(AS) and phosphate buffered saline (PBS), the water uptake of the PEM/THFM 
decreased with the osmolarity of the external solutions, and the behaviour 
progressively became more Fickian (Sawtell et al., 1997). This indicated that not 
only was the uptake affected by the presence of water-soluble moieties in the 
material, but also the concentration of the external solution had effects on the 
water uptake. The uptake varied from -30% in distilled water to 2.5% in solutions 
and the effect on the diffusion coefficient was greater since it increased by -- 1000 
fold, over the same range. This reflects the fact the key parameter is not just the 
osmotic pressure difference between the droplets and the external solutions, but 
the chemical potential gradient between the external solution and solution within 
the droplets. However, when THFM was replaced with hydroxyethyl methacrylate 
(HEMA) the system's uptake was independent of the immersion medium (Table 
2.9), as would be expected with a hydrogel, proving that PEM/THFM alone 
demonstrated this phenomenon (Sawtell et al., 1997). 
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Table 2.9 Water uptake and Desorption diffusion coefficients of 
PEM/HEMA and PEM/THFM (Sawtell et al, 1997) 
Immersion 
liquid 
Water uptake/Desorption - 
diffusion coefficients (10' 
iim2s ) 
Equilibrium 
Uptake (%) 
PEM/HEMA PEM/THFM PEM/HEMA PEM/THFM 
Water 1.48/4.96 0.0015/0.08 12.32 -30 
PBS 1.53/4.57 0.59/0.97 22.85 2.82 
CM 1.37/3.94 1.5/1.44 23.84 3.48 
FCS 1.35/3.03 0.63/1.22 17.84 2.81 
CM - CULTURE MEDIUM 
FCS - FOETAL CALF SERUM 
2.9.4 ORTHOPAEDIC APPLICATIONS 
PEM/THFM was studied (in vivo) as a possible synthetic scaffold biomaterial to 
encourage growth of defective articular cartilage (Downes et al, 1994; Reissis et 
al., 1994a; Reissis et al., 1994b) and in vitro by Wyre and Downes (2000). In the 
in vivo studies, the polymer was inserted in 4.5 mm osteochondral defects, in 
rabbit models, where it absorbed tissue fluid and bone matrix from the 
surrounding tissue, leading to proteins binding to the surface and creating a 
protein layer. The adsorbed protein layer on the biomaterial influenced cell 
attachment (Wyre and Downes, 2002). The characteristically high water uptake 
property of this material was considered an advantage for this application. The 
polymer system successfully resurfaced the articular cartilage defects (Downes et 
al, 1992) and was reported to encourage cartilage repair (Hutcheon et al, 2001). 
Furthermore, the rigidity and non-biodegradability factor of the material also 
meant it would remain intact, in the bone, and the smooth surface (compared to 
PMMA based systems) lessened the possibility of debris attaching to its' surface 
and causing wear (Downes et al, 1992). 
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2.9.5 DELIVERY OF THERAPEUTIC AGENTS 
2.9.5. a Gentamicin 
The unique properties of PEM/THFM mentioned in the above sections made this 
polymer a challenging candidate for use as a potential non-biodegradable drug 
delivery system. Hence, studies to compare the release profiles of Gentamicin 
from PMMA, PEM/nBM and PEM/THFM, were conducted (Patel et at, 1994). 
PEM/THFM displayed an enhanced release profile compared to the other two 
systems; an initial rapid release over 48 hours compared to five hours each for the 
PEM/nBM and PMMA systems. The percentage release of gentamicin was also 
higher for PEM/THFM, (21% greater than PEM/nBM and 33% greater than 
PMMA), over a time period of 21 days. This coincides with a higher water 
uptake of the PEM/THFM system also indicating a correlation between the release 
and the water uptake. This enhanced drug release encouraged further 
development of this material as a potential delivery system. 
2.9.5. b Chlorhexidine diacetate (CHD) 
NN 
NH(CHZ)y y 
NH 
CI 
J "d" 
2 AcOH 
I 
Figure 2.20 Structure of Chlorhexidine Diacetate 
Chlorhexidine diacetate (Figure 2.20) is a broad spectrum anti-bacterial and anti- 
microbial agent, which has been well established in reducing dental caries 
(Emilson, 1994) and an effective anti-plaque agent. In vitro studies provided 
evidence that chlorhexidine diacetate can inhibit the growth of Candida Albicans 
(Hiom et al., 1992; Hamers et al., 1996), a common oral fungal organism 
occurring with denture-induced stomatitis. It has been used mainly in the form of 
a mouthwash, but daily use is required for optimum effect (MacNeill et al, 1997; 
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Giuliana et al, 1997; Hiom et al, 1992). However the use of mouthwashes 
containing this drug in high concentrations, over a long period of time, has 
problems such as discolouring of teeth (Assenden and Peebles, 1974) and causing 
a bad taste in the mouth (Fardal and Turnbull, 1986). 
Alternative delivery systems, which avoid a high concentration of the drug to be 
in contact with the taste buds and visible tooth surfaces, have been considered 
such as mouthguards (Medlicott et al., 1995) and direct application of varnishes 
containing chlorhexidine (Hildebrandt et al., 1992). A tooth-bonded 
chlorhexidine delivery system was also developed, which showed greater delivery 
on the buccal side compared to the lingual side (Medlicott et al, 1999). It was 
originally thought the side closest to the tongue, would release a higher dose of 
drug, because of erosion by shearing of the tongue. Due to the lack of plaque at 
either interdental site, plaque suppression was successful but the therapeutic 
concentrations could only be maintained in small areas for about four days 
without interfering with normal oral functions. This method is not ideal for longer 
treatment. 
PEM/THFM incorporating 9% and 12% chlorhexidine diacetate respectively was 
studied with respect to water uptake and drug delivery. Microbiological studies 
showed that the two drug-loaded systems inhibited the growth of Candida 
albicans, including the azole resistant strains (Patel et al, 2001). No significant 
differences between the therapeutic efficacy of the 9 and 12% loaded systems 
were noted (Patel et al, 2001 a). However the water uptake of the systems 
increased with addition of the drug, the increase depending on the amount of drug 
added. Chiorhexidine diacetate was released with an initial burst followed by a 
diffusion controlled process, from both the 9% and 12% loaded systems. 
2.9.5. c Acetyl salicylic acid 
Acetyl salicylic acid (ASA) release from the PEM/THFM system was also studied 
however it was noted that a modified version of the drug was released, which may 
well be inactive. Hence circumspection is needed in the choice of drugs 
incorporated with free radical polymerising systems (Swai, 1997). 
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2.9.5. d Growth Factor 
Growth factors, which can be used to stimulate tissue repair around medical 
devices, were incorporated into the PEM/THFM system prior to insertion of the 
implants. Downes et al., (1992) demonstrated the successful use of PEM/THFM 
to release human growth hormone (HGH) and serum albumin proteins. HGH is a 
complex bioactive protein and there was a possibility that the bioactivity may be 
compromised on their inclusion into the PEM/THFM bone cement. However, 
these agents were not significantly compromised by the free radical 
polymerisation process. This was consistent with earlier findings on methyl 
methacrylate based bone cements, where it was shown that HGH was released and 
this promoted osteoblast and collagen proliferation (Downes, 1991). 
2.9.5. e Fluoride ion release 
The use of fluorides in dentistry is very well established (Arends et al., 1983). 
Various methods have been used to facilitate fluoride release, such as 
polyalkenoate cements, Orthodontic adhesive resins (Roehurst et al., 1998), 
copolymers (Frey and Sloglowck, 1997) and dimethacrylate systems as a tooth 
adhesive (Chin-The-Huang, 1989). Sodium fluoride (NaF) has also been 
incorporated in the PEM/THFM and the PEM/nBM system. The presence of 
fluoride drastically increased the uptake for both systems however this increase 
was greater for PEM/THFM (-140% in 6 months). The addition of a drug to this 
PEM/THFM system containing NaF, also enhanced the release of the drug (Swai, 
1997; Patel et al., 1998). The release of fluoride ions was by a diffusion 
controlled process. 
2.9.6 MODIFICATIONS OF THE PEM/THFM SYSTEM WITH POLY (IIYDROXY 
ETHYL METIIACRYLATE) (HEMA) 
Modifications to the PEM/THFM system have been further studied, in order to 
enhance its' ability to release agents in a controlled manner. The effects of 
increasing the hydrophilicity of the system, by gelling PEM/THFM with a more 
hydrophilic monomer, hydroxyethyl methacrylate (HEMA) (Figure 2.21) at 
various ratios was investigated (Di silvio et al., 1994; Downes et al., 1995). One 
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of the agents incorporated in to this system was bovine serum albumin (BSA) and 
release was observed to have increased for all the different ratios studied, 
compared to gelling with THFM. This was thought to be due to the high diffusion 
coefficient and the higher water uptake of the systems gelled with HEMA. The 
amount of albumin released was inversely related to the HEMA content of the 
system (Scotchford et al., 1997). 
CH3 CH3 
II 
CH2 =C --º --[-CHz--C------- ] 
COOC2H4OH COO C2H4OH 
Hydroxyethyl methacrylate Poly(hydroxyethyl methacrylate) 
(HEMA) poly(HEMA) 
Figure 2.21 Structure of Hydroxyethyl methacrylate and Poly (hydroxyethyl 
methacrylate) 
Another study concerned the delivery of Recombinant Human Bone 
Morphogenetic Protein II (rhBMP II) from PEM/THFM systems. These systems 
were modified, where part of the THFM was replaced by HEMA. Animal studies 
by King et al (1998) showed that implantation of rhBMP II in periodontal bony 
defects in rats, promoted bone growth in the periodontium. A separate study by 
Patel et al (2001b), on the release kinetics of rhBMPII showed this to be a 
diffusion process, with diffusion coefficients in the range 0.29-1.43 x10'13m2sec'1, 
depending on the THFM/HEMA ratio. Replacing 10% THFM with HEMA, 
increased the release of the rhBMP-2, however on increasing the HEMA content 
to 30% had no further effect. This indicated that increasing the hydrophilicity 
does not enhance the release, alone, as expected. Other studies demonstrated that 
the addition of HEMA completely changed the mechanism of water uptake, from 
a cluster-dominated to a more continuum-based process (Patel et al, 2001a). 
In an attempt to enhance the release of hydrocortisone sodium succinate from 
PMMA bone cements, HEMA was incorporated into the monomer. However it 
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reduced the delivery of the drug due to the plasticising effect of HEMA, resulting 
in a reduction of crazing, which was thought to be the mechanism by which 
release took place (Brook and Van Noort, 1985). 
2.10 PLASTICISERS 
A plasticiser is a substance which can increase the compliance, flexibility or 
workability of the material its' incorporated into, by reducing its glass transition 
temperature (Tg) (Van Krevelen, 1976). In the polymer, the plasticiser increases 
the free volume and provides room for increased long-range motion of the 
polymer, reducing the intermolecular forces between molecules. Plasticisers are 
in effect non-volatile solvents. 
The relevant theory concerning the interaction of an uncross-linked polymer and 
liquid is that due to the Flory Huggins (Flory, 1952) equation: 
µ= RT[ln(1-v2) +v2 +Xv22] Equation 2.18 
where µ is the chemical potential, R the Universal Gas Constant, T temperature 
(K), V2 the volume fraction of polymer, and x the so-called Flory interaction 
parameter, which is specific to a given liquid/polymer system; (v1 the volume 
fraction of liquid =1-v2). If x is < 0.5, then µ. is negative for all values of v2, and 
the polymer and liquid are completely miscible, i. e. the polymer dissolves in the 
liquid. If x is > 0.5, then the polymer absorbs the liquid (swells) until µ =0, a state 
of equilibrium swelling. 
x is given by: 
X= k(Si-S2)2 Equation 2.19 
where k is a constant 81, and 62 are the solubility parameters of polymer and 
liquid respectively. Clearly, the criterion for how good a solvent (or plasticiser) a 
given liquid is, for a given polymer, depends on how close its solubility parameter 
is to that of the polymer. These concepts are further explored in the discussion. 
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Table 2.10 contains a list of commonly used plasticisers, of which phthalate esters 
are the most frequently used (Parker et al, 1997). Phthalates have received 
particular attention in relation to their toxicology and environmental hazards. The 
toxicological concerns are health related i. e. induction of Asthma (Willoughby et 
al., 2000). Despite this, butylglycol butylglycolate is still used in denture soft 
lining materials and tissue conditioners, although the liquids now carry a health 
hazard warning (Parker and Braden, 2001). Di-2-ethylhexyl phthalate (DEHP) 
(medical grade) is commonly used as a plasticiser; examples include inclusion 
with polyvinyl chloride (PVC) for blood bags and blood transfusion tubing (Inoue 
et al., 2005; Haishima et al., 2005). Although more recent assessments have 
confirmed that the short-term exposure of the general population to DEHP gives 
no cause for concern (Butala et al., 2004), studies have been reported on the use 
of citrate plasticisers as alternatives for the latter. The conclusions for the long- 
term exposure effects are still being studied (Voss et al., 2005; Kambia et al., 
2002). Hence there remains a need to consider alternative plasticisers, particularly 
ones that have been considered biologically safe, for example n-methyl- 
pyrrolidone (nMP) (Akril et al., 2003). 
Since plasticisers are not chemically bound to the polymer, they are subject to 
loss/leaching, however this must be kept with in acceptable limits. The molecular 
weight of a plasticiser is important in this respect since it needs to be sufficiently 
sized to enable it to diffuse into the polymer, but also be able to remain within the 
material and not diffuse out immediately. Although plasticisers are low molecular 
weight molecules compared to polymers, they are relatively high molecular 
weight molecules compared to organic solvents. The addition of a plasticiser can 
be used to modify the water sorption characteristic of the PEM/THFM and in turn 
improve its' drug release properties as well as confer compliance as flexibility is 
needed for mucosal patches. 
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Table 2.10 Commonly used groups of plasticisers 
Phthalates: 
Dialkyl phthalates e. g. 
Dimethyl phthalate 
Diethyl phthalate 
Dibutyl phthalate 
Butyl benzyl phthalates 
Bisphthalates 
Alicyclic phthalates 
Glycol ethers 
I Epoxy: 
Epoxidised linseed oil 
Epoxidised soya oil 
Polymeric: 
Poly (alkylene adipates, sebacates, or azelates) 
Fire retardants: 
Chorinated paraffins 
Phosphate esters 
Citrates 
Benzoates 
2.10.1 n-METIIYL PYRROLIDONE (nMP) 
Hi CHZ 
H2C C=0 
/ 
N 
CH3 
Figure 2.22 Structure of n-Methyl Pyrrolidone 
nMP has been selected for use as a plasticiser in the PEM/THFM system 
primarily due to its biocompatibility (Akesson and Jonsson, 2000) (Figure 2.22). 
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Table 2.11 lists the physical properties of this plasticiser. Several groups have 
conducted in vivo studies to assess the toxicity levels of this substance (Bartsch et 
al, 1976; Malley et al, 1999; Jonsson and Akesson, 1997). 
Table 2.11 Physical properties of n-Methyl Pyrrolidone 
nMP 
CAS number 872-50-4 
Appearance Clear liquid 
Boiling point 101.3kPa 202°C 
UK Occupational Exposure 
Standard(OES) 
25ppm 
S L hort Term Exposure Limit 75ppm 
Inhalation studies have shown that there are no detectable or developmental 
effects of nMP, at levels of 10 and 51ppm, and with a slight decrease in foetal 
weight at levels of 161ppm (Soloman et al, 1995). At higher levels of exposure 
(>2 years) rats experienced some irregular respiratory effects and weight loss; 
these were reversible. Other dosages and toxicological endpoints examined were 
unaffected by nMP which indicated nMP to be a biologically safe plasticiser (Lee 
et al., 1987). This compound can be exposed to the oral cavity at controlled 
levels, below 150ppm (Soloman et at, 1995). 
nMP has also been shown to have apparent permeation enhancing properties, by 
being readily absorbed through skin; the skin permeability has been measured as 
171 g m'2h (Ursi et al, 1995). This has lead to the pharmaceutical industry 
investigating it as a permeation enhancer for skin (Barry, 1987; Priborsky et al, 
1988; Sasaki et al, 1988). When incorporated in a transdermal patch its effects 
were similar to those of oleic acid, and it was more effective than polysorbate 20 
and dimethyl sulfoxide, among other known potent enhancers (Buyuktimkin et al, 
1997). However, it has not been proven to be more effective than fatty alcohols, 
such as oleyl alcohol and lauryl alcohol (Park et al, 2001). 
The effects of enhancers are dependent on and specific to the drug delivery 
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vehicle, drug concentration and other factors (Aungst et at, 1989). For example, 
when used as a permeation enhancer for Zidovudine (AZT), a HIV drug, the level 
of enhancement varied depending on the co-solvent used (Kim and Chefin, 1996). 
The ethanol/ tricaprylin system, had little enhancing effect, whereas in the 
ethanol/water (60: 40) system nMP significantly increased the permeation rate of 
the drugs. 
Various derivatives of nMP have been developed as transdermal permeation 
enhancers (Sasaki et al, 1988). Preliminary acute toxicity and primary skin 
irritation studies were conducted; acute toxicity was observed at a dose of 500 
mg/kg following intraperitoneal administration in mice. Certain derivatives 
caused greater skin irritation compared to others. The level of irritation was not 
relative to the accumulation on the skin but to the enhancing effects. For 
example, 1-lauryl-2-pyrrolidone had the most enhancing effect but induced the 
most severe irritation amongst the derivatives. However, derivatives containing 
methyl and methyloxycarbonyl groups caused least irritation but had a decreased 
enhancement effect compared to nMP itself. Therefore the derivatives, which 
balanced their enhancing activity and irritation were 1-hexyl-4-methyoxycarbonyl 
and 1-lauryl-4-methyloxycarbonyl-2-pyrrolidone; these were considered as 
adequate enhancers (Sasaki et al, 1988). 
2.11 CIIITOSAN 
The drug delivery system must be retained on the site for a sufficient period of 
time to enable the drug to be released and subsequently permeate across the 
mucosa. Mucoadhesives such as CarbopolTM (based on polyacrylic acid) have 
been used for this purpose, however they can cause irritation and damage to the 
surface. Chitosan has recently received a great deal of interest for medical and 
pharmaceutical applications due to its biocompatibility and bioadhesive properties 
(Figure 2.23). Its positive charges at physiological pH increases retention at the 
site of application (He et al., 1999; Prego et al., 2005). 
Chitosan, a copolymer, (4) linked 2-amino-2-deoxy ß-D-glucan, is the result of N- 
deacetylation of chitin in concentrated sodium hydroxide (40-50% w/v) under 
82 
Chapter 2: Literature Review 
heat; the chitin comes from decalcified crab shells. It is metabolised by certain 
human enzymes especially lysozyme, which contributes to its biodegradable 
properties (Muzzarelli et al, 1999). 
HOCH HO H2 
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HO OO j-H 
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HO H2 CHZOH 
Figure 2.23 Structure of Chitosan 
The main parameters influencing the characteristics of chitosan are its molecular 
weight and degree of deacetylation. The molecular weight can be lowered by 
acidic depolymerisation (Muzzarelli, 1973). The degree of N-deacetylation 
defines the higher order of purified chitosan, which can be prepared by repeating 
the deacetylation process after rinsing with water. The nitrogen content of chitin 
varies from 5 to 8% depending on the extent of deacetylation, and is mostly in the 
form of primary aliphatic amino groups in chitosan. Therefore chitosan 
undergoes reactions typical of amines of which N-acetylation and Schiff reactions 
are of the most important. Chitosan derivatives are easily obtained under mild pH 
conditions and can be considered as a substituted glucan (Kumar et al., 2000 and 
Toffey et al., 1996). 
Apart from its use as a bioadhesive, Chitosan has also had uses in various medical 
applications such as topical ocular gels (Felt et al., 1999), implantation (Patashnik 
et al., 1997) or injection (Song et al., 2001). It has been reported to act as a 
penetration enhancer for macromolecules across intestinal and nasal barriers, by 
opening epithelial tight-junctions (Borchard et al, 1996; Junginger & Verhoef, 
1998; Kotze et al., 1999). It posses many useful properties as a permeation 
enhancer: non-toxicity, high biocompatibility and non-antigenicity, all of which 
offer several advantages for other possible clinical use (Polk et al, 1994). 
83 
Chapter 2: Literature Review 
It has also been reported to have wound healing properties (Muzzarelli et al., 
1999; Ueno et al., 2001 & 2007), by stimulating cell proliferation and tissue 
organisation and has bacteriostatic effects (Felt et al., 2000). It acts as an 
inductive primer to repair and physiologically rebuild damaged tissue (Muzzarelli 
et al., 1989). 
It was Ilium et al. (1994) who first reported that chitosan is able to promote the 
transmucosal absorption of small polar molecules as well as peptide and protein 
drugs from nasal epithelia. Since then, investigations into the uses of chitosan in 
polymer complexes, hydrogels and tablets amongst others, to enhance the 
permeation of the drugs, have been conducted (Ahn et al, 2002; YiYi and Chien, 
1997, Dodane and Vilvalam, 1998; Thanou et al., 2001). 
Due to the nature of its chemical configuration, the chitosan chain has a rather 
rigid configuration and this property has been successfully used for the 
preparation of films, gels and spheres. Currently these are used in the biomedical, 
cosmetic and food industries (Higuera-Ciapara et al, 2004). One of the main 
applications is in the production of microcapsules with delayed release of drugs in 
which the chitosan chains are cross-linked with dialdehydes such as 
glutaraldehyde (Higuera-Ciapara et al, 2004) or gelatine (YiYi and Chien, 1997). 
They usually encapsulate compounds that have intrinsically high instability since 
the micro encapsulation process generally forms a polymeric matrix or coating 
layer around the particular compound in order to protect its biological activity and 
enhance its physiochemical stability. Drugs such as cimetidine, astaxanthin and 
other anti-inflammatory drugs, such as triamicinol acetonide (Ahn et al., 2002) 
have been incorporated into chitosan polymer complexes and they were 
successfully released through the polymer systems by non-Fickian diffusion. 
The enhancement effect of chitosan in a gel form for the oral mucosa was 
investigated with a large bioactive peptide, a transforming growth factor (Senal et 
al., 2000). These results showed a 6-7 fold increase in permeability of the 
compound, which was otherwise considered to be impermeable in the buccal 
mucosa, due to its' size. The effect was not found to be time-dependant, 
demonstrating a reservoir function in the superficial epithelial layer. The surface 
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layer became saturated with drug uptake within 10 minutes therefore further 
uptake became slower. 
In all the polymer systems the presence of chitosan's strong adhesive forces and 
limited solubility was clearly evident. It was suggested the bioadhesive nature 
contributed to the increase in permeation by increasing the retention of the drug 
on the site. These are essential requirements for developing a transmucosal drug 
delivery system. 
Another mechanism by which Chitosan may also act as a permeation enhancer is 
by interfering with the lipid organisation in the buccal epithelium (Muzzarelli et 
al., 1999). One of the most important factors is that it has not been shown to 
damage the tissue. This is a great advantage and hence its' incorporation into the 
polymeric system, PEM/THFM, is investigated in this thesis. 
2.12 DEXTRANS 
To elucidate the mechanism by which the release occurs from the PEM/THFM 
and the modified systems, dextrans with differing molecular masses have been 
used as model drugs within this study. Dextrans are hydrophilic polysaccharides 
elaborated by leuconostoc bacteria. They also have good water solubility and low 
toxicity. The high proportion of a-1,6 polyglucose linkage (see Figure 2.24) 
makes them resistant to acid and alkaline hydrolysis. 
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Figure 2.24 Structure of a fragment of dextran molecule 
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Fluorescien Isothiocyanate-dextran (FITC-dextran) consists of dextrans covalently 
linked with a fluorescent group, the FITC (De Beider et al., 1973). Due to their 
fluorescent nature, FITC-dextrans are used in a wide variety of applications as 
tracers. They serve as translational diffusion of macromolecules in the cytoplasm 
of cells by microinjection (Arrio-Dupont et al., 1996; Seksek et al., 1997), for 
intracellular delivery by endocytosis (Schreiber and Hassinger, 1995), vesicle 
fusion (Trigiante and Huestis, 2000) and electroporation (Rols and Teissie, 1998). 
They are also well adapted for kinetic studies on drug delivery from delivery 
systems (Hoogstrate et al., 1996; Mancheno et al., 1996; Chowdhury and Mitra, 
1999; Nakamura et al., 2002). 
The FITC-dextran can be analysed and quantified by using Fluorimeter or by a 
more recent methodology, high-performance gel exclusion chromatography 
(HPLC-GEC) (Andrieux et al., 1998). The latter methodology provides a 
potential tool to quantify the number of functional groups grafted per polymer 
chain and to separate labelled polymer molecules from unlabeled ones, whereas 
the Fluorimeter only quantifies the labelled polymer molecules. 
2.13 OVERALL CONCLUSIONS 
The literature indicates that PEM/THFM has potential as a controlled drug 
delivery system and Dextran as the model drug. However as a potential buccal 
mucosa systemic drug delivery system, the system needs to be modified suitably. 
Modifications to the system could potentially increase the rate of release from the 
polymeric system particularly for high molecular weight drugs. The use of a 
plasticiser is one possible method of enhancing release rate and conferring 
compliance, but the plasticiser must be biocompatible. From the Literature 
survey, nMP is a suitable candidate and is the plasticiser of choice in this thesis. 
Furthermore, because of the known characterisation of chitosan, such as 
bioadhesion, this material has also been included. 
Therefore the basis of this thesis involves modifications to the PEM/THFM 
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system, by the incorporation of n methyl pyrrolidone and chitosan, both separately 
and together. Dextrans have been used as models for high molecular weight drugs, 
for the reasons explained above. One other polymeric system was included, 
namely poly(ethyl methacrylate)/ tetrahydrofurfuryl acrylate, which is flexible 
without the addition of a plasticiser (most polyacrylates are elastomeric). As 
mentioned in the Introduction, it must be emphasised that this system is not 
suitable for clinical applications, due to the well known toxicity of acrylate 
monomers in general (Nethercott, 1978). 
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Chapter 3- Materials and Methods 
CHAPTER 3 MATERIALS AND METHODS 
3.1 INTRODUCTION 
A range of experimental systems were formulated, using different combinations 
of poly(ethyl methacrylate) (PEM) powder, liquid monomers and plasticisers, to 
study their potential for release of active soluble species. Three molecular 
weights of dextran (10,35 and 71kD) were used as a model for the active species. 
Also the effects of the addition of nMP and chitosan were investigated. 
Furthermore the compliant system poly(ethyl methacrylate)/tetrahydrofurfuryl 
acrylate was studied for comparison purposes. 
3.2 EXPERIMENTAL MATERIALS 
The components used to formulate the experimental materials are shown in Table 
3.1. 
3.2.1 ARTIFICIAL SALIVA (AS) 
The artificial saliva used as an immersion medium was Orthano Saliva, supplied 
by A. S Pharma Ltd., The Court House, 20 Simpson Road, Fenny Stratford, Milton 
Keynes, MK2 2DD, U. K. Orthano Saliva contains the components reported in 
Table 3.2. 
3.2.2 IIPLC SOLVENTS 
The solvents used for HPLC analysis are listed in Table 3.3. 
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Table 3.1 Components of the Experimental Materials 
Abbreviation Component Source Function 
PEM Poly(ethyl methacrylate) Lucite (Bonar Polymers Ltd). Polymer 
(contains 0.6% residual Newton Aycliffe Durham, UK 
benzoyl peroxide) (TS 
1364) 
THFM Tetrahydrofurfuryl Rähm Chemie GmbH, Monomer 
Methacrylate Darmstradt, Germany 
DMPT N, N-dimethyl-p-toluidine Sigma-Aldrich Company Ltd, Initiator 
Fancy Road, Poole, Dorset, 
BH12 4QH, UK 
nMP n-Methyl Pyrollidone Sigma-Aldrich Company Ltd, Plasticiser 
Fancy Road, Poole, Dorset, 
BH12 4QH, UK 
THFA Tetrahydrofurfuryl Sigma-Aldrich Company Ltd, Monomer 
Acrylate Fancy Road, Poole, Dorset, 
BH12 4QH, UK 
D Dextran (molecular Sigma-Aldrich Company Ltd, Active 
weights of IOkD, 35kD and Fancy Road, Poole, Dorset, Species 
7l1 D) BH12 4QH, UK 
FD Fluorescien Isothiocyanate- Sigma-Aldrich Company Ltd, Tag 
Dextran (FITC-Dextran) Fancy Road, Poole, Dorset, 
BH12 4QH, UK 
C Chitosan Sigma-Aldrich Company Ltd, Mucoadhe 
Fancy Road, Poole, Dorset, sive/perm 
BH12 4QH, UK eation 
enhancer 
3.2.3 COMPOSITION of PEM/TIIFM 
The principle polymeric powder used throughout this study is PEM (containing 
0.6 % residual benzoyl peroxide), which was stored at room temperature. The 
benzoyl peroxide is a polymerisation initiator. The monomer, THFM contains a 
room temperature polymerisation activator, N, N-dimethyl-p-toluidine liquid 
(DMPT), at a level of 2.5 %v/v (w. r. t. monomer). All solutions were stored in a 
refrigerator at 4 ±1 °C. 
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Table 3.2 Components of artificial saliva (Saliva Orthano) 
Component Amount (g/100ml) 
Mucin Gastric 3.5 
Xylitol 2.0 
Methyl parahydroxybenzoate 0.1 
[E. D. r. A. disodium 0.05 
Mentae pipertae aetheroteum 0.005 
Spearmint oil 0.005 
Benzalkonium chloride 0.002 
Sodium fluoride 0.00042 
I NNa' 1 0.08 
K 0.07 
Ca 0.025 
W. 0.015 
HPO4 ' 0.022 
Cl' 0.12 
Table 3.3 Solvents used for HPLC analysis 
Solvent Manufacturer 
Methanol (UV grade) Merck 
Acetonitrile (UV grade) Merck 
The PEM powder and the THFM liquid were used in the proportions of 1 g: 0.6ml 
respectively, which was a 1: 1 ratio of polymer and monomer for complete 
polymerisation. The system was prepared by room temperature curing the PEM 
powder with the monomer using the method described in Section 3.3. 
3.3 GENERAL. SAMPLE PREPARATION 
The polymer powder (5g) was added to the monomer (3ml), in a ceramic bowl 
and the two components were mixed thoroughly using a spatula by carefully 
folding the mixture to avoid the introduction of air bubbles. This continued for 
-30 seconds until a thick viscous consistency was achieved. 
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The mixture was poured into a rectangular polytetrafluoroethylene (PTFE) mould 
(1 Ox4Ox 1 mm), placed on a glass microscope slide covered with an acetate sheet 
(Figure 3.1). This was used to prevent adhesion of the set resin to the glass. 
Another acetate sheet covered the mould and a glass slide was placed on top. 
These were clamped together with two bulldog clips. The whole assembly was 
placed in a dry pressure cooker and cured at room temperature for approximately 
20-30 minutes, under a pressure of 2 bars. The specimens were removed from the 
mould and subsequently filed using dry emery paper, to eliminate excess flash and 
polish the edges. Any specimens which contained porosity were discarded. 
9y "' Glass slide ddý 
3.3.1 NOVEL PEM/THFM BASED SYSTEMS 
A plasticiser (nMP) was incorporated into the PEM/THFM system with the 
objective of increasing molecular mobility in order to accelerate both water 
uptake and dextran release. N-methyl pyrrolidone (nMP) was selected for reasons 
discussed in 2.10; a secondary objective was to increase elastic compliance. 
However, the effect of nMP on water uptake and release has been the focus in the 
thesis. It should be noted that nMP is miscible with water; while this may be 
expected also to enhance release of dextran, there is of course a risk of extraction 
of the nMP. These various aspects are addressed later in this thesis. 
The THFM monomer was partially replaced by 25% and 50% n-methyl 
pyrrolidone (nMP) v/v respectively as shown in Table 3.2. The novel monomer 
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mixture containing 2.5% v/v DMPT was then mixed with the PEM powder and 
samples of PEM/THFM/nMP were prepared as outlined in section 3.3. 
Table 3.4 Composition of THFM with 25 and 50% nMP per 100m1 
Components 
25% nMP 
(ml) 
50%nMP 
(ml) 
THFM " 75 50 
nMP 25 50 
Total 100 100 
For comparison purposes an elastomeric system was prepared by replacing THFM 
with tetrahydrofurfuryl acrylate (THFA). THFA had 1.0 %v/v DMPT added 
(w. r. t. monomer) since it is more reactive than THFM. The PEM/THFA 
specimens were also prepared as described in section 3.3. 
3.3.2 INCORPORATION OF DEXTRAN AND CIIITOSAN 
3.3.2. a UNTAGGED DEXTRAN 
In order to investigate the effects of the model drug Dextran, additional 
preparation of specimens incorporating 9% dextran were required. These were 
used to investigate the effects of Dextran on the absorption and leaching from the 
polymeric systems as described in 3.4,1 a and 3.4.4. Dextran was used due to the 
range of varying molecular weights available, enabling the effects of molecular 
weight to be studied on the polymeric systems. 9.0 g of 10,35 and 7lkD dextrans 
were added to 91.0 g of PEM respectively. The mixture was placed in a ceramic 
mixing container and was ball milled (with 10 small balls) for 3 hrs to ensure an 
even distribution of the additive. Then the method in 3.3 was followed to prepare 
samples of PEM/THFM, PEM/THFM/nMP and PEM/THFA containing the three 
molecular weight dextrans, respectively. 
3.3.2. b TAGGED DEXTRAN 
In order to measure the release of dextran from the polymeric systems the native 
dextran had to be tagged with 1% Fluorescinated (FITC) dextran, for analysis by 
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using a fluorometer (section 3.4.2). 45 mg of FITC-dextran was added to 4500 
mg of native dextran and mixed thoroughly. Subsequently, this mixture was 
added to 45 g of PEM powder in a ceramic mixing container and placed on a 
shaker for 1 hr. The balls were not placed in the ceramic mixing container in 
order to avoid damaging the FITC molecules attached to the dextrans. In this 
study only two molecular weights of FITC dextrans were studied due to cost and 
time constraints. Two molecular weight dextrans (10 and 70 kD) were studied in 
order to investigate the effects of the high and low molecular weights, 
respectively. The PEM mixtures were stored in amber containers, in a cool place, 
prior to the addition to the monomer, and the method described in section 3.3 was 
followed to prepare FITC based samples. 
3.3.2. c PEM INCORPORATING CIIITOSAN 
The effect of adding Chitosan, a mucoadhesive permeation enhancer, to the parent 
systems (PT, PM25, PM50 and PA, Table 3.6, pg 96) has also been studied. A 
basic deacetylated Chitosan was used, which was in the form of flakes. Further 
details of the component, as supplied by Sigma-Aldrich, are given in Table 3.5. 
Table 3.5 Technical specification of Chitosan, as supplied by Sigma-Aldrich 
Physical data i Chitosan 
Appearance White to tan, powder/flakes with bulk 
density of 0.15-0.3g/cc 
Solubility I Insoluble in water or organic solvents 
Hazy solutions can be prepared in 1M 
acetic acid (10mg/ml) 
The chitosan particles have limited solubility in water, except in the presence of 
acidic solutions, such as lactic or acetic acid. Subsequent to dissolving the 
chitosan flakes in a 2% lactic acid solution, a highly viscous mixture was 
produced, which proved to be insoluble in the monomer, THFM. Therefore, the 
chitosan it self (in the powder form) was added to the PEM polymeric powder, as 
described below. 
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The chitosan flakes were ground down using a pestle and mortar until visible 
agglomerates were broken down. Subsequently the ground chitosan was screened 
through a 63 gm mesh sieve. A 2%w/w (w. r. t. polymer) of Chitosan in PEM was 
obtained by adding 2g of sieved Chitosan to 98g PEM powder and ball milled for 
1 hour (with balls), in order to achieve an even distribution of the chitosan within 
the PEM powder. Specimens of these were prepared according to section 3.3. 
3.3.2. d PEM INCORPORATING CIIITOSAN AND FITC DEXTRAN 
A composition containing chitosan and dextran within the PEM powder was also 
prepared to assess the effects of dextran release in the presence of chitosan. 9g of 
tagged lOkD dextran was added to 91 g of the pre-prepared PEM powder with 
Chitosan (as detailed in Section 3.3.2. c). Hence the PEM powder used for these 
systems consisted of 2% w/w Chitosan and 9% w/w Dextran (tagged with 1% 
FITC-Dextran). This was placed in a ceramic container and mixed using a shaker 
for 1 hr (without balls). Specimens were then prepared as described in section 
3.3. Figure 3.2 shows a flow diagram of all the polymeric systems formulated for 
water update and dextran release studies. 
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PEM/THFM (PT) 
i Dextran 
PEM/THFM + PEM/THFM + PEMTTHFA 
25% nMP (PM25) 50% nMP (PM50) (PA) 
35 kD Dextran 1 171 kD Dextran 
I Incorporation of FITC-dextran 
10 kD FITC- 
dextran 
kD FITC- II Addition of 
dextran Chitosan 
10 kÜ 1F ITC-dextran 
with Chitosan 
Figure 3.2 Flow diagram of the various formulated polymeric systems 
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Table 3.6 Abbreviations used to describe the experimental PEM formulations 
Polymeric Powder Liquid 
monomer 
PEM THFM 
PEM containing 9% 
w/w (w. r. t. polymer) 
of 10,35or7lkD 
Dextran 
PEM containing 1% 
w/w (w. r. t. polymer) 
of Chitosan 
THFA 
THFM 
THFA 
THFM 
THFA 
Plasticiser 
nMP 25%v/v (w. r. t. 
monomer) 
nMP 50%v/v (w. r. t. 
monomer) 
nMP 25%v/v (w. r. t. 
monomer) 
nMP 50%v/v (w. r. t. 
monomer) 
nMP 25%v/v (w. r. t. 
monomer) 
nMP 50%v/v (w. r. t. 
monomer) 
Abbre. 
PT 
PM25 
PM50 
PA 
PT D 
PT25D (molecular 
size of Dextran) 
e. g. 25D10 
PT50D (+ molecular 
size of Dextran) 
PAD (+ molecular 
size of Dextran) 
PTC 
PM25C 
PM50C 
PAC 
3.4 EXPERIMENTAL METHODS 
All the systems in Table 3.6 were preconditioned to a constant weight, in a drying 
oven containing silica gel, at 37°C +/- 1 °C, prior to commencing water absorption 
and dextran release studies. This initial weight was denoted Wo. 
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3.4.1 EFFECT OF STORAGE IN WATER AND PHYSIOLOGICAL ENVIRONMENT 
3.4.1. a WATER ABSORPTION 
Triplicate samples per polymeric system, per immersion solution (DW and AS) 
were used for this study. Each specimen was weighed (f 0.0001g), on a balance 
(Mettler), and immersed in individual screw top bottles filled with 100ml of DW 
or AS, pre-equilibrated at 37°C +/- 1°C. Each specimen was removed from the 
solution using tweezers, at predetermined time intervals (Table 3.7), placed on a 
filter paper and then the paper was folded over the specimen to remove the excess 
surface fluid. This takes 10-15 seconds, following which the weight was recorded 
and the specimen was re-immersed in the respective solution. This overall 
process must be carried out within 20-30 seconds, since immediately after 
removal from the solution the specimen begins to lose weight, through 
dehydration. This process was repeated until the samples reached equilibrium/or 
a quasi-equilibrium. 
Table 3.7 The actual times at which water uptake readings were taken 
Day Time (min) 
Interval 
Cumulative Time (min) 
0 0 
5 5 
10 is 
15 35 
20 75 
40 135 
60 195 
60 255 
60 315 
60 375 
60 435 
60 495 
Week 1= 2x da 
Week 21x day 
Week 3 2x week 
lx a week until equilibrium/quasi equilibrium 
The percentage weight change at time `t' was calculated for each specimen (using 
Equation 3.1), where Wo represented the initial weight at time = 0, and the weight 
at time (t) was denoted Wt. 
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WeightChange(%) = 
W`WW o x100 Equation 3.1 
The mean weight change (%) was calculated for each polymeric system and 
plotted against timeln (seconds) to produce the weight change profile of the 
systems, where the plots were linear with respect to 112 ,D values were 
calculated from equation 2.14. 
3.4.1. b DESORPTION 
After reaching a quasi-equilibrium or equilibrium, two of the three specimens in 
solution, were transferred to an oven at 37°C+/- l "C. The specimens were 
removed from the oven and the same weighing procedure described for 
absorption, was followed for desorption, until a constant minimum weight was 
reached (Wd). The third sample remained in the initial solution and weight 
measurements were continued at regular intervals. 
The mean weight change (%) was calculated and plotted with respect to timeln for 
samples which had undergone desorption, to demonstrate the characteristic 
desorption profile for each polymeric system. D values were calculated as 
described above. The solubility of the systems was calculated by subtracting the 
weight after desorption (Wd) from the initial specimen weight (Wo) (Equation 
3.2). This equates to the total mass of the components leached from the polymeric 
systems. 
Solubili %= 
ýl'Wa 
ýý ý 
Wo x100 
Equation 3.2 
The diffusion coefficient measures the rate of transfer of the water during 
absorption and desorption, which was calculated using equations derived from 
Fick's second law for the initial stages of diffusion (Section 2.7.4. a). 
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3.4.2 DEXTRAN RELEASE STUDIES 
In parallel to the water absorption studies, the release of the dextran was 
monitored over a1 week time period to assess the release potential of the various 
formulations. The immersion medium was reduced, for the release study, from 
100ml to 50m1, due to the shorter immersion time from -3 months to 1 week. 
This was done on the assumption that the solution will not be saturated with 
leachants and dextran, within a week. Saturation of the immersion medium is 
affected by the length of the immersion time, as well as the solubility of the 
leachants/dextran, in that medium. 
3.4.2. a CUMULATIVE DEXTRAN RELEASE 
Specimens (n=2) were prepared according to sections 3.3 and 3.3.2. b containing 
9% dextran of which 1% was tagged. They were weighed (± 0.0001g) and 
immersed in glass amber jars, to protect the FITC dextran, containing 50m1 of 
distilled water pre-equilibrated at 37°C. One ml aliquot of immersion solution 
was removed from each jar and placed in separate amber glass vials, at the 
following time points, 15 minutes, 1,4,8,24,48 hours and Iweek (Table 3.8). 
Table 3.8 Sample collection time points for drug release 
Day Time (min) 
1 0 
1 15 
1 60 
1 240 
1 480 
2 24 hr 
3 48 hr 
7 168hr 
3.4.2. b SEQUENTIAL DRUG RELEASE 
The procedure in 3.4.2. a was followed for the sequential study, however with one 
difference. At each time point, when each specimen was removed from the 
respective jar to be weighed and an aliquot was removed, the specimen was 
placed in a new amber jar containing fresh distilled water (50m1); hence at each 
100 
Chapter 3- Materials and Methods 
time point the specimen was placed in a new amber jar containing fresh distilled 
water (54ml). 
3.4.3 QUANTITATIVE ANALYSIS OF DEXTRAN 
Prior to incorporation of the FITC tagged dextran, the release from the polymeric 
systems was initially analysed using an ultraviolet spectrometer (UV). This was 
unsuccessful since the dextran lacks the presence of an unsaturated group, also 
known as a chromophore. These are responsible for absorptions within the UV 
and visible regions of the spectrometer, in the wavelength range of 200-800 nm, 
which are of value for diagnostic purposes and quantitative analysis. However 
dextran gives rise to an absorption spectrum in the far UV region below 200 nm, 
which is of little analytical use. FITC-dextran was incorporated in the 
formulations as described in section 3.3.2. b. It transpired that UV spectrometer 
was not effective at measuring the low levels of FITC-Dextran released into the 
immersion solution (distilled water). Because the FITC tag causes 
photoluminescence, fluorometric analysis was used to measure the released FITC 
dextran. Photoluminescence is a general term for describing relaxation of excited 
species emitting radiation on return to the ground state. This gives rise to a 
fluorescent emission spectrum. Although Fluorimetry is not as extensively used 
as absorbimetry, since there are a limited number of naturally fluorescing 
compounds, fluorometry is inherently more selective and sensitive than the UV 
spectrophotometer. 
3.4.3. a FLUOROMETER ANALYSIS METHOD 
The dextran release was quantified by analysing the immersion medium from the 
cumulative and sequential studies (3.4.2. a & 3.4.2. b) using a Fluorometer (Hitachi 
model F-4500 Fluorescence spectrophotometer (Figure 3.3), with a 250-0339 
Turret cell holder unit. A wavelength scan ranging from 400-800nm was 
performed, for both excitation and emission spectra of FITC-dextran, to find the 
optimum wavelength for analysis of FITC-dextran. The FITC-dextran shows 
strong characteristic fluorescence peaks at wavelengths of 490 nm and 51 S nm for 
excitation and emission, as shown in Figure 3.4. The samples were analysed 
according to the parameters detailed in Table 3.9. 
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Specimen 
Holder 
Source 
Beam 
Attenuator 
Excitation Filter 
or Sample 
Monochromator 
V 
Excitation Filter 
or 
Monochromator 
Reference Sample " 
Photomultiplier Photomultipliei 
Difference amplifier 
Figure 3.3 Hitachi model F-4500 Fluorescence spectrophotometer and 
schematic diagram of a fluorometer 
Error! Objects cannot be created from editing field codes. 
Figure 3.4 A Characteristic Spectrum of FITC dextran 
Table 3.9 Instrument Parameters for the Fluorometer 
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Instrument F-4500 FL spectrophotomer 
Measurement type Photometry 
Data mode Fluorescence 
Number of Wavelengths 1 
Wavelength mode EX WL Fixed 
EX Fixed WL 490nm 
EM WL 1 515nm 
Integration time 2. Os 
Delay is 
EX Slit 2.5nm 
EM Slit 2.5nm 
PMT Voltage 700V 
3.4.3. a. i CALIBRATION 
In order to measure the dextran released into the immersion solutions, by 
Fluorometry, standard solutions of varying concentrations of FITC dextran were 
prepared. Calibration of the Fluorometer was carried out by using a series of 
FITC dextran standard solutions. 
A range of FITC-dextran standards (from 50-0.01 µg/ml) were prepared and 
analysed, and a quantifiable range between 2.5- 0.04pg/m1 was identified. These 
dilutions were made by first preparing a stock solution of 5µg/ml by weighing 
0.0125g (± 0.0001g) of FITC dextran into a 250 ml volumetric flask. The FITC- 
dextran was ultra-sonicated for lminute in 100 ml of distilled water. 
Subsequently, the volumetric flask was made up to the mark with distilled water 
and mixed vigorously. Further dilutions to the stock solution were made 
according to Table 3.10 with distilled water. For example 1000 µg of 500 µg/ml, 
added to lml of DW, produced 2.5 pg/ml standard solution. The background 
absorbance was determined by placing distilled water in both the specimen and 
reference curvettes; the fluorescence was then recorded as the reference. Aliquots 
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of the standard solutions were transferred to 1 ml quartz curvettes and placed in 
the Fluorometer (Figure 3.3). The calibration process was carried out prior to 
every sample analysis, to ensure the instrument was correctly calibrated. 
Table 3.10 Standard Preparation of FITC-Dextran 
1000 µl of 
Standard Solution 
(µg/ml) 
Volume of Diluent 
(Distilled Water) 
(ml) 
Standard 
Concentration 
(µg/ml) 
5.00 1 2.50 
2.50 1 1.25 
1.25 1 0.63 
0.63 1 0.31 
0.31 1 0.16 
0.16 1 0.08 
0.08 1 0.04 
A calibration curve was produced which shows the relationship between the 
fluorescence and the concentration of FITC-dextran (Figure 3.5). 
Figure 3.5 Typical Standard Calibrations plots for FITC-Dextran on the 
Fluorometer 
3.4.3. a. ii SYSTEM SUITABILITY 
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A standard solution was measured 10 times consecutively giving a Relative 
Standard Deviation (RSD) of 1.4%. This demonstrated that the fluorometer 
reading did not vary significantly between each individual sample solution, and 
that the readings were reproducible. The calculated RSD (1.4%) is within 
acceptable limits of error. 
3.4.3. a. iii ANALYSIS OF SAMPLE SOLUTIONS FOR DEXTRAN RELEASE 
The sample solutions were analysed by transferring the 1 ml aliquots from the 
amber glass vials into the quartz curvettes, respectively. Distilled water was used 
as the reference solution (Figure 3.3). Prior to each batch of analysis the 
instrument was reset. 
3.4.3. a. iv DEXTRAN RELEASE CALCULATIONS 
There is a linear relation between the concentration of a fluorescent analyte (C) 
and intensity of emission (1), given by equation 3.3. 
kL=2.303logjo(Ip/IF) Equation 3.3 
where k is the absorption coefficient of the fluorescing compounds, respectively. 
Io is the incident intensity. IF is the intensity of the excited radiation and 1 is the 
path length of the sample cell. The concentration of FITC-dextran was calculated 
from the gradient of the standard curve where absorbance was plotted against time 
(Figure 3.5). 
The FITC-dextran concentration (µg/ml) for each aliquot removed was calculated, 
then multiplied by 50 to give the total concentration in 50 mis (total immersion 
medium). The value was multiplied by 100 since this was the dilution factor of 
FITC-dextran in native dextran. It is assumed that the dispersion of the FITC- 
dextran is representative of the native dextran. A cumulative concentration of 
dextran released over time was calculated and expressed as a percentage of the 
dextran initially incorporated into the polymeric systems. 
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3.4.4 ANALYSIS OF LEACHANTS 
There were four main components that had been added to the polymeric systems, 
which could potentially leach out. A method of analysis, which could identify the 
separate components and quantify the amounts leached was required. The HPLC 
(High Performance Liquid Chromatography) was selected due to its ability to 
separate and identify a wide range of volatile and non volatile compounds. 
Subsequently, these could also be quantified, providing an indication to the extent 
of polymerisation within each system in addition to the form and amount of free . 
components present. HPLC is a highly sensitive technique which is able to detect 
and identify even trace amounts of the leached substance. However a novel 
method had to be developed for the HPLC analyses of the potential leached 
components, nMP, THFA, THFM and DMPT, since there were no prior methods 
published. This work was conducted in the department of Bioanalytical Science 
with Professor D. Perrett, Barts and the London School of Medicine and 
Dentistry. 
3.4.4. a HPLC PILOT STUDY 
During the development of this novel method, consideration had to be given to the 
choice of the mobile phase, column type, flow rate and wavelength of detector. 
Each of the components was considered to achieve optimum separation of the 
leached compounds. 
Initially acetonitrile (ACN) was used as the mobile phase at a wavelength of 250 
nm and a flow rate of 1 ml/min. However the peaks for each of the different 
components, at 250 nm were not detected clearly (Figure 3.6). Hence the 
wavelength was changed to 200 nm. Now the peaks appeared close to the solvent 
front. Therefore, in order to delay the retention time of the peaks, the ratio of 
deionised water and ACN was varied until the optimum ratio of 75: 25, H20: ACN 
was reached. The latter mobile phase allowed successful separation of the peaks 
for each of the different components, within a sample mixture. However, the 
runtime had to be extended from the initial 5 min to 10 min in order to capture the 
peaks since they eluted at a later time. The HPLC system was re-equilibriated 
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each time the ratio of the mobile phase was changed, by pumping it through the 
HPLC at 2 ml/min for 10 minutes. 
In order to ensure there is no contamination from one sample injection to 
subsequent sample injections, a 50: 50, methanol: water mixture was used to wash 
the systems. 
Before finalising the parameters, a test was conducted to confirm that the same 
compound was being detected in the sample and the standard solution. The 
standard and the sample solutions were analysed at two wavelength 250 mit and 
200 nm. The peak areas for each solution, at the two wavelengths were compared 
Ratio = Peak area of Solution at 200 nm Equation 3.4 
Peak area of Solution at 250 nm 
A similar ratio of 10: 1 and 11: 2 was calculated for standard and sample solutions 
respectively, confirming the same compound was being eluted in the two 
solutions. 
Peak 
Area 
I 
nmp TIJFA DMPT TIIFM 
&A IA 3.0 4.0 i. a LA 70 /. a 'o ! CA 
' 
. +. ý.. F........ +" "a--. º+.. .... 4M... a +M'm-"i.. . ...................... D DD 5a IN H1 a riO 1111 RD DDD 
Time 
Figure 3.6 A Typical Chromatogram of a Mixed Standard Solution at 250 nm 
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7µ4 
ýº+r Pump 
Injector 
Auto 
sampler 
-- -- 
3.4.4. b FINAL HPLC ANALYSIS METHOD 
A Shimadzu HPLC with a UV-Vis spectrophotometric detector (Figure 3.7 
labelled with the key components), was used to analyse aliquots obtained from the 
water absorption and drug delivery studies, 3.4.1 and 3.4.2. 
The optimum conditions of the HPLC deduced from the above method 
development study are shown in Table 3.11. These enabled separation and 
identification of all the leached compounds in the solute. The solute was passed 
through a C18, spherisorb, 3µ column (Waters SpherisorbTM), and the compounds 
were eluted with 75: 25, H20: ACN. The elutants were detected by a UV detector 
and the responses were displayed on a chart recorder or a computer screen, to 
create a chromatogram (Figure 3.8). 
Table 3.11 HPLC Equipment and Instrument Parameters 
Instrument I HPLC Shimadzu 
Detector I SPD-6 A UV-Vis 
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Spectrophotometric 
System controller SCL-6B 
Auto injector SIL-6B 
Pump LC-6A 
Column 
C13 Reversed phase - Spherisorb, 
3 micron 
Flow rate lml/min 
Volume injected 10µ1 
Runtime 10 minutes 
Wavelength 200nm 
Mobile Phase 
25% Acetonitrile (HPLC 
gradient, low UV) in water 
Peak Area 
Retention time 
Figure 3.8 A Typical Chromatogram of Deionised Water on the HPLC at 
200nm, with a flow rate of I ml/min 
3.4.4. c CALIBRATION 
Prior to every batch of sample analysis the instrument had to be calibrated for 
each component. Firstly, a quantifiable range of standards was identified for each 
component. These differed for each component due to the varying amounts of 
components present in the solute. The linearity ranges for THFM, THFA, nMP 
and DMPT were 0.7-5.6mM, 1.2-6.0mM, 2.0-9.8mM and 1.3-7.9mM, 
respectively. 
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A stock solution was prepared following Table 3.12, by pippetting 250 pl of the 
respective component into a 250 ml volumetric flask and mixing well with 
approximately 100mI deionised water. Subsequent to this the volumetric flask 
was made up to the mark with deionised water and mixed vigorously. The 
linearity range standards were prepared by further diluting the stock solution with 
deionised water, in a 10m1 volumetric flask (Table 3.12). The standard solutions 
were placed in glass vials, then analysed on the HPLC. The standards were 
always analysed lowest to highest concentration to avoid carryover -of the 
component, and deionised water was injected prior to each component's standard 
analysis. A calibration curve was produced to show the relationship between the 
absorbance and concentration of the components (Figure 3.9). 
Table 3.12 A Typical Standard Preparation for the HPLC - THFA 
Stock Solution = 250µ1 of THFA in a 250m1 volumetric flask, made up to the mark with 
deionised water 
Vol. of Diluent (Deionised 
water) (ml) 
Vol. of Stock Solution 
(MI) 
Standard Concentration 
(mM) 
2 8 4.8 
4 6 3.6 
6 4 2.4 
8 2 1.2 
120 
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Figure 3.9 A Typical Standard Calibration for THFM on the HPLC 
3.4.4. d HPLC SYSTEM SUITABILITY 
The reproducibility of the HPLC was assessed by injecting the same standard 
solution 10 times consecutively, and calculating the Relative Standard Deviation 
(RSD) of the peak areas obtained (Table 3.13). This was carried out separately 
for each of the components and they all had very low RSD values. Although 
DMPT had a slightly higher value of 5.24%, due to small peaks that were 
obtained for this component, thus causing integration problems; it was still below 
the acceptable range of <8% (Crawley, 2005). This demonstrated that the HPLC 
data did not vary significantly between each individual injection, and that the data 
were reproducible. 
Table 3.13 The Interassay RSD of the Four Components on the HPLC 
Component 
RSD of Peak 
Area (n=5) 
THFM 1.16 
NMP 0.14 
THFA 0.17 
DMPT 5.24 
A mixed standard (prepared as per Table 3.14) was measured following every 
batch of samples (n=10) to ensure the instrument remained calibrated. The RSD 
was calculated subsequently demonstrating the reproducibility of the data for the 
respective sample solutions. 
Table 3.14 The preparation of mixed samples 
Vol. Added 
Component Of 
Component 
Conc (mM) Component 
(MI) 
THFM 5.6 2 
THFA 6.0 2 Mixed 
Standard 
Solution 
(8ml) 
111 
Chapter 3- Materials and Methods 
nMP 9.8 2 
DMPT 7.9 2 
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Figure 3.10 A Typical Chromatogram of a Mixed Standard Solution 
Figures 3.10 and 3.11 are chromatograms of a mixed standard solution and a 
sample solution, respectively. The separate peaks at different retention times 
represent the various compounds present within the solution. The peak area 
reported by the HPLC is used to calculate the amount of each compound present 
by extrapolating off the calibration curve (e. g. Figure 3.9). 
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Figure 3.11 A Typical Chromatogram of sample (PM2501) on the HPLC at 
200nm, with a flow rate of I ml/min 
3.4.4. e HPLC LEACHANT ANALYSIS CALCULATIONS 
The percentage leachants were calculated in terms of molar concentrations of the 
individual components leached, taking into consideration the amount of the 
particular component incorporated. The concentration of the experimental 
solutions was calculated from the absorbance reading of the standard (See 
equation 3.5) and represented as a percentage of the amount of the respective 
component incorporated into the polymeric system (Equation 3.6). 
Concentration = Sample Absorbance x standard concentration x 0.1 
in solute (pmoles) Standard Absorbance 
Equation 3.5 
% Leaching = Concentration in solute (Rmoles) x 100 
Amount in a sample (pmoles) 
Equation 3.6 
3.4.5 OSMOLARITY 
The osmotic pressure is important in the water absorption and dextran delivery 
process hence the osmolarity of the dextran solutions were measured using a 
MOD 100 Osmometer (Figure 3.12) -The measured values were subsequently 
compared to the theoretical osmotic pressures, calculated from the published 
molecular weights of the various dextrans in solution. 
3.4.5. a RELATION BETWEEN OSAIOLARITY AND DEPRESSION OF FREEZING 
POINT 
The osmotic pressures developed in droplets in a polymer matrix is an integral 
part of this thesis. Hence the ability to calculate osmotic pressures of the relevant 
solutions is necessary. 
For dilute solutions the Osmotic Pressure (II) is given by the van t`Hoff Law 
(Glasstone, 1945, i): 
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II = (l+a)c; RT/M Equation 3.7 
Where a is the degree of dissociation, c; the concentration of solute, R is the 
Universal Gas Constant, T temperature (K), and M the molecular weight of the 
solute. Clearly the variable part of this equation is: (l+a)c; /M, usually designated 
as the osmolarity. 
The Osmometer measures the Depression of Freezing Point (OT) of the test 
solution. For dilute solutions AT is given by (Glasstone S, 1945 ii): 
AT = [RTZ/Lf] [(l+(x)c; /MJ Equation 3.8 
Where Lf is the Latent Heat of Fusion of the solvent (water), hence AT is directly 
proportional to the Osmolarity, and the constant of calibration is easily calculated. 
One pl of distilled water was pipetted in to a2 ml plastic tube, and placed in the 
osmometer holder. The solution is frozen in the cooler and subsequent to this a 
probe is embedded into the frozen solution to measure the depression of the 
freezing point. Distilled water is used to calibrate the system, as pure water 
freezes at 0°C. One mol of substance dissolved in 1 kg water gives a solution of 1 
Osmol/kg if it is an ideal solution and the substance does not dissociate. The 
various molecular weight dextran solutions were measured using the same process 
as that used to measure distilled water. 
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Osmometer 
holder 
Figure 3.12 MOD 100 Manual Osmometer 
3.4.6 SCANNING ELECTRON MICROSCOPY (SEM) 
The influence of water uptake on the morphology of the fractured and external 
surfaces of these experimental acrylic systems were observed, using a JEOL JSM- 
6300TM series scanning electron microscope (SEM) (JEOL®, Welwyn Garden 
City, Herts., U. K., Figure 3.13). SEM uses electrons as opposed to white light to 
view the specimen. It is capable of high magnification, of over 100,000 times, 
and has a great depth of field. It also provides three dimensional images of the 
specimens. 
Images are produced by scanning a focused electron beam across the surface of a 
specimen. In the most common mode, the low energy secondary electrons 
emitted (reflected back off the specimen) are detected and transmitted to a screen 
where the image is viewed and digitally captured. Only inanimate specimens can 
be viewed under an SEM, since it is a destructive method, due to being coated 
with gold in this instance to allow the specimen to be conductive. 
A1 Ox4Ox 1 mm specimen was scored and fractured to ensure that both the 
external and fractured surface, of the same specimen, could be viewed 
simultaneously. One half of the specimen was then mounted, at an angle, onto 
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SEM stubs using conductive carbon cement (Leit-CTM, Neubauer Chemikalien, 
Munster, Germany) and then placed into the chamber of the Polaron Sputter 
coater (SC7640, Fisons Instrument, UK). Under vacuum conditions the 
specimens were coated with palladium gold under an argon atmosphere for 100 
seconds. The SEM was turned on and left to equilibriate for 20 minutes following 
this the specimens were placed into the chamber and subjected to an accelerating 
voltage of 10kV, which was used to examine the surfaces of the systems. 
Digitally captured micrographs were obtained at high and low magnifications. 
The surface morphology and cross-sections of the four parent systems in 
duplicates (PT, PT25, PT50 and PA), were examined, as shown in Figure 3.14 (pg 
118). Comparisons were made for each material by viewing the images before 
immersion in water and after desorption. 
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Figure 3.14 The Areas of the specimens viewed by the SEM (a) Surface 
morphology (b) Cross-section of specimen 
3.4.7 CONFOCAL LASER SCANNING MICROSCOPY (CLSM) 
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Confocal laser scanning microscopy (CLSM) has recently emerged as a 
significantly new technique for the inspection and analysis of living tissue 
samples, in a wide range of industrial research programmes, primarily working 
within the biomedical industry. Unlike conventional confocal designs, laser 
microscopy employs a specialised optical fiber to transfer concentrated laser light 
to a sample at controlled wavelengths. The same optical fiber can serve as the 
return path for the resulting fluorescence medium, as it returns back through the 
optical trajectory and passes through a confocal pinhole. The light is then 
interpreted as a digital image, via an electronic detector and viewed using a 
computer screen (Figure 3.15). 
The fundamental principle of the confocal pinhole is to enable optical sectioning 
of the observed material. A three dimensional image can be recreated using this 
theory, by slowly and progressively changing the focal plan through the entire 3D 
specimen (the axial z scan). Alongside this, successive xy scans are performed 
and then stacked as separate images, successively, by automatically accumulating 
only in-focus data into a single photographic or digital image (Sheppard, 1997). 
This method involves direct non-invasive sectioning of specimens, which is a 
fundamental advantage when studying intact and living cells, due to its non 
destructive nature. The sensitivity of this technique exceeds that of the 
fluorescence microscope. This is due to the combination of the removal of noise, 
by rejecting the out-of -focus blur, and reduction of noise, by producing a final 
image that is the sum of the emissions observed from many frames. 
CLSM can only penetrate a certain distance into the specimen ranging from a few 
nanometers to a millimetre depending on the subject (Carlsson, 1995). The 
effective thickness of the sections generated by the CLSM is largely governed by 
the numerical aperture of the objective and detector confocal pinholes. However, 
the smaller the pinhole, the less the signal to noise ratio since more out of focus 
information is prevented from entering the detector. Hence the latter should not 
be used to regulate the specimen thickness (Sheppard et a1,1993). 
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Figure 3.15 Schematic of laser-scanning confocal microscope (Sheppard 1997) 
CLSM was used here to contribute to an understanding of the Dextran release 
mechanisms involved. An experimental regime was devised and work was 
conducted at Cambridge University, Department of Medical Materials, with Dr Jie 
Huang. A previous study had been carried out to determine and understand the 
water absorption behaviour of PEM/THFM, by immersing specimens in distilled 
water with a fluorescent dye, EOSIN yellow, and observing the influx of the dye 
into the specimen, with the CLSM (Rahman, 2004). 
3.4.7. a CSLM METHOD 
An experimental regime was devised, involving the following systems; PT, 
PM50, PA, PTC, PM50C and PAC incorporating FITC Dextran, and these were 
immersed in distilled water, at 37°C for various amounts of time, over 7 days, 
prior to testing. Since this was not a quantitative method of analysis, only one 
nMP percentage formulation was studied. Specimens were placed in individual 
amber glass bottles in 50m1 of distilled water (DW). This method was to 
complement the water absorption studies and to determine and understand the 
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water absorption mechanisms involved. At each time point, the sample was 
removed from the water, placed in a petri dish of distilled water and observed 
with an immersion lens, on the Leica SP2 Confocal Scanning Laser Microscope 
(CLSM) (Leica Microsystems, Milton Keynes, UK). Testing was conducted on 
the 1st, 3rd, ich day and duplicate specimens were used. 
Confocal images were obtained using the CLSM (Figure 3.15 & 17). The laser 
was argon/krypton, for the excitation of the FITC at 488nm. The emission of the 
photons were collected at a wavelength of 500-550nm. A Helium-Neon (HeNe) 
(red) laser was used for the reflection mode at a wavelength of 633nm. Immersion 
lens 40 x HCXAPOL, 0.8 were used with both fluorescence and reflection modes 
(Figure 3.16). 
Figure 3.16 Typical CLSM Images 
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Figure 3.17 Leica SP2 Confocal Scanning Laser Microscope 
3.4.8 TISSUE CULTURE STUDY 
Preliminary testing on the effects of the leachants and Dextran on a tissue culture 
model were studied using Viability and IL- la and IL-8 assays. These are detailed 
in the methodology discussed below. They were carried out for the four parent 
polymeric systems with and without Chitosan. 
The reconstituted human epithelium model used in this study was prepared and 
supplied by Skinethic Laboratories, Nice, France. It is a three-dimensional tissue 
culture model obtained by culturing transformed oral keratinocytes (TR146) 
derived from a buccal carcinoma (Regnier et a! 1987, Rupniak et a! 1985). The 
cells were seeded (8 x 105 cells/cm2) on a 0.5cm2 inert polycarbonate membrane 
and cultivated in a defined medium (Rosdy and Clauss, 1990) for 14 days at the 
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air-liquid interface. The resulting culture formed a stratified epithelium with 5-7 
cell layers devoid of stratum corneum. Skinethic Laboratories also supplied 
maintenance medium (MCDB 153 containing 5µg/ml insulin and 1.5mM Ca2) 
for use in the experiments. 
The model cultures were shipped on agar and on arrival were transferred into a 
new 24 well culture plate (Costar, UK), containing 500pl maintenance medium 
per well and incubated for 2 hours, at 37°C in 5% CO2 in a 100% humidified 
atmosphere. The cultures were transferred to a new 24 well plate containing fresh 
media for all experiments (see Figure 3.18). 
PT, PM25, PM50, PA, PTC, PM25C, PM50C and PAC specimens were prepared 
according to section 3.3.1. However the dimensions of each specimen were 
adjusted to a radius of 10 mm, to enable the polymeric system to be placed on top 
of the cell culture in the well. 
Epithelial Surface 
Insert 
Experimental 
Sample 
Culture Medium 
Epithelium Polycärbonate Membrane 
Figure 3.18 Stratified Culture (Courtesy of Dr AT Cruchley, Oral Disease 
Research Centre, Barts and the London, Queen Mary's School of Medicine and 
Dentistry) 
3.4.8. a VIABILITY ASSAY 
Viability assays are designed to quantify the proportion of cells that fail to survive 
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under experimental conditions. In this study the modified MTT viability assay 
have been selected. 
3.4.8. a. i MODIFIED MTT ASSAY 
The viability of exposed cultures was measured by the quantification of 
mitochondrial dehydrogenase activity using a modified MTT assay (Mosmann 
1993). MTT assay involves the use of a colour reaction as a measure of cell 
activity. MTT (3-(4,5-dimethyl-thiazol-2-yl)-2,5-diphenyltetrazolium bromide) is 
a pale yellow substrate, which is reduced to a dark blue insoluble formazan 
product, when incubated with living cells. The amount of formazan uptake is 
measured using densitometry (Mosmann 1993). 
At the end of the treatment period, the cultures were transferred into a new 24 
well plate containing 300µl MTT solution (0.5mg/ml in PBS) and a insert of the 
experimental sample. The plate was wrapped in aluminium foil and incubated for 
60 minutes at 37°C in 5%C02 in a humidified atmosphere. After incubation, the 
cultures were transferred to a new 24-well plate containing 750µ1 isopropyl 
alcohol per well and 750µl of isopropyl alcohol applied to the epithelial surface. 
The plate was carefully sealed with Parafilm®, to prevent evaporation, and then 
incubated for a further 2 hours at 37°C to extract the formazan. The insert was 
then removed and any surface solution retained in the well. The plate was agitated 
gently in order to equilibrate the colour density. Expended cultures were 
discarded. 
Three 200µl aliquots from each well were transferred to a 96-well plate (Costar 
UK) and the optical density (OD) was determined using a Titertek Multiskan Plus 
plate reader. Epithelial viability was expressed as the absorbance at 570nm. 
Epithelial Viability = OD (570im) Test / OD (570nm) control x 100 Equation 3.10 
3.4.8. b CYTOKINE RELEASE 
The effect of Ieachants was assessed using commercially available assay kits 
(Quantikine, R&D Systems). Cytokine release was measured by collecting the 
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culture supernatants from treated cultures that were subsequently used for testing 
viability. Supernatents were frozen at -20°C until required for testing. 
Supernatents were defrosted ready for testing and mixed on a vortex mixer. 
Cytokine was measured by following the manufacturer's protocol and the 
concentration released by the epithelial cultures during the treatment period, 
expressed as pg/ml. Freeze and thaw cycles were minimised to maximise the 
detection of cytokine. 
3.4.8. b. i IL-la ASSAY 
Assay diluent (buffered protein base) was added in each well of the plate. The 
sample was then added to each well and incubated at room temperature whilst 
covered with an adhesive strip. After a fixed incubation period, the wells were 
aspirated and washed appropriately with 400µ1 of wash buffer using the 
autowasher. The conjugate enzyme was then added to the wells and incubated at 
room temperature whilst covered with an adhesive strip. All wells were aspirated 
and underwent an identical wash cycle. The substrate solution (colour reagent A- 
hydrogen peroxide, colour B-chromogen, in equal volume) was mixed within 
fifteen minutes of use and protected from light. The appropriate volume was 
added to each well. The plate was protected with an adhesive strip and protected 
from light by wrapping in aluminium foil. After the appropriate incubation period, 
the stop solution (sulphuric acid) was added to each well. Optical density was 
measured at the appropriate corrected wavelength and read within 20 minutes. A 
standard curve was plotted for each standard series. Cytokine concentration was 
plotted across the x-axis and optical density or absorbance was plotted on the y- 
axis. Microsoft's Excel® spreadsheet was used to complete a regression analysis 
of the points, as a line of best fit (trendlive) (Figure 3.19). A straight line graph is 
represented by the equation y= Mx + C, where M represents the gradient of the 
line and C represents a constant. M and C are determined from the standard 
concentration plot. The optical density, y, was measured by densitometry and 
plotted. The concentration, X of cytokine released in pg/ml was calculated by 
rearranging the equation for the line of best fit, 
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0 
Figure 3.19 Cytokine standard curve 
3.4.8. b. ii IL-8 assay 
100µl of Assay Diluent RD1-8 was added to each well. 5µl of standard and 45µl 
of Calibrator Diluent RD5P (1X) was also added to each well in order to produce 
a ten-fold dilution. IOOpI of conjugate antibody was also added to each well with 
sufficient force to mix, and the sample was placed in each well. The plate was 
covered with an adhesive strip and incubated for 2.5 hours at room temperature. 
The plate was then washed six times using 400µ1 of wash buffer. 200µ1 of 
substrate solution was applied to each well. The plate was covered with an 
adhesive strip and protected from light. S0µ1 of stop solution was applied to each 
well and the optical density was read at 570nm and 450nm within 30 minutes. 
Data was processed in an identical manner to IL-la assays but multiplied by ten 
to correct for dilution. 
3.4.8. c Statistical analysis 
The results were analysed using an independent `Student t"test'. Significant 
differences were recorded at p<0.05. 
3.5 Statistical Methods 
With the exception of the work under 3.4.8, the only method used in this thesis is 
Regression Analysis, including determination of correlation coefficients (Lambe, 
1968). 
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CHAPTER 4 SORPTION & LEACHANT 
ANALYSIS - PARENT SYSTEMS 
4.1 INTRODUCTION 
As outlined in section 2.7.1, published literature indicates that hydration is a 
precursor to the release of the drug. Gravimetric analysis of the water and 
physiological saline absorption properties has been conducted to examine the 
polymeric systems for use as potential drug delivery systems. Section 4.1.1 
examines the water absorption/desorption properties of PEM/THFM (PT), 
PEM/THFA (PA) systems, and PEM/THFM with varying amounts of nMP 
incorporated (PM25 & PM50). The PA system exhibits elastomeric properties 
and was studied as a comparative system, for the rigid PT and plasticised PT 
systems. These studies are intended to provide insight into the mechanisms of 
water sorption and subsequent release of leachants (section 4.1.2) and dextran 
from the PT and other novel systems. Additionally, imaging analysis has been 
carried out using scanning electron microscopy (SEM), in section 4.1.4. The 
parent systems are the PEM/monomer with/without nMP containing no other 
additives (i. e. dextran and chitosan) (Table 3.6). 
4.1.1 WATER ABSORPTION AND DESORPTION OF PARENT POLYMERIC 
SYSTEMS 
Water absorption data was obtained from the polymeric systems following the 
procedure described in 3.4.1. The results were analysed for evidence of Fickian- 
type diffusion in their early-stages of immersion since at this point there should be 
little time for matrix relaxation or impurity dissolution. For diffusion to be 
Fickian, plots of Mt/M. (weight change of sample at time (t)/equilibrium weight 
of sample) against square root of time would yield a linear relationship. However 
many of the systems did not reach equilibrium hence the percentage net weight 
change (i. e. the sum of weight change due to absorbed water and constituents 
leached) was plotted against t/ instead. 
127 
Chapter 4: Characterisation of the Parent systems 
4.1.1. a WATER SORPTION OF PEM/THFM AND PEM/THFA 
Figure 4.1 is a plot of percentage weight change against the square root of time for 
the PEM/THFM (PT, n=3) and PEM/THFA (PA, n=3) systems. Triplicate 
samples were used for each system, however PA02 (PA, sample 2) broke 
following the 24hr time point therefore its data was not incorporated. Up to the 
breaking point the uptake pattern for PA02 was similar to the corresponding other 
two specimens. Plots for the PT and PA samples demonstrate the results to be 
reproducible with a scatter of ±0.02%. 
The initial uptake is linear, for both systems. After 300sß (3 days) (PT) and 500sß 
(4 days) (PA) there is an increase of 1.5% and 5.0% weight change respectively 
(Figure 4.1). This is followed by a long protracted uptake for both systems 
(Figure 4.2). The maximum percentage weight change is greater for the PA 
systems compared to the PT system (6.9% at 1500s'12 and 2.3% at 1000s'/2 
respectively). However the PA systems also begin to exhibit weight loss after 
_2000s112 (45 days), whereas the PT systems appear to semi equilibrate after being 
immersed in water for --3500s"2 (5 months). 
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Figure 4.1 Water uptake of PEM/THFM (PT) (n=3) & PEM/THFA (PA) 
(n=2) in DW 
Duration -1 week 
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Figure 4.2 Water uptake of PEM/THFM (PT) (n = 3) & PEM/THFA (PA) 
(n=2) in DW 
Duration -5 months 
It was observed that the transparent PT samples turned opaque after being in 
water for a short time (within the first day) as noted previously by Swai (1997). 
4.1.1. b WATER SORPTION OF PLASTICISED PEM/THFM 
Figure 4.3 shows plots of percentage weight change versus time'l for the 
PEM/THFM system containing 25% (PM25, n=3) and 50% (PM50, n=3) nMP 
respectively. The addition of nMP increased the percentage water uptake of the 
system by over twelve fold, from 2.3% (PT) to a maximum uptake of 34% for 
PM25 and an eight fold increase to 24% for PM50, over 48 hours (Figures 4.1 and 
4.3). The rate of uptake slows after 450s"2 (3 days) for PM50, and at 600s"2 (5 
days) for PM25, with the latter having a higher water uptake of the two systems. 
Following these time points the weight change demonstrates long protracted 
weight loss over the remaining - 4.5 months of immersion. These profiles are 
different to the PT and the PA systems despite the latter also showing weight loss. 
The loss of weight indicates loss of water absorbed and/or loss of other substances 
from within these systems. Analysis of the immersion solute in Section 4.1.2 
provides more information on this. 
ý,.. 
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Figure 4.3 Water Uptake of PEM/THFM with 25% nMP (PM25) and 50% 
(PM50) in Distilled Water against Time' h'2 
Duration =5 months 
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Figure 4.4 Average Water Uptake of PEM/THFM with 25% nMP (PM25) and 
50% nMP (PM50) in Distilled Water against Time 
Duration = 15 days (n=3) 
The results for triplicate specimens of each system are reproducible up to the 
maximum uptake point (PM25 - 600s'n; PM50 - 450s'n) with a scatter of ±0.2 - 
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± 1.5). Subsequent to this point variable amounts of weight loss begin to occur 
between the specimens. Figure 4.3 also demonstrates that the plots are non-linear 
with respect to t1/2; in fact they appear to be convex to the tI' axis. The percentage 
water uptake was plotted against time, for these plasticised systems, to determine 
whether the uptake was Case II diffusion (Figure 4.4) (see section 2.7.4). 
However, here the initial uptake is concave to the t axis, indicating that the uptake 
does not follow Case II diffusion either. This will be explored further in the 
discussion section. 
Figure 4.5 compares the maximum percentage water uptake for the four polymeric 
systems. As previously mentioned, PM25 appears to have the highest water 
uptake followed by PM50, PA and PT. 
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Figure 4.5 The Maximum Water Uptake of the Parent Polymeric Systems 
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4.1.1. c WATER SORPTION BY PARENT SYSTEMS FROM SOLUTION 
This section investigates the effect of the external solution on uptake by the 
polymeric systems. The samples were immersed in artificial saliva (AS) to 
simulate the oral environment, and observe the effect of the osmolarity of the 
external solution on mass loss and uptake. 
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Figure 4.6 plots percentage weight change against tv for the PEM/THFM system 
(n=3) immersed in AS. The initial uptake is linear with respect to tß/2. The plots of 
the triplicate specimens are reproducible with a small scatter of ± 0.2. 
Figure 4.6 demonstrates the uptake profile of PT in AS is similar to the PT in 
distilled water. On closer inspection it can be seen that this is only true for the 
initial absorption up to 60sv (Figure 4.7). There are differences between the two 
profiles subsequent to this, where the DW uptake rate is slower than the AS 
uptake (Figure 4.7). Despite this the samples in DW have a higher maximum 
uptake compared to the AS samples, since the latter begin to plateau after . 950s/ 
(Figure 4.6) If this study was continued over a longer period of time a more 
significant difference in the weight change could have been seen as noted by 
previous studies (Sawtell, 1997; Parker et al 1997). They have shown samples in 
distilled water to continue to absorb water over months, whereas the artificial 
saliva samples had already equilibrated. 
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Figure 4.6 Water Absorption of PEM/THFM (PT) immersed in Artificial 
Saliva (AS) 
Duration 5 months (n = 3) 
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Water uptake of PEM/THFM (PT) immersed in Artificial Saliva 
(AS) 
Duration =4 days (n =3) 
The uptake of the plasticised polymeric systems immersed in AS do not appear to 
be affected by the external solution during the earlier stages of water uptake, as 
shown by Figure 4.8. The uptake process appears to be very similar to the DW 
samples. Figure 4.8 shows the plasticised systems to have a two stage absorption 
process, the first linear region is up to 160 s'/ and the second stage up to 500s/, is 
concave to the t2 axis (see discussion Section 4.2.3) (Figure 4.9). This is followed 
by progressive weight loss. 
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Figure 4.9 Water Uptake of PEM/THFM with 25% nMP (PM25) and 50% 
(PM50) in Artificial Saliva against Timet/2 
Duration =5 months 
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4.1.1. d DESORPTION OF SYSTEMS IMMERSED IN DISTILLED WATER AND 
ARTIFICIAL SALIVA 
Once the samples had reached a quasi equilibrium they were desorbed according 
to section 3.4.1. b. This is a rapid process compared to water absorption and 
equilibrium was achieved within a few weeks. 
Figure 4.10 plots water loss for each system as Mt/M,,, with respect to time/. 
Water loss was linear with respect to Ofor the four polymeric systems (PT, PA, 
PM25 and PM50) in DW and AS, obeying classical diffusion theory. The 
plasticised systems did demonstrate a slight lead in to the linear region for the AS 
specimens (Figure 4.11, see arrow). This maybe symptomatic due to the surface 
concentration not being instantaneously zero, for these specimen; this will be 
discussed further in Section 4.2. Figures 4.10 and 4.11 also demonstrate that the 
PT samples have a different pattern of desorption to the plasticised systems; the 
former reach equilibrium at -400s'/' whereas the plasticised systems stabilised 
later, at _800sý/. These observations are consistent with the diffusion coefficient 
values, 2.58 x 10-12 m2/sec, 1.02 and 1.08 x 10-13 m2/sec obtained for PT, PM25 
and PM50 respectively (Table 4.1). The diffusion coefficients were calculated (as 
described in section 2.7.4. a), using the initial linear region of the percentage 
weight change versus tý' plots; the highest maximum uptake value was taken as 
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Figure 4.10 Average Desorption of the Polymeric Systems, PEM/THFM (PT), 
PEM/THFM with 25% (PM25) and 50% nMP (PM50) and PEM/THFA (PA) 
from DW Duration = 20 days (n=3) 
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Figure 4.11 Average Desorption of Polymeric Systems PEM/THFM (PTAS), 
PEM/THFM with 25% (PM5AS) and 50% nMP (PM50AS) from AS 
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Figure 4.12 Desorption of PEM/THFM from Distilled Water (Filled points) 
and Artificial Saliva (Unfilled points) 
Figure 4.12 compares the PT system desorption plots for artificial saliva and 
distilled water. The effect of the external solution is apparent; uptake is reduced 
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in artificial saliva. There is a clear separation between the DW points and AS 
points. The findings are consistent with previous studies conducted by Patel et al 
(1991). The PT AS samples showed a slightly lower weight change of -2.0% 
compared to when immersed in DW -2.5% as is clear in Figure 4.12. 
4.1.2 ANALYSIS OF EXTRACTED MATERIAL FROM THE PARENT POLYMERIC 
SYSTEMS 
Gravimetric analysis indicated that as well as water/solution absorption some 
particular systems also experienced mass loss; possibly due to loss of substances 
from the polymeric systems. The immersion solutes of the four systems were 
analysed using a Shimadzu High Performance Liquid Chromatography (HPLC) 
with a SPD-6 UV-Vis Spectrophotometeric detector, after 100 days of immersion, 
to identify the residual monomers and leachables, as described in 3.4.4. Two 
random immersion solution samples of each system were analysed. The 
variability of these results ranged from 0.05%- 2.0% leached for the plasticised 
and the PA systems. 
The HPLC analysis not only identified the presence of individual components 
leached from each polymeric system, but it also quantified the actual amount 
present of each. The main components identified were THFM, n-MP and THFA 
and they are shown as percentages of the initial amount incorporated in Figure 
4.13. 
Figure 4.13 demonstrates that very, little THFM was present in the solute of the 
PT based system. The PA system had a fairly high residual THFA (4.4%); this is 
consistent with the comparatively high solubility value obtained (7.78%) detailed 
in Table 4.1. The immersion solute of both of the plasticised systems contained 
significant amounts of nMP. Although the PM25 solute contained a higher 
percentage of nMP (-24.5%) compared to PM50 (12.4%), the actual molar 
amounts leached were very similar for both systems (PM25 = 480.1; PM50 
482.6 icmoles). DMPT was not detected in any of the immersion solutes, at this 
stage. 
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Figure 4.13 Percentage amount leached of various substances from PEM/THFM 
(PT), PEM/THFM with 25% (PM25) and 50% nMP (PM50), PEM/THFA (PA) 
Duration 100 days (n=2) 
4.1.3 SUMMARY OF SORPTION, DESORPTION AND EXTRACTED MATERIALS 
Following desorption of the samples, the percentage solubility, adjusted water 
uptake and sorption and desorption diffusion coefficients were determined. The 
results for the systems in both DW and AS, are shown in Table 4.1. 
The diffusion coefficient values for sorption for the polymeric systems in AS were 
higher, as shown in Table 4.1 (i. e. PT = 4.43x10-12 and 8.00x 10-12M2 /sec for DW 
and AS respectively), consistent with a lower uptake (discussed later). 
The solubility is the total leachable content from the material into the immersion 
solution, and is calculated using equation 4.1. 
% Solubility = (initial sample weight - Final desorbed weight) x 100 Equation 4.1 
initial sample weight 
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Generally the PT systems have very low percentage solubility since there is little 
or no residual leaching from these polymeric systems. However the addition of 
nMP vastly increased the percentage solubility indicating that loss of nMP occurs 
from the plasticised systems. Table 4.1 shows PM25 has a slightly higher residual 
loss in DW compared to PM50, as shown by this solubility values of 14.00% and 
12.71% respectively. PA has a higher solubility (7.78%) than expected 
demonstrating residual loss also occurs from this system. 
Table 4.1 shows PM25 to have the highest maximum percentage uptake in both 
DW and AS (30.0% and 34.0%), followed by PM50, PA and finally PT. The 
adjusted water uptake is the sum of loss of soluble constituents and the water 
sorption of the materials; so it is a measure of the actual water content. 
Theoretically, the percentage gain and percentage solubility should equal the 
percentage loss; this is true for PT as it has a low solubility percentage. However 
there is a discrepancy of approximately 7% for PM25 and 4% for PM50, between 
the adjusted water uptake and the percentage desorbed (Figure 4.14). 
Maximum weight 
Gain - Final 
s 
a 
.ý 
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Start of desorption** 
(refer to Table 4.2) 
Time 
Figure 4.14 A diagram to illustrate the difference between maximum and final 
eight change of the plasticised system 
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The adjusted water uptake values ranged from PT (2.6%) having the lowest 
uptake and PM25 (38.9%) having the highest value. The PM25 systems had a 
higher percentage uptake than the PM50 (29.5%). This was unexpected since a 
higher percentage of plasticiser is thought to increase the water uptake potential 
due to its increased molecular mobility. However, it should be noted that there 
appears to be more than one process occurring (i. e. not only water uptake but 
leaching of other components). Hence this could account for this unexpected 
result. However there was no difference between the percentage leached when 
calculated as a percentage of the whole system, this is discussed further in 4.2.6. 
The leaching of the plasticiser also contributes to the water content of the 
polymer. Hence when a substantial amount of nMP has leached, it begins to 
affect the water uptake ability of the polymer, in the sense that water diffuses out. 
It may be that the polymer also begins to loss its molecular mobility as the 
plasticiser leaches out of the system. This is discussed in detail in section 4.2. " 
Table 4.2 The differences between the weight gain and loss for the 
plasticised systems 
Adjusted water Gain-Final Composition Desorption Difference 
uptake (%)* (%b) 
PM25 38.6 31.6 7.0 5.1 
PM50 29.5 24.4 5.1 5.5 
*Adjusted water uptake = loss of soluble constituents + water sorption of the materials 
** Final uptake is the final time point on the uptake graph at which desorption starts (see Figure 
4.14) 
The difference between the adjusted water absorption and desorption values for 
the plasticised systems are similar to the differences between the maximum and 
final weight change (Table 4.1 & Table 4.2; PM50 = 5.1 & 5.5 respectively and 
PM25 = 7.0 and 5.1 respectively). Some differences are possible because the 
systems have riot equilibrated when desorption begins. 
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4.1.4 SCANNING ELECTRON MICROSCOPY 
The internal fractured surface and the external surface of the systems prior to 
water absorption and following desorption were studied using scanning electron 
microscopy (SEM). The samples were immersed in DW for approximately 100 
days. Figure 4.15 depicts a fractured surface of PEM/THFM, which consists of a 
stepped, rough region and a smooth area, reflecting the ductile nature of the 
acrylic. The enhanced image (Figure 4.15b) shows the fractured surfaces for 
PEM/THFM as being relatively smooth. PEM beads can be seen clearly within 
the THFM matrix since some did not appear to be dissolved in the matrix (Figure 
4.15c). The dark circles visible in Figure 4.15b are thought to be craters of PEM 
polymer beads. 
Figure 4.15 SEM of fracture surface of PEM/THFM a) marker bar = 100µm; 
b) marker bar = 10 µm; c) close-up of PEM bead 
A fractured surface of desorbed PEM/THFM (treated) is shown in Figure 4.16. 
The same dark circles are visible (PEM bead craters) alongside intact PEM beads 
142 
Chapter 4: Characterisation of the Parent systems 
(Figure 4.16a). Also pores of up to 10µm in diameter can be seen on the surface 
(Figure 4.16b). Rounded clusters of beads are observed on the surface of these 
pores (Figure 4.16b & c). This indicates that the material becomes brittle and 
fractures much more easily, enabling some polymer beads to remain intact as 
opposed to Figure 4.15 where a rough surface is observed. 
Figure 4.16 SEM of Desorbed (Treated) fractured surface of PEM/THFM a) 
marker bar = 10 µm; b) marker bar =1 µm c) marker bar =I µm 
Figure 4.17 shows the fractured surface of PEM/THFM with 25% nMP which 
visually possesses similar morphologies to PEM/THFM, consisting of stepped 
regions of PEM beads and bead craters (Figure 4.16). However, the former 
fractured surface has a higher stepped region compared to the latter. The 
fractured surface shows unexposed PEM beads, covered by the matrix (Figure 
4.17b), compared to the exposed PEM bead for PT system (Figure 4.15c). When 
the beads are absent, a smooth crater like indent is present, where the bead may 
have been (Figure 4.17c). 
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The fractured surface of the desorbed plasticised specimen reveals a more rougher 
stepped region (Figure 4.18a) compared to that observed for PEM/THFM (Figure 
4.16), however it also contains a porous structure (Figure 4.18b & c). The 
morphology of the plasticised system is very similar to the elastomeric system, 
PEM/THFA, which has a porous structure following desorption (Figure 4.19). 
Hence maybe the plasticisation of the system does cause it to adapt some 
characterisations of an elastomeric system. Some beads do not appear to have 
dissolved within the matrix for the plasticised system (Figure 4.18a). 
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Figure 4.17 SEM of fractured surface of PEM/THFM with 25% nMP (PM25) a) 
marker bar = 100 µm; b) marker bar = 10 µm c) marker bar = 10 µm 
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Figure 4.18 SEM of Desorbed (Treated) fractured surface of PEM/THFM with 
25% nMP (PM25) a) marker bar = 10 µm; b) marker bar = 10 µm c) marker bar = 
Iµm 
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4.2 DISCUSSION OF THE PARENT SYSTEMS 
4.2.1 WATER UPTAKE OF PEM/THFM 
The water uptake of PEM/THFM has been previously studied in detail, stating it 
to be anomalous when compared to other glassy polymer systems (Patel, 1987, 
Swai, 1997) (Section 2.9.3). This was characterised by a small linear portion, 
conforming to Case I Fickian behaviour followed by a protracted secondary Case 
II process, which was associated with clustering. The high uptake has been 
attributed to the THFM since poly(THFM) has been noted to absorb 75% water 
over -3 years (Patel and Braden, 1991). The PEM forms an interpenetrating 
network with the monomer, merely restricting the uptake to below 30% over two 
years. This behaviour is in marked contrast to most glassy polymers where a 
genuine equilibrium is reached and the diffusion coefficient can be calculated. 
4.2.2 APPLICABILITY OF GENERAL DIFFUSION THEORY 
The diffusion coefficient (water uptake) (Table 4.1, pg 139) was then used to 
calculate a theoretical plot using equation 4.2 for comparison with the 
experimental data (Figure 4.20) (Section 2.7.4. a; Equation 2.15). The 
experimental data for PEM/THFM is in good agreement with the theoretical for 
the initial linear portion. However, it was noted that the experimental points 
departed from the theoretical at the latter stages, indicating the former process was 
slower than predicted. 
M, /M, = 1-8/ exp [- 73 s2d16] Equation 4.2 
(The terms are defined in section 2.7.4. a. ) This is symptomatic of the diffusion 
coefficient being a function of concentration in the sense that D decreases with 
increasing C (Crank 1999). The first term of the series has been used as shown in 
section 2.7.4. a. The secondary uptake process is suppressed when the sample is 
immersed in aqueous solutions (Sawtell et al., 1997). 
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Figure 4.20 Experimental and Theoretical Water uptake of PEM/THFM (PT) in 
DW. Duration = 45 days 
In the case of PEM/THFA the uptake is higher than the PEM/THFM (-6.5% to 
-2%) possibly because THFA is more polar than THFM. Also the PEM/THFA is 
more elastomeric hence the compliance of the matrix would be greater, permitting 
enhanced water sorption, consistent with the Muniandy and Thomas theory 
(section 2.7.4. b). 
An important difference between the two systems is that after reaching a quasi 
equilibrium, the PA samples gave a negative percentage weight change over the 
course of the experiment (5 months) (Figure 4.2, pg 128). 
4.2.3 EFFECTS OF PLASTISICATION 
The plasticised systems took longer to reach a maximum water uptake with a 
much higher and very different pattern of uptake to the other materials 
investigated, as seen in Figure 4.3. 
The addition of nMP gave non-classical absorption behaviour; the uptake was not 
by simple diffusion but by a combination of Case I and II diffusion (Section 
2.7.4. d. i, pg 65), whereby: 
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M, =at '/2+bt Equation 4.3 
(See Section 2.7.4. d. i) 
Rearranging 4.3 gives: 
M, /t'/' =a+ bt 1/2 Equation 4.4 
(See Section 2.7.4. d. i) 
The percentage weight change/timeý1/2 was plotted against time/, according to 
Equation 4.3 (Figure 4.21). This shows an initial linear region, demonstrating that 
the uptake for the PEM/THFM based systems containing n-methyl pyrrolidone, in 
distilled water and artificial saliva, follows intermediate diffusion theory. 
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Figure 4.21 An Example of an Intermediate Diffusion plot of PEM/THFM 
with 25% (blue) and 50% (lilac) nMP in Distilled Water 
Duration =4 days 
500 
The linear regression analysis shows the Mt/th versus t/' plots are significantly 
linear, confirming that these systems confer to the intermediate diffusion process. 
Figure 4.22 is a typical plot with an R2 value of 0.998, R=0.999. Table 4.3 
summarises the R values together with the terms a and b, which are calculated 
from the slope and intercept of the intermediate plots, respectively (Figure 4.22). 
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The correlation coefficient values (R) are well within the confidence limits at the 
significance limits of 0.05% (Crawley, 2005). 
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Table 4.3 A statistical analysis on the intermediate diffusion of the various 
plasticised systems 
Polymeric 
System 
R Degrees of 
freedom 
*Confidence 
Level 
a b 
PM25 0.8551 13 <0.1 hs 0.00008 0.0222 
PM50 0.7321 13 <0.05s 0.00005 0.0243 
hs = highly significant s= significant 
*That is the probability of the null hypothesis 
The intermediate diffusion is a mixture of both Fickian and Case II diffusion 
process. It has been previously reported by Peppas and co-workers to explain the 
behaviour of polymers, such as hydrogels, where the water uptake process is 
complex (Peppas 1984; Colombo et al., 1996) (Section 2.7.4. di). 
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Using the a and b values (Table 4.3), Figure 4.23 plots the ls` term (Fickian, btu') 
and 2nd term (Case II, at) respectively, of Equation 4.3 separately to assess the 
contribution of the two processes. For completeness the overall sorption is also 
plotted. It can be seen that initially the Fickian and Case II values are very 
similar, clearly however, Case II diffusion becomes more prominent as time 
increases. Therefore it appears that there is a very short initial period of Fickian 
diffusion followed by an increasingly dominant Case II process. 
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Figure 4.23 The Intermediate Diffusion Plot (Triangles- uptake plot; 
diamonds-Case II; squares Fickian) 
The plasticised systems demonstrate that the enhanced droplet growth occurs due 
to the substantial molecular relaxation which occurs. The internal growth is 
substantiated by the clear presence of raised bumps on the external surface of 
these specimens. Other authors have observed this swelling with polymers which 
have had limited elasticity (Robinson, 1950; Wong et al, 1969). Large internal 
stresses develop within the system as the swelling polymer and the central un- 
attacked core interact. 
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As described in Section 2.7.4. c, classical Case II is associated with the molecular 
relaxation that occurs when a solvent diffuses into the polymer. However, the 
current work does not involve a solvent. Since Figure 4.23 confirms that Case II- 
like processes predominate, it suggests that the addition of nMP confers sufficient 
molecular mobility to allow substantial molecular relaxation in the otherwise rigid 
PEMITHFM system. This enables a higher water uptake for the plasticised 
systems and consequently rapid droplet growth within the systems. This is an 
important extension of the Muniandy and Thomas (1987) concept for droplet 
formation in elastomers. 
The plasticised systems also experience negative percentage weight change, 
similar to the PA system. This will be discussed further in Section 4.2.6. 
4.2.4 EFFECTS OF ARTIFICIAL SALIVA 
When the polymeric systems are in a solution such as artificial saliva, the uptake 
is reduced, clustering is not present and the uptake is Fickian. This confirms that 
there are osmotically active sites present in the material, which lead to clustering, 
and enhanced absorption in water itself. It also confirms the role of the external 
solution predicted by equation A5 (Appendix I pg 179). 
The diffusion coefficients (D) in Table 4.1 indicate that D is lower in water but 
higher in solution. This is because the uptake is lower in solution and hence D is 
higher. 
The uptake and desorption data for PEM/THFM in DW and AS, from this study, 
has shown consistency with previous findings (Sawtell, 1997). However, as 
reported earlier by Sawtell et al (1997), the external solution has a critical effect 
on the uptake by PT, at extended times. The present work had a shorter 
immersion time of 6 months compared to the previous studies, since the focus was 
more on understanding the initial mechanism and process of absorption in relation 
to drug release. This shorter time period meant the effects of the external solution 
was not completely apparent for the PT systems, since the differences between the 
profiles are more obvious at a latter time point. PA was not studied in solution 
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because it exhibits classical water sorption behaviour. 
The mechanism by which the solution uptake occurs for the plasticised systems 
appears not to be effected by the osmolarity of the external solutions. nMP 
increases water sorption due to the miscibility of nMP and water. If this occurs 
the osmolarity of the external solution would not have an effect. nMP, as the 
plasticiser, mixes intimately with the polymer network, at the molecular level. 
4.2.5 DESORPTION PROCESS FOR PARENT SYSTEMS 
In general, desorption of water from all the polymeric systems studied was 
Fickian diffusion. The diffusion coefficients were calculated from the Fickian 
plots. The desorption process is more rapid than absorption, which is not unusual 
as many glassy polymers give higher rates of diffusion during desorption (Crank, 
1999), and is consistent with previous studies (Patel et al, 1998,2001; Riggs 
1999,2001). 
4.2.6 MASS LOSS AND ITS IMPLICATIONS 
During uptake measurements, both PA and plasticised PT samples exhibit weight 
loss continuously after reaching a maximum (Figures 4.2 and 4.3). Clearly this 
weight loss is indicative of material being extracted. 
4.2.6. a PA SYSTEM 
While this is not altogether unexpected in the case of the plasticised samples, the 
reason was not immediately apparent in the case of the PA. However, HPLC 
analysis of the immersion medium showed the weight loss to be un-reacted THFA 
monomer. Furthermore, analysis over 48 hours showed the leaching to be 
continuous, reaching about 4.5% (w/w). This may reflect a higher residual 
monomer content per se, as well as the higher solubility of THFA in water of 
7.78%. Hydrolysis of the poly(THFA) seems unlikely, in that no corresponding 
tetrahydrofurfuryl alcohol (THFOH) was detected. in the analysis. A higher 
residual DMPT was also found, possibly indicating incomplete polymerisation of 
the THFA. As reported in Chapter 3 (Materials and Methods section 3.3.1) a 
lower % of DMPT was used in the PA system compared to that of the PT (1% c/f 
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2.5%), due to the higher reactivity of the THFA; it is possible the DMPT content 
could be further optimised. 
4.2.6. b PT SYSTEM 
In marked contrast to the PA systems, the amount of residual monomer and 
DMPT from the PT system, were too small to be detected (Figure 4.14). It is of 
interest to compare these results with those of Davy and Braden (1991), where 
measurable amounts of residual monomer was detected in the bone cements, but 
much smaller amounts were leached from a PEM/nBM system. The lower 
solubility and higher molecular size of THFM (170 mw compared to 100mw for 
methyl methacryläte and 142 mw for n-butyl methacrylate) may have been factors 
here. 
4.2.6. c PM25 AND PM50 SYSTEMS 
As expected, large amounts of plastisicer were extracted (Figure 4.14), given that 
nMP is a relatively small molecule and is water soluble. Surprisingly, more nMP 
was apparently extracted from the PM25 than the PM5O system (Figure 4.14). If 
the same results are expressed in the actual molar amount extracted (% extracted x 
% incorporated), the amounts are 480.1 and 482.6 pmoles, respectively. 
The enhanced water uptake of PM25 and PM50 is presumably due to the water 
solubility of the nMP. Hence as nMP subsequently leaches out, the solubility of 
water in the system will also decrease and excess water will also be lost. (In 
thermodynamic terms, there is a reversal of chemical potential. ) The total mass 
changes at any given time therefore include loss of nMP, other reagents and water. 
The picture is further complicated by the fact that desorption is generally started 
some time after the maximum uptake point in the absorption plot; hence the final 
desorbed amount will not correspond to the maximum uptake. Ideally the 
difference between the maximum uptake and the desorbed amount should equal 
the difference between the maximum uptake and' the uptake value at which 
desorption was started. In Table 4.2 it is seen that this is approximately true for 
PM50 (5.1% and 5.5%) and less so for PM25 (7% and 5.1%). Given the 
complexity of the processes during the sorption cycle, this is not unexpected. 
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CHAPTER 5 SORPTION, RELEASE, & 
LEA CHANTANAL YSIS OF THE POL YMERIC 
SYSTEMS IN THE PRESENCE OF. DEXTRAN 
5.1 INTRODUCTION 
This section investigates the dextran release behaviour, using dextran as a model 
drug, from the PEM/THFM, PEMiTHFA systems and PEM/THFM containing, 
25%nMP and 50% nMP, respectively. The effect of the molecular weight of the 
dextran on water sorption and dextran release were studied. Dextrans were used 
as a model drug since various molecular weights are available without altering 
their molecular structure. The molecular weights studied were 10,35 and 71kD. 
The water uptake and desorption characteristics of these systems are described in 
Section 5.1.1. The preliminary dextran release data is reported in Section 5.1.2, 
using 10 and 70kD FITC-dextrans, analysed by Fluorometry. Section 5.1.3 
details the HPLC analysis of the external solutions, in order to identify and 
quantify the components leached from these systems. A novel technique (CLSM) 
was undertaken to study the transport of the FITC dextran molecules within the 
polymeric systems immersed in water, over 7 days (Section 5.1.5). 
5.1.1 WATER ABSORPTION AND DESORPTION 
The water absorption data for the polymeric systems were obtained in the same 
manner as the parent polymeric systems, according to the procedures described in 
3.4. l. a. The addition of dextran was conducted as described in section 3.3.2. The 
mean of the triplicate specimens have been plotted with error bars, throughout this 
chapter. It should be noted that in general the reproducibility between the three 
specimens was reasonable. 
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5.1.1. a WATER SORPTION OF PEM/THFM AND PEM/THFA INCORPORATING 
DEXTRANS 
The effects of lOkD, 35kD and 7lkD molecular weight dextrans on the water 
absorption for PT and PA systems are shown in Figure 5.1. The percentage 
weight change was plotted against square root of time. The initial linear region 
extends up to -'300s"12 for PT and -600s"12 for PA. Clearly, the incorporation of 
the dextrans has substantially enhanced the total absorption compared to the 
corresponding parent systems (e. g. from -2% for PT to 22.8% for PTD10 and 
24.3% for PTD35 and from -6.5% for PA to 16.5% for PAD35). 
Although the PT systems appear to equilibrate over the time scale, of the 
experiment, the PA systems reach a quasi-equilibrium before undergoing weight 
loss as noted in 4.1.1. a. These PA systems have been immersed in water for 
-16.5 months and show no sign of equilibrating. Visual inspection of all the 
samples showed the surface to contain raised bubble-like features, again as 
previously noted for the parent systems. 
At this stage there appears to be little correlation between percentage uptake and 
the molecular weight of the dextran incorporated. This is initially surprising, 
because if the absorption is largely through droplet formation, then according to 
Muniandy and Thomas theory (Muniandy and Thomas, 1987), absorption should 
be inversely proportional to the molecular weight of the dextran. There seems to 
be little correlation between the percentage uptake and the molecular weight of 
the incorporated dextran for both PT and PA systems; this feature is discussed 
further in section 5.2 
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bii) 
Figure 5.1 Water uptake of 10,35 and 71kD dextran loaded PEM/THFM (ai 
and bi) and PEM/THFA (aii and bii) in Distilled Water 
Duration a)-16.5 months b) 15 days (n=3) 
5.1.1. b WATER SORPTION OF PEM/THFM CONTAINING DEXTRANS AND 25 % 
OR 50% NMP 
Figure 5.2 demonstrates that the water sorption of the plasticised systems 
containing dextrans, are similar to the plasticised systems without dextran. The 
sorption profile of the plasticised systems with dextran is convex to the t"2 axis 
and concave to the t axis as observed in section 4.1. l. b. Figure 5.3 confirms that a 
linear plot is achieved when the data were re-plotted as percentage uptake/ timet/2 
'/2 versus time, similar to their corresponding parent systems. 
The plasticised systems reached a maximum water uptake at 500,600 and 800sý1/ 
incorporating 10,35 and 7lkD dextrans respectively, followed by a -8% decrease 
in weight until -3500sI (Figure 5.4). Note that Figures 5.2 and 5.4 differ in time 
scale, from -1000 to 5000s' /2 respectively, in order to clearly demonstrate the 
uptake trends over time, for these systems. The inclusion of dextran appears to 
have the same effect as on PT and PA systems by increasing the maximum 
percentage water uptake by -10% (for example from 34% for PM25 to 42% for 
PM25D10,24% for PM50 to 31% for PM50D10). The incorporation of the three 
molecular weight dextrans showed similar sorption profiles up to the point of the 
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maximum weight change. Subsequent to this point the negative weight change 
which follows demonstrates variability in the percentage amount absorbed, but 
there are departures beyond this point for each system. There is no particular 
trend observed for the different molecular weights. 
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Figure 5.2 Water Uptake of 10,35 and 71kD dextran loaded PEM/THFM 
with 25% (PM25) (Unfilled) and 50% (PM50) (Filled) nMP in Distilled Water 
Duration - 15 days (n=3) 
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Figure 5.3 Intermediate Diffusion plot of 10,35 and 71 kD dextran loaded 
PEM/THFM with 25% (Unfilled) and 50% (Filled) nMP in Distilled Water 
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Figure 5.4 Water Uptake of 10,35 and 71kD dextran loaded PEM/THFM 
with 25% (PM25) (Unfilled) and 50% (PM50) (Unfilled) nMP in Distilled Water 
Duration - 14 months (n=3) 
5.1.1. c WATER SORPTION OF POLYMERIC SYSTEMS CONTAINING FITC- 
DEXTRANS 
As mentioned earlier, in order to identify/quantify dextran release from these 
polymeric systems, the dextran needed to be spiked with 1% FITC dextran. The 
water absorption behaviour of the spiked drug loaded systems was investigated to 
see if the spiked dextran affected the absorption profiles. 
Figure 5.5 demonstrates that by spiking the lOkD dextran with 1 %w/w of lOkD 
FITC-dextran the percentage water sorption profiles are not altered for the four 
polymeric systems PT, PM25, PM50 and PA (Figures 5. Ibi, 5.2 & 5.5). The 
duplicate samples demonstrate good reproducibility, however Table 5.1 highlights 
that the addition of FITC increases the sorption by a further 10% for all the 
polymeric systems, although the total absorption differs, for each system. Clearly 
the FITC contains hydrophilic moieties. 
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Figure 5.5 Water uptake of IOkD FITC-dextran loaded polymeric systems 
Table 5.1 Comparison of the Water Sorption of the lOkD dextran and the lOkD 
FITC dextran 
Water Absorption (%) @ 800s'2 
Polymeric systems 10kD dextran 1OkD FITC dextran Difference 
PT 8 18 10 
PM25 40 50 10 
PM50 29 39 10 
PA 12 21 9 
5.1.1. d DESORPTION OF PEM/THFM, PEM/THFA AND PEM/THFM WITH 
NMP SYSTEMS INCORPORATING VARIOUS MOLECULAR WEIGHT 
DEXTRANS 
Figures 5.6 (a and b) and 5.7 are plots of percentage desorption versus square root 
time and M, /Mm versus square root time respectively, for the dextran loaded 
systems, PT and PA. The two plots have been incorporated since the difference 
between the percentage desorption, for each system, can be observed in Figures 
5.6a & b, as opposed to Figure 5.7, where the data has been normalised. Figure 
5.7 shows that on a normalised plot there is very little difference between the PAD 
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and PTD systems. 
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Figure 5.6 Desorption of the polymeric systems, a) PEM/THFM (PT) and b) 
PEM/THFA (PA), with 10,35 and 71kD dextran, in Distilled Water 
Duration = 10 days (n=3) 
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Figure 5.7 Normalised desorption plot of the polymeric systems, PEM/THFM 
(PT) and PEM/THFA (PA) with 10,35 and 71kD dextran, in Distilled Water 
Duration = 10 days (n=3) 
Figure 5.8 is a plot of MAIM. versus square root time for the desorption of the 
plasticised systems containing dextran. The slopes of Figures 5.7 & 5.8 are 
governed by the thickness of the specimens and the diffusion coefficients. Since 
the thickness is the same for all specimens they demonstrate that the diffusion 
coefficients are also similar, in the respective tables. 
It is evident that the desorption weight loss is similar to that of the corresponding 
parent systems and, as mentioned in section 4.1.1. d, desorption is much more 
rapid than absorption since equilibrium was reached over a period of two weeks 
for all the systems. The water loss on desorption follows simple diffusion theory, 
with all the plots going through the origin, (Figures 5.7 and 5.8), indicating the 
water loss mechanism to be Fickian Case II. 
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Figure 5.8 Desorption of the polymeric systems, PEM/THFM with 25% 
(PM25) and 50% nMP (PM50), with 10,35 and 7lkD dextran, in Distilled Water 
Duration = 10 days (n=3) 
5.1.2 DEXTRAN RELEASE 
This section investigates the drug release behaviour of the four polymeric 
systems, using Fluoresceinated dextran (FITC-dextran) as a model drug, as 
described in 3.4.2. Two molecular weights of FITC dextrans of lOkD and 70kD 
were incorporated in the systems respectively, according to 3.3.2. b, to ensure that 
their release could be analysed by fluorometry (Section 3.4.3). Cumulative and 
sequential release studies were (defined below) performed to assess the amount of 
dextran released, following the experimental procedures outlined in Section 
3.4.3. aiii. 
5.1.2. a CUMULATIVE STUDY: RELEASE OF 10KD AND 70KD FITC-DEXTRAN 
FROM POLYMERIC SYSTEMS 
The cumulative drug release profiles for the four systems are shown in Figure 5.9. 
The percentage release has been plotted against the square root of time for the 
lOkD FITC-dextran loaded PT (PTFD10), PM25 (25FD10), PM50 (50FD10) and 
PA (PAFD10) systems. Duplicate specimens per system have been used as 
opposed to triplicate samples in order to reduce the sample numbers for analysis. 
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The results were consistent and reproducible and all subsequent plots are shown 
as an average of the duplicate samples with error bars. 
The percentage release gradually increased up to -120s1/2 for all four polymeric 
systems. Following this, there was a slight decrease in release prior to a further 
increase for three of the polymeric systems, with the exception of PAFD10. The 
latter continued to show a decrease in dextran release. The latter is very unlikely 
to be the case since the immersion solution remained the same throughout the 
experiment. This will be discussed further in Section 5.2. 
When the 70kD FITC dextran release data was plotted against t"'', no clear trend 
was observed, for any of the systems (Figure 5.10). Hence, in order to investigate 
if the leached substances reacted with the FITC-dextran, a sequential study was 
carried out. 
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Figure 5.9 Cumulative Percentage Release of IOkD FITC-dextran from FITC- 
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Figure 5.10 Cumulative Percentage Release of 70kD FITC-dextran 
from FITC-dextran loaded Polymer Systems PTFD10,25FD10,50FDIO and 
PAFD 10 
5.1.2. b SEQUENTIAL STUDY RELEASE OF 10KD AND 70KD FITC-DEXTRAN 
FROM POLYMERIC SYSTEMS 
In the sequential release the samples were placed in fresh distilled water following 
each time point. Here the aliquots analysed would contain the dextran released 
from one timepoint to the next only. These results are added together to produce a 
more relevant in vivo release profile use (i. e. in the mouth). 
Since the total dextran incorporated was spiked with 1% of FITC dextran the 
release data was multiplied by 100 to show the apparent dextran released. As the 
density of THFM monomer is 1.041g/cc, the weight of 3 ml = 3.1.23. Hence 
8.123g polymerised PEM/THFM contains 0.45g dextran, in other words the 
specimen contains 0.45/8.123x 100 = -5.4% dextran or 0.054% FITC dextran. 
Figures 5.11 and 5.12a and b have been plotted as percentage release against the 
square root of time for PTFD, PM25FD, PM50FD and PAFD with lOkD and 
70kD FITC-dextrans, respectively. In Figure 5.11, there is an initial linear region 
for the PTFD, PAFD polymeric systems up to -200 seconds ýý. The release 
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profiles then begin to depart from linearity. However PAFD continues to release 
more dextran, whereas PTFD slows down and appears to stabilise. The sequential 
plot also demonstrates that the amount of FITC-dextran released increases with 
time for all the systems, as opposed to the cumulative plot, where it appeared to 
decrease for PAFD (Figure 5.10). The sequential plot confirms that the 
accumulation of THFA in the solute does interfere with the analysis of FITC- 
dextran. 
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Figure 5.11 Sequential Percentage Release of lOkD FITC-dextran from 
PTFD10 and PAFD10 systems 
PM50FDIO shows an anomalously high percentage release in this experiment 
(Figure 5.12a). Hence the release data for all four systems excluding PM50FD 10 
were re-plotted on a smaller percentage release scale to show the release profiles 
of these systems clearly (Figure 5.12b). The latter plot confirms, as noted with 
the cumulative release data, that the 50% nMP system has the highest percentage 
dextran release, 50FD 10 (56%) and 50FD70 (14%), followed by the 25FD 
(10&70), PAFD (70& 10) and PTFD (70& 10). 
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Figure 5.12 Sequential Percentage Release of 10 and 70kD FITC- 
dextran Polymer Systems PTFD, 25FD, 50FD and PAFD a) overview of 
dextran release for all systems b) Enhanced view of dextran release up to 16% 
Weight changes, were noted simultaneously to the dextran release, which 
demonstrated PM25 to have the highest percentage water uptake (Figure 5.5), 
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whereas PM50 appears to have a higher percentage dextran release for both IOkD 
and 70kD dextran. 
The larger molecular weight dextran (70kD) samples generally had a lower 
percentage release as expected (Figure 5.12a), since the larger molecule would be 
expected to experience more difficulty in diffusing through the partial 
interpenetrating polymeric network. 
Figure 5.13a demonstrates that the release pattern of the polymeric systems is 
generally consistent; but the graphs for the duplicate specimens are not very 
reproducible when plotted in this manner. It is suggested that this reflects the 
uneven distribution of labelled molecules, and that the actual release of dextran 
itself is more reproducible than at first appears. In order to test this hypothesis the 
results have been normalised in those cases where the release profile has flattened 
out over a longer time period (Figure 5.13b). When the data is normalised as 
M, 1M0. plotted against the square root of time for each specimen, Figure 5.13b 
shows that the reproducibility improves significantly. This is discussed further in 
section 5.2. 
a) 
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Figure 5.13 Sequential Percentage Release of 70kD FITC-dextran Polymer 
Systems PTFD 10,25FD 10,50FD 10 and PAFD 10 a) percentage release 
b) Mt/M versus timet/2 
5.1.3 ANALYSIS OF EXTRACTED MATERIAL FROM POLYMERIC SYSTEMS 
INCORPORATING VARIOUS MOLECULAR WEIGHT DEXTRANS AND FITC- 
DEXTRAN 
The external solutions of the polymeric systems containing dextrans were 
analysed on the HPLC, following -90 days of immersion, and 21 days for the 
FITC-dextran samples. This was to determine the effects of incorporating various 
molecular weight dextrans and FITC-dextrans, on the leaching of components. 
The analysis of the extracted materials for the dextran incorporated polymeric 
systems demonstrated that the amount leached had not been greatly influenced by 
the molecular weight of the dextran. A very small amount of THFM monomer 
was released, like the parent PT system as shown in Figure 5.14, which compares 
the leachant amounts from the dextran loaded (block) and the parent (striped) 
systems. 
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Figure 5.14 Percentage leaching of THFM, nMP and THFA from different 
molecular weight dextran loaded systems at approximately 90 days (n = 2) 
The plasticised systems do not appear to have been affected greatly; in fact these 
systems appear to have leached slightly less on the inclusion of dextran. The ratio 
of nMP leaching from the PM25 and PM50 systems remained 2: 1 for parent and 
the dextran loaded systems as seen with the parent systems. The residual leaching 
of THFA has increased very slightly with the incorporation of 10 and 71 kD 
dextrans (PA (without dextran) = 4.5%; IOkD=5.4% and 71 kD=5.0%). 
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Figure 5.15 Leached components from the polymeric systems PT, PM25, PM50 
and PA loaded with IOkD and 71kD FITC dextran (ns = fresh DW solution) a) 
molar amount b) percentage amount (n=2) 
The amount of DMPT leached is very small, however it must be noted that Figure 
5.15a shows that prior to dextran addition, DMPT was not detected in the 
immersion solutions. 
The incorporation of FITC-dextran increases the percentage leaching of THFA 
and nMP (i. e. PA- I OkD FITC = 7.8%; 71 kD FITC = 6.0%) (Figure 5.15b). The 
IOkD FITC-dextran specimens showed exceptions to this and leached slightly 
lower amounts (nMP - 25FD10 = 18.3%; 50FD10 = 10.3%). It must be noted that 
these specimens were in solution for 7 days whereas all other samples were 
immersed for 21 days. The lOkD FITC-dextran specimens were placed in new 
solution (ns) following the initial 7 days, to verify if leaching was affected by 
saturation of the solutions. Figure 5.15 demonstrates that FD l OkD (ns) leaches 
more FITC dextran (i. e. leaching continues) when placed in new solution. 
5.1.4 OSMOTIC MEASUREMENTS ON DEXTRAN SOLUTIONS 
The osmolarity of both the artificial saliva used (Orthano) as well as the various 
dextran solutions was measured as described in section 3.4.5. These experimental 
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values were compared with theoretical values. In the case of the artificial saliva, 
the theoretical value was calculated from the osmolarity (0) using: 
0=c, /Mi equation 5.1 
Where i=1,2,3 etc are for each of the various constituents of Orthana as 
obtained from the manufacturer; electrolytes are given as the concentration of 
each ion present. M= molecular weight of each constituent, c= concentration of 
that constituent. This gave 0= 246m. moles/Kg, compared with an experimental 
value of 235.2m. moles/Kg (from the osmometer). In the case of dextrans, 
O=c/M equation 5.2 
Where M is the molecular weight of the dextran, as published by the 
manufacturer. This data, along with that for the Orthano is presented in Table 5.2. 
Table 5.2 Experimental and Theoretical Osmolarity Measurements of Dextran 
Dextran Concentration Osmolarity (mmol/L) Calculated 
(manufacturers M) (g/L) Experimental Theoretical (Me) 
lOkD 
5.26 3 0.526 1754 
11.1 5 1.11 2222 
7lkD 11.1 4 0.176 3125 
Clearly there are marked discrepancies between the theoretical and experimental 
osmolarities. It is therefore instructive to calculate the molecular weights of the 
two dextrans from the available data. The molecular weight (Me) was calculated 
using equation 5.3: 
MM=CIO equation 5.3 
Where 0 is obtained from the osmometer and c is the concentration of the 
solutions. This data is also presented in Table 5.2, together with the manufactures 
published values. There are disparities between the molecular weights calculated 
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and those given by the manufacturer. This will be discussed further in section 
5.. 2.1. b. It should be noted that the values for osmolarity of 3-5 osmol/kg are at 
the lower limit of the instrument. 
5.1.5 SUMMARY OF SORPTION, DESORPTION, DRUG RELEASE AND EXTRACTED 
MATERIALS 
Table 5.3 summarises and compares the mass gain and loss, percentage solubility, 
adjusted water uptake, percentage leached, sorption and desorption diffusion 
coefficients and dextran release for the four polymeric systems, (PT, PM25, PM50 
and PA) incorporating different molecular weight dextrans. The PM25D71 had 
the highest water uptake (46.9%) followed by PM25D35 (44.2%) and with 
PM25D1O (42.3%). The presence of dextrans increased the water uptake of all 
the polymeric systems (cf Table 4.1, page 139), however the effects were largely 
independent of the manufactures published molecular weight of the dextrans. 
As mentioned in section 4.1.3 the diffusion coefficient of nMP absorption could 
not be calculated since a non-Fickian process applied (intermediate). However it 
must be noted that PM25 continues to have the highest maximum percentage 
uptake for all three molecular weight dextrans. 
The desorption diffusion coefficients of the PT and PA systems remained 
significantly faster than the absorption, and the overall diffusion values for both 
absorption and desorption appear to have increased with the addition of dextran, 
compared to their corresponding parent systems (e. g. 4.43 & 9.49 x 10'12 m2/sec 
for PT and PTD 10, Table 4.1 & 5.3 respectively). 
Although the percentage loss was expected to be similar to the sum of percentage 
gain and solubility, it did not prove to be the case for -the plasticised systems 
(Table 5.4). For the latter the percentage loss was greater than the sum of gain 
and solubility; as observed for the parent systems. However, the addition of 
dextran appears to have increased this difference between the loss and the 
adjusted water uptake values from approximately 7% to 14.3% (mean of lOkD, 
35kD & 7lkD dextrans). 
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The final column in Table 5.4 shows the difference between the maximum 
absorption and the final weight change before the desorption measurements begin, 
obtained from the relevant graphs (see Figures 4.13 and 5.4). While this data does 
not correspond exactly with the data in the previous column, it accounts in some 
degree for the apparent disparities. That it does not do so exactly may well reflect 
that at no point during the sorption cycle are these systems at equilibrium. 
Table 5.4 Difference between the weight gain and loss for the plasticised systems 
Composition 
Adjusted 
water 
sorption (%) 
Desorption Difference 
Gain-Final 
(%) 
IOkD 54.0 40.8 13.6 8.6 
PM25 351W 55.4 40.9 14.5 12.2 
7lkD 57.5 42.2 14.7 10.4 
101W 41.7 34.0 7.7 7.5 
PM50 35kD 42.9 33.8 9.1 10.7 
r71kD 46.7 36.8 9.9 4.7 
5.2 DISCUSSION ON DEXTRAN INCORPORATION 
5.2.1 THE EFFECT OF DEXTRAN ON TIIE MASS GAIN AND LOSS 
5.2.1. a INTRODUCTION 
When the polymeric systems (particularly the plasticised systems) had dextrans of 
10,35, and 7lkD molecular weight incorporated, the water uptake was greatly 
enhanced (- 10 fold) as seen in Figures 5.1 & 5.2 (pg 157 and 158). The initial 
part of the uptake remained linear with respect to 0 exhibiting Fickian uptake. 
This indicates that water diffuses into the polymer and saturates the matrix prior to 
partially dissolving the dextran/drug. Droplets form around the soluble particles, 
which grow until either equilibrium is reached, or failure occurs. In the case of the 
dextran loaded systems the osmotically driven droplet formation, at the site of the 
dextran, overrides the effect of the existing osmotic sites in the PEM/THFM 
system (See section 2.7.3. b). 
Jenneson et al. 1998, states that when water is absorbed by the material it 
associates with the matrix more readily, as opposed to forming droplets. However 
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in the case of the PT itself previous researchers have demonstrated that there is a 
strong clustering mechanism in place (Patel et al, 1998 & 2001; Rigg et al., 1999). 
This phenomenon is enhanced by the presence of dextran as it is a water soluble 
additive added at 5.4% w/w. This leads to greater water ingress into the dextran 
sites and with droplet formation. Previous researchers who incorporated water 
soluble additives in to the PEM/THFM system also found absorption increases 
(Patel et al, 1994; Di Silvo et al, 1994,; Patel et al, 1998; Sawtel et al, 1997; Swai 
1997; Patel et al, 2001). Hence in the present work it has been found that the 
water uptake is governed by the presence of dextran. 
5.2.1. b THEORETICAL CONSIDERATIONS 
Muniandy and Thomas observed similar behaviour to the above when water 
soluble moieties were incorporated in poly(cis isoprene), for which they 
established a theoretical basis (Muniandy and Thomas, 1987 & Section 2.7.4. b). 
They highlighted an osmotic process, whereby the water soluble moieties dissolve 
in the water diffusing through the polymer matrix, and form droplets which grow 
by the osmotic pressures developed, thus developing elastic strains. The 
theoretical treatment uses the form of Fick's Law in terms of chemical potential. 
The principles established by Muniandy and Thomas for elastomers can be used 
in the current work, but needs changing to apply to a rigid, ductile polymer, since 
the elastic forces developed here are in a rigid polymer. The elastic pressure must 
be formulated in terms of classical elasticity theory. (See Appendix I for the 
detailed theory. ) The salient points from this theory are : 
i) The calculated circumferential strains around the droplets are very 
much higher than the estimated elastic limit of the PEM/TIIFM 
system i. e the implication is that the bulk of the droplet growth 
process is by plastic (irrreversible) flow. This would seem to be 
supported by the fact that the opacity that occurs in the polymer 
system during the water uptake process, persists on desorption. 
ii) The, pressure required for the circumferential strain to exceed the 
elastic limit is -2MPa 
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iii) The osmotic pressure within the droplet calculated from the 
concentration of dextran within the polymer and the maximum water 
uptake is --0.41MPa- less than the required elastic pressure by a 
factor of -5. However the equation for osmotic pressure used is for 
dilute solutions, and the concentration of dextran in the droplets is 
26%. This suggests that an equation for the osmotic pressure for 
concentrated solutions should be used. eg: 
II cRT/M ( 1+Ac+Bc2+ Ec3 ----] 
This suggestion is supported by the observation that when the immersion medium 
is artificial saliva (Orthano), there is a small reduction in the water uptake. 
However the osmolarity of the artificial saliva is 246m. osmols/kilo (see Section 
5.1.4); the osmolarity of the dextran solutions within the droplets, using the 
simple vant'Hoff equation is 148m. osmols/Kg. Clearly, this is less than the 
measured osmolarity of the artificial saliva, and under these conditions the uptake 
would only be that of the polymer system itself; in fact the uptake in artificial 
saliva is only slightly less than that in water, indicating that the actual osmolarity 
in the droplets is> 246milli osmols/Kg 
The water uptake process consists of two stages, primary and secondary. This has 
been illustrated in Figure 5.16 where the PEM/THFM in DW uptake data has been 
subtracted from the PEM/THFM with 70kD dextran (red circles) data. Here the 
change in mechanism is more obvious following approximately 40 minutes/. Up 
to 10 minutes/ the PTD70 and the PT plots coincide. Beyond this point the 
PTD70 plot accelerates exhibiting a secondary process of which is linear. This is 
reminiscent of the data obtained by Muniandy and Thomas, when droplets formed 
in cross-linked polyisoprene doped with NaCl (1987). In the Muniandy and 
Thomas work, it was interesting to note that the intercept was not present on the t' 
axis, and the plots went through the origin. The part corresponding to the initial 
saturation of the polymer matrix was indiscernible; this was hardly surprising, in 
that the equilibrium sorption of the poly isoprene matrix was -0.023%, and the 
diffusion coefficient was -10"10m2sec'1. 
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Figure 5.16 70kD dextran-water uptake data - water uptake of PEM/THFM 
The intercept time varied for the 35kD and 70kD systems, at -400 and 625 
minutes, respectively. Hence it is interesting to note that the intercept of the 
secondary region with the t" axis appears to be a function of molecular weight 
(Figure 5.17), although there are only three molecular weight dextrans in this 
study. (Please note the molecular weights used here are those provided by the 
manufactures). 
f: 
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Figure 5.17 Relation between intercept time for the change in uptake and the 
molecular weight of dextran 
5.2.1. c PLASTICISED SYSTEMS 
The plasticised systems also followed the intermediate diffusion process with the 
inclusion of the three molecular weight dextrans. The statistical analysis in Table 
5.5 confirms this. In all cases the correlation coefficient (R) shows a significant 
linear correlation at confidence levels indicated in Table 5.5. 
Obviously nMP has substantially increased the water absorption of the PT system 
itself. This could be for two reasons: 
i. nMP is completely miscible with water, so its incorporation will confer 
some hydrophilicity on the PT system. 
ii. nMP will lower the modulus of the PT system and thus enhance the 
secondary absorption process of the PT system itself. 
It is also of note that the presence of dextrans further increases the absorption of 
the plasticised systems, presumably as a result of the lower modulus as predicted 
in equation Al (Appendix 1). 
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Table 5.5 A statistical analysis on the intermediate diffusion of the various 
plasticised systems 
System R Degrees of 
freedom 
*Confdence 
Level 
a B 
PM25 0.8551 13 <0.1 hs 0.00008 0.0222 
PM50 0.7321 13 <0.05 s 0.00005 0.0243 
PM25D10 0.8431 13 <0.01 hs 0.0002 0.0395 
PM50D 10 0.8717 13 <0.01 hs 0.0002 0.0308 
PM25D35 0.8698 13 <0.01 hs 0.0002 0.0381 
PM50D35 0.8818 13 <0.01 hs 0.0002 0.0321 
PM25D71 0.8555 13 <0.01 hs 0.0002 0.0337 
PM50D71 0.8422 13 <0.01 hs 0.0002 0.0343 
hs = highly Significant s= significant 
*that is probability of the null hypothesis 
5.2.2 DEXTRAN RELEASE 
Parallel experiments on FITC-dextran release analysis were carried out 
simultaneously on the water sorption profiles of the same specimens. Previous 
studies reported that the methodology of removing aliquots of the immersion 
medium for analysis may affect the concentration gradient which in turn will 
affect water absorption and drug release (Medlicott et al, 1999). Some studies 
have shown that there is no significant difference caused by the removal of the 
aliquots (Meththananda, 2004). In the cumulative method, dextran builds up in 
the immersion liquid, as this increases, the rate of release from the specimen 
decreases. Both the above are avoided by using the sequential method, where the 
immersion solution is changed at regular intervals. 
5.2.2. a RELEASE FROM TUE PT AND PA SYSTEMS 
When cumulative release was plotted for the PA system it appeared that the F1TC- 
dextran content was decreasing. However the sequential plot demonstrated a 
steady increase in release (Figure 5.11). This confirmed that the former was a 
result of accumulated THFA that had leached in the solute, was interfering with 
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the analysis of FITC-dextran. Since THFA is a more reactive monomer compared 
to THFM (Tani and Hashimoto, 1982), there is a possibility that the THFA was 
reacting with the FITC part of the FITC-dextran molecule, by either breaking it 
down or inhibiting its fluorescence. 
In general the release profiles appear to be linear with respect to ti ß, but it has not 
always been possible to determine diffusion coefficients because equilibrium has 
not always been obtained. 
Over the time scale of the experiments (2 weeks), very small amounts of the two 
molecular weight dextrans were released from PT, (1.9 and 1.6% for 10 and 70kD 
systems respectively (Figure 5.11)). Rather more was released from the 
PEM/THFA system (4.4 and 3.9 % 10 and 70kD systems respectively), but the 
release process had not equilibrated and the plots were still approximately linear. 
This indicates the important role of molecular flexibility. 
The Diffusion Coefficient for the release of dextran was not calculated since 
equilibrium was not achieved for release. 
5.2.2. b RELEASE FROM THE PLASTICISED SYSTEMS 
It is evident from Figure 5.12 that over the time scale of the experiment (7-days), 
the presence of nMP has enhanced release of dextran by a factor of 6-14 fold. 
More quantitative conclusions are not possible because of the limited data 
available. Hence one of the objectives of this current work has been achieved 
(Section 1.1), although considerably more work is needed to get a full 
understanding of the process involved 
The role of nMP transpires to be critical in enhancing the release of dextrans from 
PEM/THFM. This in turn is attributable to the enhanced water uptake in the 
presence nMP, due to its hydrophilic nature as well as its' plasticiser action. If for 
example, a phthalate plastisicer had been used, there would have been no 
enhancement of water uptake because phthalates are hydrophobic. 
182 
Chapter 5: Addition of Dextran 
Although the polymer systems with 25% nMP had higher water absorption, the 
50% nMP systems had higher dextran release for the lOkD and 70kD dextran 
loaded systems. This shows that PM50 has an overall lower percentage weight 
change due to the high dextran release. Some additional water/solution loss will 
occur, from the systems, with the release of dextran, which will also affect the 
overall weight change. Hence for the systems where multiple processes are being 
undertaken simultaneously (i. e. nMP leaching, sorption, dexran release) it can not 
be assumed that the percentage weight change profile shows the complete water 
absorption capacity. 
The desorption process will also only indicate the loss of water which remains 
within the system at the beginning of the desorption process. However, the lOkD 
dextran release was much higher, at --55% (for 50FD10; Figure 5.12a) of the 
original amount incorporated, which could be due to the size of the molecule, 
within the systems. This could be due to an anomalous result for the lOkD 
dextran systems or alternatively it could be a due to the larger molecular weight 
dextran (7OkD) experiencing more difficultly in diffusing through the partial 
interpenetrating polymeric network. This leads to the 70kD dextran systems 
generally having a lower percentage release. 
5.2.3 ANALYSIS OF EXTRACTED MATERIAL 
As noted in section 4.2.6, THFM is not extracted in measurable amounts from the 
various systems studied (Figure 4.13). This remains true even subsequent to the 
inclusion of dextran. However THFA (MW = 168) was extracted from the PA 
system containing the various molecular weight dextrans, in the current work 
(Figures 5.14 and 5.15). 
The addition of FITC-dextran increased the residual leaching of THFA, hence it 
can be deduced that although dextran is not thought to partake chemically in the 
polymerisation process, the presence of such large molecules appears to further 
interfere with the polymerisation process. The FITC part of the molecule appears 
to cause greater interference leading to incomplete polymerisation. However the 
FITC dextran did not affect the residual leaching of THEM from the systems. 
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The addition of FITC-dextran also increased the over all loss of nMP, with the 
exception of IOkD FITC-dextran incorporated samples, which were immersed in 
solution for a shorter period of time (7 days as opposed to 21 days) (25FD10 = 
18.3%; 50FD10 = 10.3%). However there seems to be no clear trend between 
percentage amount of nMP incorporated and the amount extracted. Although the 
inclusion of dextran and FITC dextran has increased the actual amount leached, 
this increase has been consistent for both systems. The immersion period for 
lOkD was shorter as these samples were withdrawn and placed in a new solution 
(ns) to review the effects of the external solution on the extraction of the 
constituents. Figure 5.15a illustrated that once the specimens are placed in new 
solution the extraction of the constituents continues and an even greater amount is 
extracted. 
The leaching process appears to be influenced by the presence of water soluble 
moieties in the water. This in turn indicates that the external solution influences 
the leaching process hence it would probably also affect the dextran release 
process. So not only is the water sorption process influenced by the internal and 
external osmotic potentials, it seems that the drug release and the leaching 
processes are also inter-connected. Hence understanding this relationship is vital 
in creating a predictable delivery device. 
Addition of dextran decreased the setting time further, possibly due to ball milling 
increasing the surface area of the particles 
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CHAPTER 6 ADDITION OF 
CHITOSAN TO METHACRYZATE BASED 
POLYMERIC SYSTEMS 
6.1 INTRODUCTION 
Further modifications to the experimental PEM based systems discussed in the 
previous chapters, involved adding chitosan, a mucoadhesive material (Calvo et 
al, 1997) and a possible permeation enhancer (Borchard et al, 1996) (see literature 
review, section 2.11). This pilot study was carried out to examine the effects of 
incorporating chitosan on the water sorption and lOkD FITC-dextran release 
properties of the parent systems (6.1.1 & 6.1.2). The results of the analysed 
external solutions and leached components are shown in section 6.1.3. 
6.1.1 WATER SORPTION OF CIIITOSAN INCORPORATED SYSTEMS 
Water sorption studies were undertaken for all four polymeric systems 
incorporating IOkD FITC-dextran and chitosan, using three specimens per system. 
The water absorption profiles of the four systems are shown in Figure 6.1 as plots 
of percentage weight change against time1/2. All these systems had a rapid initial 
uptake with a change in absorption pattern after 75s't2 (ihrs) (see arrow on Figure 
6.1). This also occurs for the plasticised systems with chitosan. PT and PA 
appear to stabilise between -400- 1100s'n. 25FDIOC and 50FD1OC have 
maximum weight changes at 400s' (25FD1OC= 23%; 50FD1OC = 33%). From 
75-200sm the systems began to vary in that the PT and PA systems absorb water 
in a more protracted manner, they do not appear to stabilise but instead peak at 
"200s1"2, before the protracted absorption continues. The plasticised systems 
appear to have a more steep absorption up to the -400s'n, following which they 
appear to equilibrate. 
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Figure 6.1 Water uptake of Chitosan loaded Polymeric Systems, PTFDIOC, 
25FD l OC, 50FD l OC and PAFD l OC 
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Figure 6.2 Average Water uptake of Chitosan loaded Polymeric Systems, 
PTFD 1 OC, 25FD 1 OC, 50FD l OC and PAFD I OC percentage weight against t up to 
-9hrs 
It must be noted that following the 100s/2 point the sorption profiles for the 
plasticised systems appear to be convex to t/ (up to -200 sh'`) (Figure 6.1). 
Hence, the data were re-plotted against time instead of square root of time up to 
-9 hours (Figure 6.2). Here there appears to be a small change in uptake up to 15 
minutes (-900 seconds); subsequent to this, the uptake is linear with time, up to 9 
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hours (30000s), and then starts to slow down. PTFDIOC and PAFDIOC behave 
conventionally i. e. Case I. 
6.1.2 DEXTRAN RELEASE 
The effects of Chitosan on the dextran release characteristics of the systems were 
studied, over 7 days, by incorporating lOkD FITC-dextran. The dextran release 
patterns are shown in Figure 6.3a, by plotting percentage release of FITC-dextran 
against the square root of time, for the Chitosan incorporated PT (PTFDIOC), 
PM25 and PM5O (25FDIOC and 50FDIOC) and PA (PAFDIOC) systems. 
Duplicate specimens were used for these studies due to time constraints, and the 
mean of these were plotted with error bars. For comparison purposes, the 
corresponding systems without chitosan also appear in this Figure. 
The eight systems shown in Figure 6.3a are linear with respect to tý up to _200s/. 
Beyond this point the 25FDIOC and 50FD1OC plots diverge, with substantial 
increases in the amounts released, compared to the plasticised system without 
chitosan. Hence the data was plotted as percentage release versus time, to 
ascertain whether release is zero order (Figure 6.3b). 
Figure 6.3 (b) shows that over much of the release period, 25FDIOC and 
50FD1OC, the plots are linear with time with correlation coefficients of 0.9791 
and 0.9758 respectively, which is significant at 0.05% level for 4°F. Hence in the 
presence of nMP and Chitosan, zero order release of dextran is achieved, with 
much higher yields (60-70%). However the PTFDIOC and PAFDIOC systems do 
not exhibit zero order release. The initial region up to 0= 50s/ is ill-defined. 
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As mentioned earlier in section 4.2.3, the reproducibility was not consistent when 
the individual specimen percentage release results were plotted against 0. 
However when plotted as Mt/M. versus square root of time the release profiles 
show reasonable reproducibility (Figure 6.4). 
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Figure 6.4 Sequential Percentage Release of 10kD FITC-Dextran Polymer 
Systems PAFD 10 M, /M versus time/ 
6.1.3 ANALYSIS OF EXTRACTED MATERIALS 
The solute from the water absorption and drug release studies for PTFD1OC, 
25FDIOC, 50FD1OC and PAFDl0C were analysed using HPLC. The percentage 
amount of components leached (i. e. THFM, nMP, THFA and DMPT), from these 
systems, based on the amount incorporated, were analysed after 50 days of 
immersion, following the water uptake study (Figure 6.5). 
25FD1OC leached a larger percentage of nMP in comparison to 50FD1OC (45- 
27% respectively) (Figure 6.5b). However the molar amounts leached, from these 
two plasticised systems are very similar, (25FD1OC = 880pmoles and FD1050C = 
1050µmoles), as noted with the parent system with and without dextrans (Figure 
6.5a). However when these values are compared to the molar amounts of nMP 
leached from the 25FD10 and 50FD10 systems (25FD10 = 480.1; 50FD10 = 
190 
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482.6; Section 4.1.2), it is apparent that the Chitosan incorporated systems 
leached approximately twice the amount of nMP out of the systems. 
PAFDIOC has a higher residual leaching of THFA (9.2%, 4.64V moles), compared 
to PTFDIOC, which leaches THFM (0.2%, 1.64pmole); the latter is too small to 
be represented in Figures 6.5 a and b. It must also be noted that the amount of 
DMPT leached for the PAFD l OC system is larger than that leached for the other 
systems with Chitosan (i. e. PTFD I OC, 25FD l OC or 50FD l OC). 
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The solutes from the 3 timepoints of the drug release study of the four systems 
with lOkD FITC-dextran were analysed using HPLC. These immersion solutes 
were analysed, in order to determine the leaching profiles of the components, over 
a 48 hour time period at 8,24 and 48 hours after immersion (Figure 6.6 & 6.8). 
The leaching of DMPT from the dextran-chitosan incorporated polymeric systems 
was observed to increase with time. The PTFD l OC system had very little 
leaching of this component as opposed to the other systems and cannot be 
represented graphically. Detectable amounts of DMPT were present in the 
PAF1OC solute at the 1s` time point of 8 hours, whereas it was not detected in the 
plasticised systems solutes until the 48 hours time point (Figure 6.6). There was 
also a relatively higher concentration of DMPT present in the PAF1OC at 48hrs 
solute. The two plasticised systems appear to have leached similar amounts of 
DMPT subsequent to 48 hours of immersion. 
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Figure 6.6 Amount of DMPT Leaching from the polymeric systems 
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Figure 6.7 compares the leaching of components (nMP and THFA) from the four 
polymeric systems incorporating dextran (10,35 and 7lkD) and the Chitosan 
lOkD dextran incorporated systems. The addition of chitosan resulted in a 
consistent increase in leachants of two times that of corresponding systems 
without Chitosan. 
A very slight residual amount of THFM was found to leach from the respective 
systems, hence it is not shown in Figure 6.7, consistent with previous findings. 
The leaching profile for nMP was similar for both plasticised systems, PM25C 
and PM50C, in terms of the release trend and the amount leached (Figure 6.8). 
Subsequent to 48 hours of immersion the solute concentration of nMP was 168 
µmoles and 182 pmoles for PM25C and PM50C systems, respectively. 
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Figure 6.7 Comparison of percentage leached of 10,35and 71kD dextran 
loaded systems and IOkD dextran loaded with chitosan system (n=2) 
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Polymeric systems containing Chitosan with lOkD FITC-Dextran 
6.2 DISCUSSION OF THE EFFECTS OF INCORPORATING CHITOSAN 
Table 6.1. summarises and compares the equilibrium water uptake data for the 
Chitosan systems incorporating lOkD FITC-dextran. The 50FD l OC had the 
highest equilibrium water absorption (33.8%) followed by 25FD10 (23.2%) then 
PAFD I OC (19.5%) and finally PTFD I OC (12.8%), (Table 6.1). 
PT systems containing Chitosan, (Figure 6.2) exhibit linear absorption with time 
(over --9hrs) hence indicting Case II diffusion. This possibly is preceded by 
Fickian diffusion for a short time (initial linear regions in t"2 plots as shown in 
Figure 6.1). This suggests that the Chitosan incorporated samples exhibit Case II 
diffusion, possibly preceded by an initial period of Case I diffusion (Crank and 
Park, 1968). The overall absorption has also increased with the addition of 
Chitosan when compared to the parent systems (PT, 2.1%; PTC, 12.8% at 1100sV, 
Figures 4.2 & Figure 6.1, respectively) over a smaller time period. The diffusion 
coefficients were not calculated for these systems due to a short experimentation 
period. The systems were unable to equilibriate and reach max weight change 
after 7days of immersion hence, the values would not accurately indicate DC 
values. 
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Table 6.1 Summary of all the data for the Chitosan polymeric systems with 
IOkD FITC-dextran incorporated over 7 days 
Dextran 
Equilibrium 
Composition Release Amount leached (%) by HPLC 
(%)Gain 
(%) 
PTFDIOC 12.8 ± 0.27 39.8 THFM - DMPT 7.1 
25FD1OC 23.2 ± 2.75 75.3 nMP 45.2 DMPT 2.1 
50FD l OC 33.8 ± 0.43 63.1 26.8 3.4 
PAFDIOC 19.5 ± 1.67 38.4 THFA 9.2 DMPT 15.3 
Although these final values are not fully comparable to the parent and the dextran 
loaded system without chitosan, this study provides insight into the mechanism of 
the process and addition of chitosan over the initial time period. This is 
essentially the time period of most interest for these delivery systems. 
The most 'important finding however was that the water absorption obeys Case 11 
kinetics, in the presence of both chitosan and nMP, preceded at short times by 
Case I diffusion, as observed previously (Crank and Park, 1969). This shows that 
molecular relaxation is now a predominant factor in water absorption, which in 
turn suggests that chitosan is an effective plasticiser for the PEM/THFM system 
i. e. chitosan is miscible with the PEM/THFM. 
Furthermore, chitosan does not alter the kinetics of release for PTC, but only 
when incorporated with nMP (see Figure 6.3b, pg 187). 
The miscibility of a liquid/polymer system is governed by the Flory Huggins 
equation and in particular by the AH term, as given in equation 6.1 (Refer to 
section 2.9): 
AH =k (81 - S2)Z 6.1 
where S1 is the solubility parameter of the polymer, and S2 that of the liquid, k= 
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constant. Ideally of course, OH should be zero. 
From the chemical structure of the repeating unit of chitosan (see Figure 2.23), its 
solubility parameter S2 was calculated from the formula (Brandrup and Immergut, 
1974): 
6=py. G/M 6.2 
where G is the Group Interaction Parameter for individual chemical groups 
(Brandrup and Immergut 1974), M the molecular weight, and p the density. The 
Solubility Parameter for the plasticiser should be similar to that of the polymer to 
ensure the Heat of Solution (OH) is minimal. The value obtained for chitosan was 
17.03 x10"3(J/m)/ compared to PEM =19,0x1003(J/m3)% (Patel and Braden, 
1989), poly(THFM) = 20 x10"3(J/m3)`h (Patel and Braden, 1989), n-MP = 
23.1x10"3(J/m3)/ respectively Butyl phthalyl butyl glycollate (BPBG) (21.56 x10- 
3(J/m3)/) (Brandrup and Immergut 1974), is a common plasticiser in soft lining 
materials and tissue conditioners (see Table 2.10); there is little difference 
between nMP and BPBG. 
However, both nMP and chitosan differ from PEM and poly(THFM) by similar 
amounts. This indicates that n-MP and chitosan will have similar MI values, but 
greater than butyl pthalyl butyl glycollate. Although the former two are not as 
good plasticisers as BPBG, it must be noted that BPBG now carries a "Deaths 
Head" classification i. e. is hazardous, hence can no longer be used within 
polymeric systems destined for use in or around the human tissue. 4 
6.2.1 DEXTRAN RELEASE IN TUE PRESENCE OF CIIITOSAN 
Chitosan was incorporated in the systems for two reasons, its' apparent 
permeation enhancing and mucoadhesive properties, as shown by several research 
studies (e. g. Polk et al. 1994). Unexpectedly, but interestingly, the kinetics of 
release of dextrans, from these systems containing nMP, changed from being 
diffusion controlled to zero order release. This was not evident for the PAC and 
PTC systems (See Figure 6.3b). 
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Most controlled release devices release drug via square root of time kinetics or 
first order kinetics with few releasing drug via zero order kinetics. Of these few 
that do so, the systems are usually complicated and involve a change in the 
geometry of the device so that zero order kinetics can be achieved. Zero order 
release kinetics is very important in controlled release devices as they ensure 
constant therapeutic levels of drug in the body (Kydonieus, 1980). 
The lOkD FITC dextran release data shows PM25C to release the highest amount 
(-75.3%) over 7 days (Table 6.1). This is followed by 50FD10C (63.1%), and 
PTFDIOC and PAFDIOC release similar amounts (39.8% and 38.4%, 
respectively). These are the largest amounts of dextran release observed in these 
studies. The rate by which the release occurs, increases by x101, with the addition 
of chitosan. 
6.2.2 EXTRACTED MATERIALS 
Analysis of THFA release for the PAC system, over 48hrs showed that leaching is 
continuous; DMPT is present in the immersion solution from the 8hr timepoint 
(Figure 6.6); the earliest time point analysed. The immersion solution of the 
remaining systems showed the initial presence of DMPT at 48 hrs. This 
corroborates with the theory that the higher percentage leaching from the PAC 
systems occur due to incomplete polymerisation, as mentioned in Section 5.1.3. 
Since DMPT is involved in the polymerisation process and the leaching of this 
component appears from the time of immersion it indicates that incomplete 
polymerisation has occurred. It appears that the inclusion of chitosan exacerbates 
this further, leading to a larger amount of residual THFA and DMPT leaching 
(Figure 6.5b). Small amounts of DMPT are extracted from all systems, after 
48hrs, with the exception of the PT system, which continues not to leach DMPT. 
This indicates chitosan has an effect on all the systems studied to some degree. 
There seems to be no clear trend between percentage amount of nMP incorporated 
and the amount extracted. However, in the presence of chitosan the amount of 
nMP extracted increases (from 20 to 45% for 25FD1OC) (Table 6.1). This study 
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measured the extractable nMP following -50 days of immersion of the specimen, 
however in practice, a mucosal patch would be used over a much shorter time (for 
example 8 hours). 
Figure 6.8 shows that nMP is not measurable until -10 hrs, even in the presence 
of chitosan. However -35 % of dextran has already been released, from these 
systems, over the first 8 hour (169.71s1'2) period (Figure 6.3a). Hence it seems 
possible to release measurable amounts of dextran before leaching of nMP occurs 
and consequent loss of flexibility. This is not' surprising since, as discussed 
earlier, the addition of chitosan increases the molecular mobility of the polymeric 
systems. 
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CHAPTER 7 CLSM (CONFOCAL LASER 
SCANNING MICROSCOPY) OBSERVATIONS OF THE 
POLYMERIC SYSTEMS WITH FITC-DEXTRAN AND THE 
EFFECTS ON IMMERSION 
7.1 INTRODUCTION 
Confocal Laser Scanning Microscopy (CLSM) was undertaken to study the 
transport of the 10kD FITC dextran molecules within the three polymeric systems 
(PT, PM50 and PA) with and without Chitosan, immersed in water, over 7 days. 
This is a novel imaging technique, for visualisation of the dextran and water 
within the novel polymeric systems, developed during this thesis. It is a non 
destructive technique and allows the specimens to be observed in situ. An 
important advantage of the CLSM is that minimum specimen preparation, and no 
dehydration, is required. Only one of the plasticised systems was used, as it was 
assumed that both plasticised systems have a similar water sorption process, 
although the amounts maybe varied. The images for the various polymeric 
systems were obtained using a Leica SP2 Confocal Laser Scanning Microscope. 
The experimental regime involved immersing the various specimens in DW, at 
37°C, for various time periods, prior to observation, as described in 3.4.7. a. 
CLSM was carried out using reflection mode to identify the water absorption 
process and fluorescent mode to identify the FITC-dextran throughout the 
polymeric systems (in situ). Three images were combined to produce a final 
overlay image. Specimens were viewed in two planes xyz (horizontal slicing) and 
xzy (vertical slicing) to produce a3 dimensional image. 
Images taken in the xyz plane showed that the depth of water absorption increased 
with time, and the movement of the FITC-dextran occurred in parallel to water 
absorption. Initially the FITC-dextran on the surfaces and edges of the samples 
was released subsequent to which the scattered dextran, embedded within the 
inner matrix of the samples, moved towards the outer edges before it was released. 
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7.1.1 CLSM IMAGES OF DISTILLED WATER MOVEMENT IN THE POLYMERIC 
SYSTEMS 
The polymeric systems incorporating lOkD FITC-Dextran, PEM/THFM 
(PTFD 10), PEM/THFM with 50% nMP (50FD 10), PEM/THFA (PAFDIO), and 
these systems with the addition of Chitosan (PTFD I OC, 50FD I OC and PAFD 1 OC) 
were placed in DW over a 1-week period. The systems were observed by CLSM 
prior to immersion (Day 0), followed by 1 day and 7 days for the PTFD10 and 
PAFD10 systems (Figure 7.1). However 50FD10 and 50FD1OC CLSM images 
were obtained on day 3 as opposed to day 7, due to the faster release of FITC- 
Dextran from these systems, hence a very small amount of FITC-dextran is 
observed by day 7. 
Figure 7.1 shows the images obtained from the CLSM, in the reflection mode in 
xyz plane, for the above six systems. Reflective CLSM highlights the movement 
of water in to the systems. Prior to immersion in water, at day zero, the samples 
produced featureless structures since no water was present to cause phase 
resolution to occur in the reflective mode. On immersion in water, the CLSM 
images show that after an influx of water into the PT and PA matrices, circular 
undefined regions are left where the water does not appear to penetrate. These 
circular regions have been deduced to be PEM beads, clearly visible in the day 7 
image (horizontal plane) (Figure 7.1) and as confirmed by SEM (see Section 
4.1.4). Day 1 images demonstrate partial highlighting of the PEM beads for all 
the systems apart from PTFD10. This system has already been shown to have a 
slower diffusion coefficient for water absorption. 
Hence, the uptake of water into the polymeric systems defines the spherical PEM 
beads, which are embedded within the THFM/THFA matrix. The images 
compliment and support the water uptake studies in Sections 4.1.1 and 5.1.1, by 
visible imaging of the influx of water into the systems. 
201 
Chapter 7: CLMS observations 
40µm 
4 
Figure 7.1 CLSM images of polymeric systems PT, PM50 and PA loaded 
with I OkD FITC dextran (xyz plane) (refer to Chapter 3, section 3.3.7) 
On closer observation of the day 3/7 images it appears that the PTFDIO, 
PTFD I OC, PAFD I Oand PAFD I OC systems show a higher number of PEM beads, 
compared to the plasticised systems; the latter shows more of the monomer 
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matrix. In general the circular voids appear to expand over a period of 7 days, for 
the PTFD 10, PTFD l OC, PAFD l Oand PAFD lOC systems. However a similar 
effect was seen over a shorter period, of 3 days, for 50FDIO and 50FDIOC. Also 
the water influx began to highlight the PEM beads for this system at day zero, 
indicating that the system had started to absorb water within minutes of placement 
in the immersion medium. A point which must be noted is that the brightness of 
the images does not necessarily indicate the amount of water taken up, it is more 
indicative of the depth of the scan images taken, i. e. the top surface scan would be 
the brightest. 
Figure 7.2 shows the features of the three polymeric systems in detail after 7 or 3 
days of immersion for the three polymeric systems, without Chitosan. The 
PEMTHFM with lOkD system, after 7 days of immersion, shows spherical PEM 
beads evenly distributed within the THFM matrix. As the circular voids increase 
in size with immersion time they combine together over time. The same appears 
to be true for the PEM/THFA system. However the THFA matrix surrounding the 
PEM beads in the PAFD10 and PAFDIOC systems appears to have disappeared 
the most, leaving large circular crater like features by day 7 (Figure 7.1, PAFD 10 
and PAFD I OC). 
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Chapter 7: CLMS observations 
Figures 7.2 and 7.3 show clusters of FITC-dextran particles, these are vaguely 
visible in the reflective mode. Note that nMP cannot be seen in particulate form 
since it was incorporated as a low molecular weight organic solvent. The fact that 
the PEM bead size appears to be smaller in the nMP materials (Figure 7.3), is 
further evidence of the solvent action of the nMP. 
Figure 7.3 shows the features of the polymeric systems with Chitosan, in detail, 
after 7 or 3 days of immersion. The PTFDIOC and PAFDIOC systems have 
evenly distributed PEM beads, and the area (matrix) surrounding them seems to 
have increased in size, compared to the PTFD10 and PAFD10 images shown at 
the 7 day time point. The images demonstrate that as the matrix expands, it 
begins to ebb away, and the circular spaces appear to merge closer together. The 
5OFD1OC image has larger circular spaces at 3 days compared to the PTFD10 
system at. day 3, probably because the matrix expands due to it being more 
flexible. The outer layer surrounding the PEM beads for the PTFD10 and 
PAFD10 systems (Figure 7.3), can not be explained at this stage. This may be 
Chitosan surrounding the PEM beads as the systems polymerised. However, this 
is more prominent at day 1 for the 50FD1OC system but not for the day 3. 
At 7 days, the FITC-Dextran clusters are only visible in the PTFDIOC system 
hence it can be assumed that the FITC-Dextran has been released faster by the 
other systems (PAFDIOC and 50FD1OC). 
7.1.2 FLUORESCENT CLSM RESULTS OF FITC-DEXTRAN WITHIN TILE 
POLYMERIC SYSTEMS IN DISTILLED WATER 
Fluorescence is another mode that was used to view the systems. These images 
showed the FITC- Dextran within the matrix. Figure 7.4 illustrates an image of 
the 50FD10 sample immersed in DW, at 37°C, in an overlay CLSM mode in the 
xyz plane. Superimposing reflection CLSM and fluorescent CLSM mode images 
gives an overlay CLSM image. This is a remarkable technique of the CLSM 
technique, since it enables a two dimensional understanding of the mechanism of 
dextran release and its possible correlation to the uptake of solution (Figure 7.4). 
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The Overlay shows that dextran clusters around the PEM beads since the FITC- 
dextran appears in bead form (green) around these. 
Combined together 
Figure 7.4 
AIn 
50FD10 overlay CLSM image produced by combining reflection and 
fluorescent CLSM modes after 1 day of immersion (40 µm) 
Figure 7.5 shows 50FD10 cross sections in the horizontal plane from 0-65 tm 
after 1 day of immersion. Although the FITC dextran appears to cluster in a bead 
form in the cross sections, it only surrounds the PEM beads; it does not diffuse 
into the bead. 
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FITC-Dextran release images after 1 day of immersion (40 µm) 
7.1.3 FITC-DEXTRAN RELEASE AND WATER ABSORP'T'ION FROM POLYMERIC 
SYSTEMS 
Figures 7.6 to Figure 7.8 show the CLSM images of 50FD IO samples immersed 
in distilled water at 37°C in an overlay mode, to show the depth of water 
penetration and the movement of the dextrans, as the influx of water occurs. 
Figures 7.6, shows cross-sections of 50FDIO, in the vertical plane (xzy), from 0- 
23.2pm, which shows the paths of water absorption and FITC dextrin release 
from the sample. At day zero the waterfront can be seen at the surface since the 
specimen has been in immersed in water in order to be viewed. The FITC- 
Dextran is visible as a large saturated cluster; the intensity of the Iluorescence is 
very strong. 
Figure 7.7 shows the cross sections of the 50FD IO system at day l from 0 to 
214.9µm. The beginning of the movement of the waterfront can be seen, which 
also highlights the PEM beads. The result of the water entering the system allows 
these features to be seen, as well as the depth of water absorption. The dextran 
particles are spherical and where they meet with the solvent front, signs of 
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dispersion can be seen, as the circular placement becomes blurred towards the 
water front. The dextran is soluble hence dissolves in the water. 
Figure 7.6 CLSM image of PEM/THFM with 50% nMP & lOkD FITC 
dextran prior to immersion in water (xzy plane) Day 0 
Figure 7.7 CLSM image of PEM/TIIFM with 50%nMP & lOkD FITC 
dextran after 1 day of immersion 
(xzy plane) 
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Following three days of immersion the depth of absorption is much higher, as 
shown in cross section from 0-112.8µm for 50FD 10 (Figure 7.8). The intensity 
of the Dextran fluorescence is less than at day l (Figure 7.7). Figure 7.7 also 
appears to be more dispersed and seems to be moving in the direction of the 
surface, as highlighted in Figure 7.9, indicating that the dextran had dissolved in 
the water and was moving out of the polymeric system. 
Figure 7.8 CLSM image of PEM/THFM with 50%nMP &lOkD FITC dextran 
after 3 days of immersion 
(xzy plane) 
Figure 7.10 shows the cross sections of 50FD l OC (i. e. Chitosan incorporated 
system), from 0-53.3 pm at day zero; this is very similar to 50FD10 (Figure 7.6). 
However, at day one the images of the cross section from 0- 107.5 pm are very 
different (Figure 7.11). The depth and intensity of absorption demonstrates that 
the addition of Chitosan has accelerated water absorption. At day three there are 
very small amount of dextrans present in the image of the cross section from 0- 
70.1 (Figure 7.12). 
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5OFD10 day 1 
Figure 7.9 Overlay CLSM image of S0FD1l) at day one zoomed image at 20 
µm 
(xzy plane) 
JUµm 
Figure 7.10 CLSM image of PEM/THFM with 50t%nMP, I OkD FITC dextran 
& Chitosan prior to immersion (40p m) 
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Figure 7.11 CLSM image of PEM/THFM with 50%% nMP, lOkD FITC dextran 
& Chitosan after 1 day of immersion (40 Nm) 
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Figure 7. I2 CLSM image of' PEM/THFM with 50%YcnMP, IOkD FITC dextrin 
& Chitosan after 3 days of immersion 
7.1.4 DiscussioN OF THE CLSM OBSERVATIONS 
CLSM microscopy is a useful and powerful technique that can be used to 
determine and understand the water absorption and drug release processes 
involved in the polymeric systems studied. The technique is non destructive and 
allows samples to be sectioned in a variety of ways to build up images that are a 
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true representation of the processes occurring within the samples. 
The polymeric systems immersed in water were observed with CLSM, which 
enabled identification of the main features within the systems, such as PEM bead 
structure and FITC Dextran. The systems containing FITC-Dextran immersed in 
water were observed in the xyz and xzy plane, in both CLSM reflection and 
overlay modes. The features were identified and the differences between each 
system studied over 7 days. The reflection mode showed the position of the PEM 
beads and confirmed that water moved through the samples. The absorbed water 
dissolves the Dextran where it had accumulated, and Dextran release followed the 
same path as absorption. However the movement of Dextran out of the system 
occurs at a slower rate than the movement of water into the system; this may be 
due to the different molecular weights of water and dextran, The Dextran 
particles were dispersed throughout the matrix of the systems and accumulated 
around the edges of PEM beads and not inside the beads. 
As water absorption occurs, the accumulated dextran around the PEM beads 
dissolves and this results in the accumulation of solution (low concentration of 
dextran solution). It can then be assumed that water droplets must form around 
the PEM beads (Rahman, 2004). This formation of droplets involves the 
development of osmotic pressures, since the concentration of dextran in the 
droplet would be greater than the concentration in the external solution, 
encouraging further water absorption (discussed in detail in section 2.7.3. b). The 
absorption will persist causing the droplet to grow, due to an osmotic gradient, 
eventually leading to plastic yielding (Section 4.2.3, pg 146). The reflective mode 
highlights the features of the polymeric systems on the influx of water, Hence 
once the matrix has yielded and the droplets have expanded, they emerge as large 
circular regions, independent of the PEM beads. 
The expansion of the droplets occurs' the most in the THFA systems, particularly 
with Chitosan (Figure 7.1). This is possibly due to the poly(THFA) matrix 
degrading. This is confirmed by the increase in the THFA leaching, analysed by 
HPLC, for the Chitosan incorporated system compared to the original 
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PEM/THFA system. 
Specimens with FITC Dextran immersed in water were observed in an xzy plane, 
in an overlay mode, to observe the water and dextran movement in a z-direction 
through the depth of the specimen and to identify the type of features associated 
with this type of sectioning. With an increase in time there is an increase in the 
amount of water absorbing into the systems, as more water enters the system the 
PEM bead and THFM matrix become more distinct and the depth of the images 
increase. Dextran particles appear to dissolve and move out of the system. The 
water absorption occurs at different rates for the various systems; it is highest for 
the plasticised systems containing Chitosan (Figure 7.12 50FD10). This 
compliments the water absorption data and diffusion coefficient data obtained in 
section 6.1.1 (pg 184). 
The CLSM instrumentation is also capable of a number of quantitative analyses of 
these images. In this case the intensity of the water and FITC-Dextran present 
within the depth of the polymeric systems was measured, for the various time 
points. 
Figure 7.12 highlights the intensity of water and FITC Dextran on the z plane of 
the 50FD IO and the 50FD 1 OC images. The FITC Dextran intensity corresponds 
to the areas where the water intensity is high; the exception to this is when the 
Dextran particles have accumulated as shown in the SOFDIOC image (Figure 
7.12). This corresponds to the theory that water is attracted to the hydrophilic 
components and clusters there, causing a droplet formation. 
Following 1 day of immersion it can be seen that the water has travelled - 35µm 
for both systems, however the intensity of water is greater in 50FD I OC (160 1) 
(Figure 7.13bi) as opposed to 50FDIO (100 1) (Figure 7.13bii). Although the rate 
is similar the amount of water taken up is greater for the Chitosan incorporated 
specimens. 
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Chapter 7: CLAM observations 
The drug release results do not indicate 100% dextran has been released by this 
time point, however, it must be noted that drug release can occur from the wetted 
areas of the polymeric systems. The movement of the solvent front may 
essentially be the limiting factor in terms of release. 
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CHAPTER 8 IMMUNOLOGICAL 
RESPONSES OF THE POLYMERIC SYSTEMS 
8.1 INTRODUCTION 
Immunological and viability studies were used to establish whether the leachants 
or released components of the polymeric systems had an inflammatory or irritant 
action on `in vitro' stratified epithelium. The stratified layer can be used to model 
the response of the oral epithelium `in vivo'. Viability and the release of IL-la and 
IL-8 were quantified. It was hoped that the results may provide further clues as to 
the mechanism of action of epithelial cytokines on enhancing the mucosal 
permeation of drugs, released from these polymeric systems, as well as 
determining the toxic effect of the various components leached/released. 
8.1.1 BIOCOMPATIBILITY 
The epithelial viability has been expressed as a percentage of cells survived for 
each polymeric system compared to the control culture simply immersed in PBS 
(Figure 8.1; n=2). The PT system (100%) shows better Immunological responses 
than any of the other systems, however on the incorporation of chitosan this is 
slightly reduced to 80%. The PA system with and without chitosan resulted in a 
significantly low cell viability (15.36 and 23.01% respectively). The presence of 
nMP in the PEM/THFM system reduced the viability by - 20% (PM25 & PMSO, 
80%) and the addition of chitosan to these nMP systems does not really alter this 
(PM25C & PM50C, 77%). 
In conjunction to the low viability, the residual release of the different 
components from the PA system increased the release of the cytokine 1L-la by 
2.3 times compared to the control (6.9pg/ml cf 2.3 pg/ml, respectively) (Figure 
8.2). PA induced the largest effect compared to the other three systems (PT, 
PM25 and PM50). 
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Figure 8.1 The effect of leachants and released components from the 
polymeric systems PEM/THFA (PA), PEM/THFM (PT), PEM/THFM with 
25%nMP (PM25) and 50% (PM50) and with Chitosan (PAC, PTC, PM25C and 
PM50C) on the viability of the epithelium 
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Figure 8.2 The Effect of the polymeric systems PEM/THFA (PA), PEM/THFM 
(PT), PEM/THFM with 25%nMP (PM25) and 50% (PM50) on the Secretion of the 
Cytokine IL-la (n=3) 
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The PM25 system resulted in a significant release of the cytokine IL-8 followed 
by the PT system, when compared to the control (Figure 8.3). It should also be 
noted that IL-8 release was detectable across a range, from 237 to 2676pg/ml for 
all treatments. Interestingly the viability of the tissue cells, as determined by 
MTT assay, was not affected by the significant release of IL-8 from PM25. 
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Figure 8.3 The Effect of the polymeric systems (PEM/THFA (PA), PEM/THFM 
(PT), PEM/THFM with 25%nMP (PM25) and 50% (PM50) on the Secretion of the 
Cytokine IL-8 (n=3) 
8.1.2 DISCUSSION OF BIOCOMPATIBILITY OF POLYMERIC SYSTEMS 
Previous research has established that the pro-inflammatory cytokines IL-1 a, IL-8 
and IL-6 are secreted by keratinocytes. Furthermore, the research by Haque et al 
(1998) suggested that these cytokines may have a role in the pathogenesis of oral 
submucous fibrosis. They found that IL-la, IL-6, IL-8 and TNF-a were all up- 
regulated in peripheral blood mononuclear cells of OSF stimulated patients. Other 
evidence does support the existence of a role for IL-la in other oral diseases. For 
example, Li et al (1996) found that oral keratinocytes and skin keratinocytes 
221 
PBS THFA THFM 25 nMP 50 nMP Treatment 
Chapter 8: Immunological responses of Polymeric Systems 
produce IL-la constitutively. They secrete IL-la at a value of 43pg/ml/W 
cells/24 hours. Partridge et al (1991) concluded that the release of IL-la in the 
epidermis encouraged the development of tumour. 
IL-8 was also selected for investigation based on the evidence that IL-8 was 
released by oral keratinocytes (Li et a! 1996). Furthermore, IL-8 was known to be 
released from the oral mucosa on application of another `irritant', mercuric 
chloride solution (Personal communication Dr AT Cruchley, Oral Diseases 
Research Centre, Barts and The London, Queen Mary's School of Medicine and 
Dentistry). IL-8 is also up-regulated in allergic contact dermatitis (Griffiths et al 
1991). 
Coquette et al (2003) analysed the expression of IL-la and IL-8 expression and 
release, in vitro, via reconstructed human epidermis for the prediction of in vivo 
skin irritation and/or sensitization. They considered that skin keratinocytes may be 
influenced by `irritant' or `sensitizing' chemical agents. They hypothesised that 
different agents may produce different pro-inflammatory cytokine profiles. They 
were indeed correct and discovered that topical treatment with a sensitizer (e. g. 
benzoic acid, sodium lauryl sulphate) induced some but comparatively little 
release of IL-Ia but a reduction in viability. 
The THFA in this study has indicated to act as an irritant by causing low cell 
viability (below 20% with and without Chitosan). However the presence of nMP 
increased the secretion of IL-8, which has been thought to act as a pro- 
inflammatory cytokine and had high cell viability. Hence it can be indicative that 
the plasticiser did not appear to act as an irritant and therefore these systems can 
be pursued further, for use as delivery systems in the oral cavity. 
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CHAPTER 9 GENERAL DISCUSSIONS 
The incorporation of various molecular weight dextrans in the PEM! I' HFM 
system increased water uptake, but the increase was sensibly independent of the 
molecular weight of the dextran, as published by the manufacturer. However, 
determination of molecular weights by osmotic pressure gave much smaller 
values than those published, and with much less differences between grades. This 
is attributed to the osmotic values being number average molecular weights of the 
molecular weight distribution of the individual dextrans (see Appendix 2). The 
enhanced water uptake is generally explicable by modifications of the Muniandy 
and Thoma's Theory (1987), with the important difference that droplet growth 
proceeds by plastic flow. This is attributed to the calculated circumferential strains 
exceeding the elastic limit of the PEMJTHFM system, which is ductile. The 
observation that the opacity of the resin, which occurs on sorption, persists on 
desorption supports this. Both sorption and desorption obey simple diffusion 
theory. 
Dextran release from the PEM/THFM system is also Case I Fickian, but only a 
small fraction of the Dextran is released; this may well reflect only the low 
molecular weight fraction of the molecular weight distribution being released over 
the time scale of the experiments. 
The addition of n-methyl pyrrolidone was originally intended to enhance 
molecular mobility, and thus both the transport of the dextrans and compliance. 
However, it not only substantially increased water uptake, but changed the uptake 
process to a combination of Case I and II diffusion (ie intermediate diffusion 
process). The Case II component suggests substantial molecular relaxation, 
consequent on the plasticising action of the nMP. Unlike classical Case II 
diffusion, which is a bulk effect, it is suggested this occurs round the droplets as 
they grow. The nMP will also reduce the elastic limit of the PEMiTIIFM matrix, 
and contribute to water uptake as it is itself water soluble. Indeed, analysis of the 
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leachants, where nMP is found, confirms its water solubility. This indicates that 
any mucosal patch based on these systems would have a limited life, but may well 
be sufficient. These effects of the nMP are reflected in enhanced release of the 
dextrans. 
The addition of Chitosan as a permeation enhancer generally enhanced the effects 
of the nMP. Water uptake in some cases was Case II, and enhanced; also the 
dextran released was by zero order kinetics with nMP and the amount enhanced. 
This strongly suggested that Chitosan itself is a plasticiser. This was confirmed by 
calculating its solubility parameter theoretically, which gave values similar to 
those of phthalates (Brandrup and Immergut, 1974). 
The experiments where THFM was replaced by THFA, whereby a more flexible 
polymer system was obtained, (polyTHFA is an elastomer) gave enhanced water 
uptake, as would be expected from the Muniandy and Thomas theory (1987), and 
enhanced dextran release. However, in both cases, these effects were very much 
less than with the PEM/THFM plasticised with nMP/Chitosan. 
For the analysis of the leachants, most of the components had no previous 
methodologies for detection, using HPLC. Therefore novel methods for analysis 
of THFM, THFA nMP, DMPT and THFOH have been developed with particular 
attention to differentiate each component by column separation techniques. 
During the course of immersion, residual monomer and DMPT were leached out, 
as well as plasticiser. The amount of residual monomer and DMPT leached was 
higher in the plasticised formulations. It should be borne in mind that the 
amounts leached during the lifetime of a patch will be less. 
Scanning Electron Microscopy (SEM) images compared the effects of water 
absorption and desorption on the various PEM/THFM based systems. Confocal 
Laser Microscopy (CLSM), a novel technique in this area, has been useful in 
imaging both the ingress of water during the immersion stage and the movement 
of fluorescinated dextrans, which were released, following absorption. The xyz 
plane CLSM images showed the influx of water over time. After one day (Figure 
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7.6) the water can be seen to have infiltrated the surface of the polymer matrix. 
As it reached the FITC dextran clusters the latter appeared to dissolve. 
Some preliminary results on the biocompatibility of the various polymeric 
systems, with the exception of the systems containing TFIFA, have shown little 
inflammatory response and high cell viability. This confirms previous work on the 
biocompatibility of the PEM/THFM system in dental (for example: Patel et al 
1998; Pearson et al 1986) and orthopaedic applications (for example: Downes et 
al 1994), and the biocompatibility of nMP and Chitosan. This therefore indicates 
that further development of these polymeric systems for use in the oral cavity is 
merited. 
9.1 CONCLUSIONS 
" The presence of dextrans in the PEM/THFM system increases water uptake by 
a Muniandy and Thomas mechanism, but droplet growth is by plastic flow. 
" It appears that the parameter governing water uptake is the number average 
number molecular weight 
" The amount of dextrans released from the PEM/TIIFM system is small; 
release is diffusion controlled. 
" The addition of nMP substantially increases water uptake, and the mechanism 
is a combination of Case I and Case Il diffusion (intermediate diffusion). 
" The presence of nMP greatly enhances the amount of dextrans released. 
" The presence of Chitosan with nMP further enhances water uptake, and the 
process is predominantly Case II 
" The presence of Chitosan with nMP further enhances the amount of dextrans 
released, and changes the mechanism to zero order. 
" The amount and chemical composition of leachants, including dextrans, nMP, 
THFM, THFA, and DMPT, were determined 
"A study of the biological effects of various components showed, not 
surprisingly, that THFA was a cell irritant, but TIIFM and nMP were 
essentially non-irritant. 
" Scanning electron microscopy showed the micro-structure of some of the 
systems studied, before and after immersion in water 
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9 CLMS was a useful technique to identify the water absorption processes, and 
FITC Dextrans movement through the polymer systems. 
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CHAPTER 10 SUGGESTIONS FOR FURTHER WORK 
"A study of the transport of dextrans from patches made from some of the systems 
described in this thesis, (including the chitosan based systems), through oral 
mucosal tissue. This will be preceded by measurements of dextrans through 
mucosal tissue, in order to determine their transport properties. Relevant 
theoretical analysis (Latham, 2006) will establish the relevant parameters, 
including the interfacial resistance. 
" The above will enable the permeation enhancing effect of Chitosan to be 
evaluated 
" Evaluation of the bioadhesive properties of Chitosan 
" Determination of the visco-elastic properties of the systems used in this work 
" Incorporating an appropriate drug, in selected systems, with a similar molecular 
weight to the dextran(s), and studying its' effect on the water absorption of the 
systems 
" Studying the drug release behaviour of the appropriate drug from the selected 
systems and comparing this to the release of dextrans. 
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APPENDIX I THE MUNIANDYAND THOMAS 
THEORY 
The starting point for the theory is the van t'Hoff equation for osmotic pressure 
(II); osmotic pressure is the pressure exerted by solute molecules on a semi- 
permeable membrane. This is defined as a membrane which is permeable to 
solvent molecules, but impermeable to solute molecules. 
For dilute solutions, II is defined by: 
II = RT (C1/Ml + C2/M2 +C3/M3 ---) Al) 
where the suffixes, l), 2) etc refer to each soluble moiety in the solution; ci is 
concentration in gIm3 and M; molecular weight of the soluble moiety. R is the 
Universal Gas Constant (8.314 J. mole'K'), T temperature (°K) 
Equation Alcan be re-written as: 
m 
n= RTEC; /M; A2) 
where m is the number of moieties in the solution 
Now consider the polymer system as depicted in fig 2.14, showing the water 
uptake after a time t of immersion. At a given depth (x), the concentration of 
water will be CW; this comprises water in the droplets, and water soluble in the 
polymer matrix (s). It follows that the concentration of water in the droplets is: 
CW s. If a system with one soluble moiety is considered (Le in the current work 
dextran) at a concentration of Ci in the polymer, then the concentration Ci (g/unit 
volume) within the droplets is: 
C; P, / (C,,, -s) A3) 
Hence, if the external medium is water, TI within the droplets is given by: 
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11 = RT C; pW, /(C, -s) M A4) 
or if the external medium is a solution (e. g. artificial saliva) then A4) becomes 
(Morawetz, 1965): 
11 = RTC; p,, (Cw-s)/M -RTECsIMns A5) 
where the suffix CAS refers to the constituents of artificial saliva. 
Next, consider the conditions surrounding the droplets; for simplification, take the 
mean radius of the particles as r, assuming spherical geometry. Then the volume 
of particle is 4/37tr3, so if there are n particles per unit volume, then the volume 
of particles per unit volume of polymer is 4/31mr3' so that the mass of particles per 
unit volume of polymer (C; ) is: 
Ci = 4/3nr3p; A6) 
Next consider the situation at time t, depth x, i. e. where the water uptake is Cw, 
then a given particle will be surrounded by a spherical shell of water, the presence 
of which will have deformed the polymer. Define the ratio of the radius of the 
droplet to that of the particle as X. Then the volume of water surrounding the 
particle will be 4/3nr3(%3-1), so that the mass of water per unit volume in the 
droplets (C, , -s) will be: 
C,, -s = 4/37tr3n(? 
3-1)pw A7) 
If equation A5 is divided by A4, the result is: 
(Cw-s)/Ci = (V-1)pw/p; AS) 
Equation A8) is very important in that the extension ratio around the droplets can 
be determined from experimentally accessible quantities. The X, usually referred 
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to as the extension ratio, refers to the elastic deformation of the polymer cg 
presence of water has stretched the polymer by the ratio X around the polymer. 
The elastic pressure (P) generated within an elastomer is given by: 
P= G/2(5- ii? 4 -4/X) 
where G is the shear modulus of the elastomer. 
A9) 
To analyse the diffusion processes involved in droplet formation, Muniandy and 
Thomas (1997) used Fick's First Law reformulated in terms of chemical 
potential(g) (Gibbs, 1928): 
F= -C/RT. aiJax A10) 
By expressing µ in terms of P and II, they were able to account for the 
experimentally observed linear t1/2 dependence, and dependence of D upon C 
(Dal /C2). 
Of particular interest in the current work is that at equilibrium uptake, osmotic and 
elastic forces balance, giving P =II 
i. e. G/2(5-l/? 4-4/a, ) = RT{C1pt/(Cw-s) -F-CASIMAS} All) 
Possibly of more use is equation A8), from which, % is readily calculated, then P if 
required. 
If, as in the current work, the polymer is rigid, then it is more useful to use the 
strain(e), which is related to X by: 
? =1+c 
Hence A8) becomes: 
A12) 
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(Cw-s)/Ci = 3epW/pj A13) 
neglecting powers of c of 2) and 3) 
It must be emphasised that the above theory assumes dilute solutions for 
equations involving osmotic pressure that the elastic limit of the polymer of the 
polymer is not exceeded with rigid polymers, and that fracture does not occur 
around the droplets with all polymers. 
This is a real possibility, and fracture is reported to support drug delivery 
(Amsden et al., 1994; Brook & Van Noort, 1985. ) 
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APPENDIX II DEFINITIONS OFMOLECULAR 
WEIGHTS OF POLYMERS 
Any polymer generally has a wide range of molecular weights, reflecting a range 
of chain lengths. Clearly some sort of average figure is needed to characterise the 
polymer. There are at least two possibilities: 
Number average (M,, ) defined by: 
Mn = En; M; A2. t) 
where n; is the number fraction of molecules having a molecular weight of M; 
Weight average (M, W) is defined as: 
MW = Ewjmj A2.2) 
where wj is the weight fraction of molecules having a molecular weight of Mj 
There are many ways of measuring the molecular weight of polymers, for 
example measuring the osmotic pressure of polymer solutions, which gives a 
number average, and light scattering which gives a weight average. 
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